---
document_datetime: 2024-09-05 09:27:07
document_pages: 87
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/betmiga-h-c-2388-x-0039-g-epar-assessment-report-variation_en.pdf
document_name: betmiga-h-c-2388-x-0039-g-epar-assessment-report-variation_en.pdf
version: success
processing_time: 83.9055228
conversion_datetime: 2025-12-30 08:28:43.337151
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

27 June 2024 EMA/330048/2024 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Betmiga

International non-proprietary name: Mirabegron

Procedure No. EMEA/H/C/002388/X/0039/G

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure..............................................                                   | 6                                                                                                          |
|----------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier                                                                                             | .....................................................................................6                     |
| 1.2. Legal basis, dossier content...................................................................................6      |                                                                                                            |
| 1.3. Information on paediatric requirements                                                                                | ..................................................................6                                        |
| 1.4. Information relating to orphan market exclusivity                                                                     | ....................................................6                                                      |
| 1.4.1. Similarity                                                                                                          | .........................................................................................................6 |
| 1.5. Scientific advice...................................................................................................6 |                                                                                                            |
| 1.6. Steps taken for the assessment of the product                                                                         | ........................................................7                                                  |
| 2. Scientific discussion................................................................................                   | 9                                                                                                          |
| 2.1. Problem statement...............................................................................................9     |                                                                                                            |
| 2.1.1. Disease or condition                                                                                                | ..........................................................................................9                |
| 2.1.2. Epidemiology                                                                                                        | ....................................................................................................9      |
| 2.1.3. Biologic features                                                                                                   | ...............................................................................................9           |
| 2.1.4. Clinical presentation, diagnosis .........................................................................          | 10                                                                                                         |
| 2.1.5. Management...................................................................................................       | 10                                                                                                         |
| 2.2. About the product ..............................................................................................      | 11                                                                                                         |
| 2.3. Type of application and aspects on development....................................................                    | 11                                                                                                         |
| 2.4. Quality aspects ..................................................................................................    | 12                                                                                                         |
| 2.4.1. Introduction....................................................................................................    | 12                                                                                                         |
| 2.4.2. Active Substance.............................................................................................       | 12                                                                                                         |
| 2.4.3. Finished Medicinal Product................................................................................          | 12                                                                                                         |
| 2.4.4. Discussion on chemical, pharmaceutical and biological aspects..............................                         | 16                                                                                                         |
| 2.4.5. Conclusions on the chemical, pharmaceutical and biological aspects                                                  | ...................... 16                                                                                  |
| 2.4.6. Recommendations for future quality development                                                                      | ............................................... 17                                                         |
| 2.5. Non-clinical aspects............................................................................................      | 17                                                                                                         |
| 2.5.1. Introduction....................................................................................................    | 17                                                                                                         |
| 2.5.2. Pharmacokinetics                                                                                                    | ............................................................................................ 17            |
| 2.5.3. Toxicology......................................................................................................    | 17                                                                                                         |
| 2.5.4. Ecotoxicity/environmental risk assessment.........................................................                  | 18                                                                                                         |
| 2.5.5. Discussion on non-clinical aspects .....................................................................            | 20                                                                                                         |
| 2.5.6. Conclusion on the non-clinical aspects                                                                              | ............................................................... 20                                         |
| 2.6. Clinical aspects                                                                                                      | .................................................................................................. 21      |
| 2.6.1. Introduction....................................................................................................    | 21                                                                                                         |
| 2.6.2. Clinical pharmacology                                                                                               | ...................................................................................... 24                  |
| 2.6.3. Discussion on clinical pharmacology...................................................................              | 33                                                                                                         |
| 2.6.4. Conclusions on clinical pharmacology.................................................................               | 35                                                                                                         |
| 2.6.5. Clinical efficacy                                                                                                   | ............................................................................................... 35         |
| 2.6.6. Discussion on clinical efficacy............................................................................         | 55                                                                                                         |
| 2.6.7. Conclusions on the clinical efficacy                                                                                | .................................................................... 59                                    |
| 2.6.8. Clinical safety                                                                                                     | ................................................................................................. 59       |

<div style=\"page-break-after: always\"></div>

| 2.6.9. Discussion on clinical safety..............................................................................       | 73                                                                                                         |
|--------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|
| 2.6.10. Conclusions on the clinical safety.....................................................................          | 76                                                                                                         |
| 2.7. Risk Management Plan........................................................................................        | 77                                                                                                         |
| 2.7.1. Safety concerns ..............................................................................................    | 77                                                                                                         |
| 2.7.2. Pharmacovigilance plan....................................................................................        | 77                                                                                                         |
| 2.7.3. Risk minimisation measures..............................................................................          | 78                                                                                                         |
| 2.7.4. Conclusion......................................................................................................  | 80                                                                                                         |
| 2.8. Pharmacovigilance .............................................................................................     | 80                                                                                                         |
| 2.8.1. Pharmacovigilance system................................................................................          | 80                                                                                                         |
| 2.8.2. Periodic Safety Update Reports submission requirements .....................................                      | 80                                                                                                         |
| 2.9. Product information............................................................................................     | 80                                                                                                         |
| 2.9.1. User consultation ............................................................................................    | 80                                                                                                         |
| 3. Benefit-Risk Balance.............................................................................                     | 80                                                                                                         |
| 3.1. Therapeutic Context ...........................................................................................     | 80                                                                                                         |
| 3.1.1. Disease or condition ........................................................................................     | 80                                                                                                         |
| 3.1.2. Available therapies and unmet medical need.......................................................                 | 81                                                                                                         |
| 3.1.3. Main clinical studies.........................................................................................    | 81                                                                                                         |
| 3.2. Favourable effects..............................................................................................    | 81                                                                                                         |
| 3.3. Uncertainties and limitations about favourable effects.............................................                 | 82                                                                                                         |
| 3.4. Unfavourable effects...........................................................................................     | 82                                                                                                         |
| 3.5. Uncertainties and limitations about unfavourable effects .........................................                  | 83                                                                                                         |
| 3.6. Effects Table...................................................................................................... | 84                                                                                                         |
| 3.7. Benefit-risk assessment and discussion.................................................................             | 85                                                                                                         |
| 3.7.1. Importance of favourable and unfavourable effects..............................................                   | 85                                                                                                         |
| 3.7.2. Balance of benefits and risks ............................................................................        | 86                                                                                                         |
| 3.8. Conclusions                                                                                                         | ....................................................................................................... 86 |
| 4. Recommendations.................................................................................                      | 86                                                                                                         |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

| AE      | adverse event                                                                                                                        |
|---------|--------------------------------------------------------------------------------------------------------------------------------------|
| AST     | aspartate aminotransferase                                                                                                           |
| AUC     | area under the concentration-time curve                                                                                              |
| AUCinf  | area under the concentration-time curve from the time of dosing extrapolated to time infinity                                        |
| AUClast | area under the concentration-time curve from the time of dosing up to the time of the last measurable concentration                  |
| AUCtau  | area under the concentration-time curve from the time of dosing to the start of the next dosing interval at multiple dose conditions |
| CFU     | Colony Forming Units                                                                                                                 |
| CIC     | clean intermittent catheterization                                                                                                   |
| Cmax    | maximum concentration                                                                                                                |
| CQAs    | Critical quality attributes                                                                                                          |
| DBP     | diastolic blood pressure                                                                                                             |
| DoE     | Design of experiments                                                                                                                |
| ECG     | electrocardiogram                                                                                                                    |
| EU      | European Union                                                                                                                       |
| FAS     | full analysis set                                                                                                                    |
| FMEA    | Failure Mode Effects Analysis                                                                                                        |
| GMP     | Good manufacturing practices                                                                                                         |
| HPLC    | High performance liquid chromatography                                                                                               |
| ICCS    | International Children's Continence Society                                                                                          |
| ICH     | International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use                |
| JEFCA   | Joint FAO/WHO Expert Committee on Food Additives                                                                                     |
| MCC     | maximum cystometric capacity                                                                                                         |
| ND      | Not detected                                                                                                                         |
| NDO     | neurogenic detrusor overactivity                                                                                                     |
| NF      | National Formulary (from the USP)                                                                                                    |
| NLT     | Not less than                                                                                                                        |

<div style=\"page-break-after: always\"></div>

| NMT      | Not more than                                                                                                                            |
|----------|------------------------------------------------------------------------------------------------------------------------------------------|
| OAB      | overactive bladder                                                                                                                       |
| PCR      | potentially clinically relevant                                                                                                          |
| PED25    | pediatric dose targeted to achieve steady-state exposures similar to those of adults administered the mirabegron 25 mg tablet once daily |
| PED50    | pediatric dose targeted to achieve steady-state exposures similar to those of adults administered the mirabegron 50 mg tablet once daily |
| PET      | Polyethylene Terephthalate                                                                                                               |
| Ph. Eur. | European Pharmacopoeia                                                                                                                   |
| PIP      | Paediatric Investigation Plan                                                                                                            |
| PVR      | postvoid residual volume                                                                                                                 |
| QTcF     | QT interval corrected by Fridericia's formula                                                                                            |
| RMP      | risk management plan                                                                                                                     |
| SAF      | safety analysis set                                                                                                                      |
| SBP      | systolic blood pressure                                                                                                                  |
| SmPC     | Summary of product characteristics                                                                                                       |
| TEAE     | treatment-emergent adverse event                                                                                                         |
| tmax     | time of the maximum concentration                                                                                                        |
| UHPLC    | Ultra-high performance liquid chromatography                                                                                             |
| USP      | United States Pharmacopeia                                                                                                               |
| USP/NF   | United States Pharmacopoeia/National Formulary                                                                                           |
| UTI      | urinary tract infection                                                                                                                  |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

Astellas Pharma Europe B.V. submitted on 22 November 2021 a group of variation(s) consisting of an extension of the marketing authorisation and the following variation(s):

| Variation(s) requested   | Variation(s) requested                                                                                                         | Type   |
|--------------------------|--------------------------------------------------------------------------------------------------------------------------------|--------|
| C.I.6.a                  | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | II     |

Extension application to introduce a new pharmaceutical form associated with new strength (8 mg/ml prolonged-release granules for oral suspension), grouped with a type II variation (C.I.6.a) to include treatment of neurogenic detrusor overactivity (NDO) in paediatric patients aged 3 to less than 18 years. The RMP (version 9.0) is updated in accordance.

Furthermore, the PI is brought in line with the latest QRD template version 10.4.

## 1.2. Legal basis, dossier content

## The legal basis for this application refers to:

Article 7.2 of Commission Regulation (EC) No 1234/2008 - Group of variations

## 1.3. Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision(s) P/0402/2021 on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application, the PIP EMEA-000597-PIP03-15-M04 was not yet completed as some measures were deferred.

## 1.4. Information relating to orphan market exclusivity

## 1.4.1. Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the MAH did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## 1.5. Scientific advice

The MAH received Scientific Advice from the CHMP on 22 July 2021 (EMA/SA/0000061504). The Scientific Advice pertained to the following non-clinical aspect:

- -Acceptability of the proposed approach to update the environmental risk assessment resulting from

<div style=\"page-break-after: always\"></div>

the intended extension of use to paediatric patients, including the request not to repeat the OECD 106 study with two soil types.

## 1.6. Steps taken for the assessment of the product

The Rapporteur appointed by the CHMP was:

CHMP Rapporteur: Maria Concepcion Prieto Yerro

| The application was received by the EMA on                                                                                                                      | 22 November 2021   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|
| The procedure started on                                                                                                                                        | 24 December 2021   |
| The CHMP Rapporteur's first Assessment Report was circulated to all CHMP and PRAC members on                                                                    | 16 March 2022      |
| The PRAC Rapporteur's first Assessment Report was circulated to all PRAC and CHMP members on                                                                    | 23 March 2022      |
| The PRAC agreed on the PRAC Assessment Overview and Advice to CHMP during the meeting on                                                                        | 07 April 2022      |
| The CHMP agreed on the consolidated List of Questions to be sent to the MAH during the meeting on                                                               | 22 April 2022      |
| The MAH submitted the responses to the CHMP consolidated List of Questions on                                                                                   | 13 July 2022       |
| The CHMP Rapporteurs circulated the CHMP and PRAC Rapporteurs Joint Assessment Report on the responses to the List of Questions to all CHMP and PRAC members on | 19 August 2022     |
| The PRAC agreed on the PRAC Assessment Overview and Advice to CHMP during the meeting on                                                                        | 01 September 2022  |
| The CHMP agreed on a list of outstanding issues in writing and/or in an oral explanation to be sent to the MAH on                                               | 15 September 2022  |
| The MAH submitted the responses to the CHMP List of Outstanding Issues on                                                                                       | 19 January 2024    |
| The PRAC Rapporteur circulated the Assessment Report on the responses to the List of Outstanding Issues to all CHMP and PRAC members on                         | 26 January 2024    |
| The CHMP Rapporteur circulated the Assessment Report on the responses to the list of outstanding issues to all CHMP and PRAC members on                         | 8 February 2024    |
| The PRAC agreed on the PRAC Assessment Overview and Advice to CHMP during the meeting on                                                                        | 8 February 2024    |
| The CHMP Rapporteur circulated the Joint Assessment Report on the                                                                                               | 15 February 2024   |

<div style=\"page-break-after: always\"></div>

| responses to the List of Outstanding Issues to all CHMP and PRAC members on                                                                                                             |                  |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| The CHMP agreed on a second list of outstanding issues in writing and/or in an oral explanation to be sent to the MAH on                                                                | 22 February 2024 |
| The MAH submitted the responses to the second CHMP List of Outstanding Issues on                                                                                                        | 27 May 2024      |
| The CHMP Rapporteur circulated the Assessment Report on the responses to the second list of outstanding issues to all CHMP and PRAC members on                                          | 14 June 2024     |
| The CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a marketing authorisation to Betmiga on | 27 June 2024     |

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Problem statement

## 2.1.1. Disease or condition

Neurogenic detrusor overactivity (NDO) is defined as the occurrence of involuntary detrusor contractions during filling cystometry that have a relevant neurological cause 1 .

Neurogenic bladder describes a variety of bladder dysfunction disorders that result from a lesion at any level in the central or peripheral nervous system. Among children, congenital neural tube defects, such as myelomeningocele, spinal dysraphism, or tethered cord lesions, are the most common causes. Acquired causes such as spinal cord tumors or trauma or sequelae of transverse myelitis are less frequent 2 .

## 2.1.2. Epidemiology

Epidemiology data in the paediatric population are limited. In 2009, an estimated 17,170 paediatric patients in the EU were diagnosed with NDO (prevalence: 1.8/10,000 children). 3,4

## 2.1.3. Biologic features

To achieve urinary continence, the bladder must perform two functions: (1) store urine produced by the kidney, and (2) expel urine when appropriate. For success of both functions, neurological input is required from the cerebral cortex, spinal cord, and peripheral nervous system; disruption anywhere along those neural pathways can lead to various degrees of bladder dysfunction. For storage of urine, the muscles of the bladder are relaxed and the external sphincter contracted, and this is reversed when voiding is desired 2 .

Disordered innervation of the detrusor musculature and external sphincter adversely affects bladder function. It can lead to dyssynergy so that the sphincter is closed when the detrusor contracts, creating high pressures within the bladder but low flow rates. An increased intravesical pressure, the leak-point pressure (the bladder pressure at which urethral leakage occurs), or detrusor external sphincter dyssynergia are now recognized as significant risk factors of subsequent upper and lower urinary tracts deterioration. When the detrusor filling pressure exceeds 40 cm H2O ureteral drainage into bladder deteriorates, leading to hydronephrosis and vesicoureteral reflux, recurrent urinary tract infections due to bladder residue, and ultimately renal insufficiency 5 .

1 Austin PF, Bauer SB, Bower W, Chase J, Franco I, Hoebeke P, et al. The standardization of terminology of lower urinary tract function in children and adolescents: update report from the standardization committee of the International Children's Continence Society. Neurourol Urodyn 2016;35:471e81.

2 Lucas E. Medical Management of Neurogenic Bladder for Children and Adults: A ReviewTop Spinal Cord Inj Rehabil 2019;25(3):195-204.

3 Astellas Pharma Europe R&amp;D. Targeted literature review of neurogenic detrusor overactivity in pediatric populations. 2009 [Data on file].

4 Bauer SB. Neurogenic bladder: etiology and assessment. Pediatr Nephrol 2008;23:541e51.

5 Larijani FJ et al. Int J Prev Med. 2013 Dec; 4(12): 1359-1364.

<div style=\"page-break-after: always\"></div>

## 2.1.4. Clinical presentation, diagnosis

At birth, the majority of patients with neurogenic bladder have normal upper urinary tracts, but bladder dysfunction will occur later in life, especially in first years due to changes in the innervation as well as the development of a tethered cord and other neurological changes. Without treatment, up to 60% to 80% may develop urological problems within the first years of life and less than 5% become continent 6,7 .

Patients with a neurogenic bladder can present with various patterns of detrusor -sphincter dyssynergia, which may lead to urine and/or stool incontinence, urinary tract infections (UTI's), vesicoureteral reflux, and ultimately renal scarring and renal failure requiring dialysis and/or transplantation.

Children with spinal dysraphism also present a neurogenic bowel, which is characterized by severe constipation, faecal incontinence, gastrointestinal motor dysfunction and altered visceral sensitivity. 8

Urodynamic studies (UDS) are relevant diagnostic tools in order to assess that storage function of the bladder remains at pressures low enough for upper urinary tract safety and to evaluate the adequacy of treatment of detrusor overactivity, and to determine sphincter reactivity to bladder emptying 9 .

## 2.1.5. Management

Goals for NDO management are to prevent or minimize upper urinary tract damage and achieve social continence. Bladder management patients relies on intermittent catheterization and treatment of overactive detrusor by oral antimuscarinics. 10

- Clean intermittent catheterization (CIC) is the preferred method of bladder drainage for neurogenic bladder patient. When used routinely, CIC effectively preserves kidney function by preventing overdistention of the bladder and reducing pressures, thereby promoting consistent blood flow to bladder walls. Among the complications associated with CIC the most common ones are the acquisition of asymptomatic bacteriuria and urinary tract infections.
- Medical therapy
- -Anticholinergics are considered first-line therapy for neurogenic bladder patients. They reduce intravesical pressure and increase bladder capacity during the storage phase and decreased episodes of leaking, incontinence, and frequency voiding. Oxybutinin is available in oral, transdermal, and intravesical instillation solution formulations. Other anticholingeric drugs include tolterodine, propiverine, trospium, solifenacin, darifenacin, and fesoterodine. However, a proportion of patients fail to respond to antimuscarinics.
- -α -Adrenergic antagonists may be used in patients with increased sphincter activity to reduce the sphincter tension to facilitate voiding, thereby reducing incontinence episodes and decreasing catheterization frequency.

6 McGuire EJ, Woodside JR, Borden TA. J Urol. 1983;129(4):823 -826.

7 Sillen U, Hansson E, Hermansson G, Hjalmas K, Jacobsson B, Jodal U. Br J Urol. 1996;78(4):596 -601.

8 Sager C, Barroso U, Netto JM, Retamal G, Ormaechea E. IBJU 2022; 48(1): 31-51

9 Stein R et al. EAU/ESPU guidelines on the management of neurogenic bladder in children and adolescent part I diagnostics and conservative treatment. Neurourology and urodynamics, 2020; 39(1):45-57.

10 Rawashdeh YF, Austin P, Siggaard C, Bauer SB, Franco I, de Jong TP, et al. International Children's Continence Society's recommendations for therapeutic intervention in congenital neuropathic bladder and bowel dysfunction in children. Neurourol Urodyn 2012;31:615e20.

<div style=\"page-break-after: always\"></div>

- -In children/adolescents with neurogenic bladder refractory to first-line therapy, injections with botulinum toxin-A (BTX) in the detrusor muscle may be considered.
- Other treatment modalities include neuromodulation and surgical interventions (urethral dilation, vesicostomy, bladder, augmentation, fascial sling, artificial urinary sphincters, and bladder neck reconstruction)

## 2.2. About the product

Mirabegron is a selective human beta 3-adrenoreceptor (AR) agonist. Mirabegron activation of beta 3-AR in the human bladder results in a relaxation of the detrusor smooth muscle during the fill-void cycle, without interfering with the voiding contraction. In OAB studies using animal models mirabegron increased the bladder capacity.

Betmiga (mirabegron, 25 mg and 50 mg tablets) is currently approved in the EU for the symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome (EMEA/H/C/002388/0000, approved 20 Dec 2012).

The new indication claimed and approved in this procedure indication is:

Betmiga is indicated for the treatment of neurogenic detrusor overactivity (NDO) in paediatric patients aged 3 to less than 18 years

The indication refers to Betmiga prolonged-release tablets and the newly introduced formulation granules for prolonged-release oral suspension

For the proposed use in paediatric patients aged 3 to less than 18 years with granules for prolonged-release oral suspension, the weight-adapted dosing is the following:

| Body weight range (kg)   |   Starting dose (ml) |   Maximum dose (ml) |
|--------------------------|----------------------|---------------------|
| 11 to < 22               |                    3 |                   6 |
| 22 to < 35               |                    4 |                   8 |
| ≥ 35                     |                    6 |                  10 |

Patients  who  reach  35 kg  or  more  while  on  treatment  may  be  switched  from  oral  suspension  to  tablet formulation, if able to swallow tablets.

## 2.3. Type of application and aspects on development

The line extension is supported by a new formulation associated with a new strength (8 mg/mL granules for prolonged-release oral suspension, to extend use to paediatric patients aged 3 years to less than 18 years with NDO. The grouped line extension and extension of indication are supported by a Phase 3 study conducted in 86 paediatric patients with NDO using clean intermittent catheterization (CIC) (study 178-CL-206A).

Supportive exposure and safety data were obtained from 4 phase 1 single-dose studies in 17 paediatric patients with NDO and 26 paediatric patients with OAB (178-CL-202 and 178-CL-203) and 49 healthy adult subjects (178-CL-201 and 178-CL-208).

<div style=\"page-break-after: always\"></div>

In compliance with the Paediatric Investigation Plan (PIP) EMEA-000597-PIP03-15-M04 (Decision number P/0402/2021), a paediatric development program has been conducted for the treatment of neurogenic detrusor overactivity (NDO) in paediatric patients aged 3 to less than 18 years.

The Applicant sought Scientific advice on the Environmental Risk Assessment on at the CHMP on environmental aspects (see above).

## 2.4. Quality aspects

## 2.4.1. Introduction

This extension application introduces a new pharmaceutical form of Betmiga associated with a new strength.

The finished product is presented as granules for prolonged-release as oral suspension containing 830 mg mirabegron as active substance. One bottle of prolonged-release granules for oral suspension contains 8.3 g granules. After reconstitution with 100 mL of water, the suspension contains 8 mg/mL of mirabegron.

Other ingredients are: sodium polystyrene sulfonate, hydrochloric acid, dilute, xanthan gum, hypromellose, mannitol (E421), magnesium stearate, acesulfame potassium, methyl parahydroxybenzoate (E218), ethyl parahydroxybenzoate (E214), simethicone and silica, colloidal hydrated.

The product is available in a polyethylene terephthalate (PET) bottle with polypropylene (PP) screw cap as described in section 6.5 of the SmPC.

A 5 mL syringe is co-packaged in addition to an adaptor.

A measuring cup of 60 mL is only co-packaged for countries where the local legislation does not allow pharmacists to reconstitute before dispensing to caregivers or for the countries where the reconstitution by pharmacists is not common practice.

## 2.4.2. Active Substance

No new information on the active substance mirabegron has been provided with this line extension application. The new presentation uses active substance of the same quality as used in the approved presentations (25 mg and 50 mg prolonged-release tablets) and the active substance is manufactured by the approved manufacturing sites. The approved specification of the active substance is suitable for the new presentation and no additional tests are required.

## 2.4.3. Finished Medicinal Product

## 2.4.3.1. Description of the product and pharmaceutical development

Betmiga granules for prolonged-release oral suspension is presented as yellowish white granules. After reconstitution, the appearance of the suspension is pale brownish yellow.

The aim of formulation development was to develop an oral dosage form suitable for the paediatric population with acceptable palatability for paediatric patients.

<div style=\"page-break-after: always\"></div>

The quality target product profile (QTPP) was defined and information on the identified critical quality attributes was provided.

The pharmaceutical development of the finished product has been adequately performed and described. The selected formulation, packaging and manufacturing process are justified.

As regards the particle size of the active substance, it has been demonstrated that the approved specification limits for particle size of mirabegron are suitable.

During formulation development, the composition was varied and three formulations of granules for oral suspension were evaluated (Formula A, B and C). The strength of the initial formulations A and B was four times lower than the commercial formulation (Formula C). The concentrated formulation (Formula C) allows for higher concentration of the solution after reconstitution, thus reducing the administration volume.

All excipients are well known pharmaceutical ingredients and their quality is compliant with Ph. Eur standards. There are no novel excipients used in the finished product formulation. The list of excipients is included in section 6.1 of the SmPC. The function of each excipient is explained, and the maximum amount of each excipient taken by the patient has been discussed.

The compatibility of the active substance and excipients was confirmed through compatibility studies

The prevention of active substance leakage from the granules was a principal challenge in developing the prolonged-release oral suspension formulation. To achieve prolonged release, a cation exchange resin (sodium polystyrene sulfonate) was selected as an adsorbent for the active substance. Sodium polystyrene sulfonate is an insoluble, strongly acidic, cation exchange resin which cannot be absorbed systemically. Mirabegron (a cationic compound) binds to the sodium polystyrene sulfonate resin by ion exchange reaction. Adsorption of the active substance ensures sustained release of mirabegron. The weight ratio of sodium polystyrene sulfonate to mirabegron has been studied and optimised. The maximum daily amount of sodium polystyrene sulfonate for a child weighing 11 kg receiving the maximum daily dose is 57-fold lower than the maintenance dose for the treatment of hyperkalemia for children. Similar justifications are given for the other excipients taking into account the acceptable daily intakes established by the Joint FAO/WHO Expert Committee on Food Additives (JEFCA).

The efficacy of antimicrobial preservation was studied. A combination of methyl parahydroxybenzoate and ethyl parahydroxybenzoate as preservatives was selected. During development, the effectiveness of the antimicrobial preservation was studied in line with Ph. Eur. 5.1.3 and different granule batches with varying concentrations of preservatives were manufactured. The proposed concentration of preservatives in the commercial formulation is therefore adequately justified. The limits proposed for preservatives methyl parahydroxybenzoate and e thyl parahydroxybenzoate are also justified in accordance with the 'Reflection paper on the use of methyl- and propylparaben as excipients in human medicinal products for oral use' and are below the maximum amount of 2.8 mg/kg/day. Methyl parahydroxybenzoate and ethyl parahydroxybenzoate are excipients with known effect and are thus indicated in section 2 of the SmPC.

During development, the bitterness of mirabegron suspension was tested. To mask a slight bitterness, a sweetener (acesulfame potassium) was added to the formulation. The palatability of finished product for paediatric patients was then evaluated in clinical trials. It could be concluded that the remaining bitterness is well tolerated, and that the proposed commercial formulation is acceptable for paediatric patients.

The development of the manufacturing process has been sufficiently described and covers in adequate detail more complex aspects. Design of experiments was used to optimise the manufacturing process. The information provided is sufficient.

<div style=\"page-break-after: always\"></div>

A bioequivalence study was conducted of the proposed commercial formulation (Formula C, 8 mg/mL) versus Formula B (see above, 2 mg/mL) (study 178-CL-208, see clinical section for further information). This study demonstrated that Formula C was bioequivalent to Formula B for the exposure parameters of interest (AUCinf and AUClast).

The development of the dissolution method used for routine quality control testing has been described in sufficient detail. Based on the data from the development studies, three evaluation time points were established for routine dissolution testing, to cover the early, middle, and late stages of the dissolution profile in line with Ph. Eur. 2.9.3., the 'Guideline on Quality of Oral Modified Release Products'.

The discriminatory power of the dissolution method has been demonstrated.

The primary packaging is an amberpolyethylene terephthalate (PET) bottle with polypropylene (PP) screwcap. The bottle filled with granules is packed into an aluminium pouch with silica gel desiccant. An oral syringe of 5 mL and an adaptor are co-packed in a carton. The choice of the container closure system has been validated by stability data and is adequate for the intended use of the product.

To prepare the oral suspension, the granules should be reconstituted with 100 mL of water prior to administration. If a measuring cup is co-packaged (see above), it should be used to measure the water volume. The measuring cup has a graduation of 10 mL and is CE marked. The measuring cup is suitable.

The oral syringe and adaptor provided with Betmiga prolonged-release granules for oral suspension should be used to measure and administer the correct dose of suspension. The syringe has a graduation of 0.1 mL and 0.5 mL (max. 5 mL) and is CE marked.

For the oral syringe, uniformity of mass of delivered doses from multiple containers according to Ph. Eur. 2.9.27 was evaluated. Tests were conducted to cover the expected minimum and maximum dosing volume (1 mL and 5 mL). The syringe is used once to administer a dose of 3 mL or 4 mL and is used twice to administer 6 mL, 8 mL or 10 mL of suspension. It has been confirmed that suitable dosing accuracy is achieved.

## 2.4.3.2. Manufacture of the product and process controls

The finished product is manufactured by one manufacturing site.

The manufacturing process consists of 11 main steps: delumping, dispersing, spray drying, separately pulverising several components, preparation of the binder solution, granulation, blending, bottle filling and packaging. The manufacturing process is considered non-standard in line with the 'Guideline on process validation for finished products' (EMA/CHMP/CVMP/QWP/BWP/70278/2012-Rev1,Corr.1), since it comprises the manufacturing of a specialised pharmaceutical dose form (prolonged-release granules for oral suspension).

The manufacturing process has been validated on three batches manufactured at the proposed commercial batch size. It has been demonstrated that the manufacturing process is capable of producing the finished product of intended quality in a reproducible manner. The in-process controls are adequate for this type of manufacturing process and pharmaceutical form.

The proposed holding times are acceptable and supported by data.

<div style=\"page-break-after: always\"></div>

## 2.4.3.3. Product specification

The finished product release and shelf-life specifications include appropriate tests for this kind of dosage form: description (visual), identification of the active substance (HPLC with photo diode array detector), identification of preservatives (HPLC), related substances (HPLC), dosing uniformity (HPLC), dissolution (in house), free active (HPLC), microbial limits (Ph. Eur.), pH (in house), loss on drying (in house), assay (HPLC), preservative assay (HPLC), N -nitroso-mirabegron (UHPLC-MS/MS).

The release and shelf-life specifications of the finished product are acceptable and cover all the relevant points for the dosage form.

The potential presence of elemental impurities in the finished product has been assessed following a riskbased approach in line with the ICH Q3D Guideline for Elemental Impurities. Batch analysis data on three batches using a validated ICP-MS method was provided, demonstrating that each relevant elemental impurity was not detected above 30% of the respective PDE. Based on the risk assessment and the presented batch data it can be concluded that it is not necessary to include any elemental impurity controls. The information on the control of elemental impurities is satisfactory.

A risk concerning the presence of nitrosamines was initially identified during the assessment and this was raised as a major objection during the procedure. In response, results from confirmatory testing of finished product were provided. During the assessment, a further risk of formation of N -nitrosamines was identified after the applicant provided a more detailed risk assessment and discussion. This was raised as a major objection during the procedure. In response, results of confirmatory testing were provided. The toxicological risk is negligible, and the major objection is resolved. A risk assessment concerning the potential presence of nitrosamine impurities in the finished product has been performed as requested considering all suspected and actual root causes in line with the 'Questions and answers for marketing authorisation holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products' (EMA/409815/2020) and the 'Assessment report- Procedure under Article 5(3) of Regulation EC (No) 726/2004- Nitrosamine impurities in human medicinal products' (EMA/369136/2020). The control of N -nitroso mirabegron is considered adequate and the specification limit in the finished product specification is acceptable.

The analytical methods used have been adequately described and appropriately validated in accordance with the ICH guidelines. Satisfactory information regarding the reference standards used for assay and impurities testing has been presented.

Batch analysis results are provided for three commercial scale batches confirming the consistency of the manufacturing process and its ability to manufacture to the intended product specification.

## 2.4.3.4. Stability of the product

Stability data from three commercial-scale batches of finished product stored for up to 36 months under long term conditions (25 ºC / 60% RH) and for up to 6 months under accelerated conditions (40 ºC / 75% RH) according to the ICH guidelines were provided. The batches of medicinal product are identical to those proposed for marketing and were packed in the primary packaging proposed for marketing. The commercial PET bottle is amber (also referred to as bottle 3). In addition, results from supportive stability studies were provided using another PET bottle which was used during development and is dark amber in colour (bottle 2).

The analytical procedures used are stability indicating and no significant changes have been observed.

<div style=\"page-break-after: always\"></div>

In addition, one batch was exposed to light as defined in the ICH Guideline on Photostability Testing of New Drug Substances and Products in the proposed commercial bottle (bottle 3) as well as in bottle 2. Results showed no significant change in tested parameters for the granules for both types of bottles. For the suspension, a slight change of appearance was observed, however the acceptance criterion was met, including with bottle 3 (amber, proposed for commercial use). Therefore, the finished product is considered photostable.

## In-use stability study

An in-use stability testing was conducted using the oral suspension dispersed with water and mimicking the conditions in which the product will be used, in line with the instructions given in the SmPC. Suspension samples were prepared using granules from stability studies, using the initial sample (time 0), samples stored for 6, 9 or 12 months under long-term conditions as well as 6 months under accelerated conditions in bottle 3 as proposed for commercial use. Stability studies were also conducted with samples stored in bottle 2. No significant changes were observed in any of the samples tested and no microbial growth was observed. The results support the proposed in-use shelf life.

Based on available stability data, the proposed shelf-life of 3 years for the unopened bottle as stated in the SmPC (section 6.3) is acceptable. As indicated in the SmPC (section 6.4) this medicinal product does not require any special temperature storage conditions. The SmPC indicates as special precaution for storage (section 6.4) 'Store the bottle in the unopened pouch to protect from moisture until the time of reconstitution'. After reconstitution, and as indicated in the SmPC (section 6.3), the reconstituted suspension can be stored below below 25°C for up to 28 days after the date the suspension is prepared. The suspension should not be refrigerated or frozen.

## 2.4.3.5. Adventitious agents

No excipients derived from animal or human origin have been used.

## 2.4.4. Discussion on chemical, pharmaceutical and biological aspects

Information on development, manufacture and control of the active substance and finished product has been presented in a satisfactory manner.

During the procedure, major objections were raised related to the risk of presence of nitrosamines (see above for details). A comprehensive risk assessment and results of confirmatory testing were presented, and the information was sufficient to resolve the major objections raised.

The results of tests carried out indicate consistency and uniformity of important product quality characteristics, and these in turn lead to the conclusion that the product should have a satisfactory and uniform performance in clinical use.

## 2.4.5. Conclusions on the chemical, pharmaceutical and biological aspects

The quality of this product is considered to be acceptable when used in accordance with the conditions defined in the SmPC. Physicochemical and biological aspects relevant to the uniform clinical performance of the product have been investigated and are controlled in a satisfactory way.

<div style=\"page-break-after: always\"></div>

## 2.4.6. Recommendations for future quality development

Not applicable.

## 2.5. Non-clinical aspects

## 2.5.1. Introduction

Mirabegron is a first-in-class, selective human beta 3-adrenoreceptor agonist, producing a relaxation of the detrusor smooth muscle during the fill-void cycle, without interfering with the voiding contraction. The nonclinical data package has been previously assessed and approved for the symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome (EMEA/H/C/002388/0000, approved 20 Dec 2012).

For this new indication (paediatric population), an abridged non-clinical development program has been presented, which includes juvenile animal studies. Also, an updated ERA has been submitted for mirabegron.

## 2.5.2. Pharmacokinetics

Analysis of the samples after repeat dose administration of mirabegron for 2 or 13 weeks in juvenile animals (PND10), showed Cmax and AUC24 values of mirabegron increased with increasing dose levels throughout the dosing period. No sex differences were observed. Exposure levels (Cmax and AUC24) were high on initial day of treatment (PND 10), decreasing after two weeks of treatment (day 14 and 12 in the 2-week and 13-week studies, respectively). In the longer study (13 weeks), an initial decrease in exposure values was reported until day 12 of treatment (PND 21), followed by an increase of exposure levels noted on days 36 and 91, indicating an effect of weaning in juvenile animals.

No additional pharmacokinetic studies (distribution, metabolism, excretion or drug interactions) have been conducted for this application.

## 2.5.3. Toxicology

## 2.5.3.1. Reproductive and developmental toxicity

Mating, fertility and embryo-foetal development were assessed in the 13-week repeat-dose toxicity study in juvenile rats.

Comparison of exposure levels between adults (initial indication) and juvenile animals (current variation) revealed higher exposure in the latter population. This aspect was attributed to the mortality observed in the DRF study at 100 mg/Kg/day. According to the calculation provided by the applicant, exposure levels at this dose level at day 1 (80155.9 and 74445.6 ng·hr/mL in males and females, respectively) are approximately 400-fold higher than the projected human systemic exposure of children. In addition, the highest dose level tested in adult rats (300 mg/kg/day) showed 61% and 52% of the juvenile rat AUC24 in males and females, respectively (48922 and 39043 ng·hr/mL for males and females, respectively).

<div style=\"page-break-after: always\"></div>

In the definitive study (13-week), animals treated at 30 mg/Kg/day showed alteration of body weight and food consumption; increases in AST and ALT; increases in urine volume; decrease in the specific gravity in females; alterations of organ weights, such as thymus, heart, submandibular gland, liver and ovary; as well as decreased lipid droplets for the agonistic activity against beta-3-adrenergic receptor. Mid dose-treated (10 mg/Kg/day) animals also showed suppressed body weight (females); and decreased lipid droplets in the brown and white adipose tissues. After recovery period, all findings were considered reversible, except ovary weight alteration.

## 2.5.3.2. Other toxicity studies

The results of the potential effects of mirabegron on hormonal plasma levels in rats after 2 weeks of treatment, showed effects on corticosterone levels (increased) in males in the 30 and 100 mg/kg groups. Also, mirabegron decreased plasma leptin concentration throughout the dosing period and dose-dependently in the 30 and 100 mg/kg groups.

## 2.5.4. Ecotoxicity/environmental risk assessment

For this variation (paediatric population), the company presents an updated ERA based on the opinion received from CHMP Scientific Advice (EMA/SA/61504). The daily dose stays the same (i.e., 50 mg/day), and the default Fpen is maintained. Therefore, the exposure concentration stays the same. The OECD 106 study was not repeated with two soils.

## Summary of main study results

| Substance (INN/Invented Name): mirabegron                           | Substance (INN/Invented Name): mirabegron                           | Substance (INN/Invented Name): mirabegron                           | Substance (INN/Invented Name): mirabegron                           |
|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|
| CAS-number (if available): 223673-61-8                              | CAS-number (if available): 223673-61-8                              | CAS-number (if available): 223673-61-8                              | CAS-number (if available): 223673-61-8                              |
| PBT screening                                                       |                                                                     | Result                                                              | Conclusion                                                          |
| Bioaccumulation potential- log K ow                                 | OECD107                                                             | ≤2.0                                                                | Potential PBT (N)                                                   |
| PBT-assessment                                                      | PBT-assessment                                                      | PBT-assessment                                                      | PBT-assessment                                                      |
| Parameter                                                           | Result relevant for conclusion                                      |                                                                     | Conclusion                                                          |
| Bioaccumulation                                                     | log K ow                                                            | -0.4 (pH 4); 0.3 (pH 7); 2.0 (pH 10)                                | not B                                                               |
| Persistence                                                         | DT50 (sediment)                                                     | >180 d at 12 ºC                                                     | vP                                                                  |
| Toxicity                                                            | NOEC (daphnia)                                                      | NOEC = 1.01 mg/L                                                    | not T                                                               |
| PBT-statement:                                                      | While very persistent, mirabegron is not considered as PBT nor vPvB | While very persistent, mirabegron is not considered as PBT nor vPvB | While very persistent, mirabegron is not considered as PBT nor vPvB |
| Phase I                                                             | Phase I                                                             | Phase I                                                             | Phase I                                                             |
| Calculation                                                         | Value                                                               | Unit                                                                | Conclusion                                                          |
| PEC surfacewater , default or refined (e.g. prevalence, literature) | 0.25                                                                | µ g/L                                                               | > 0.01 threshold (Y)                                                |
| Other concerns (e.g. chemical                                       |                                                                     |                                                                     | (N)                                                                 |

<div style=\"page-break-after: always\"></div>

| class)                                                           |                                                |                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                             |
|------------------------------------------------------------------|------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Phase II Physical-chemical properties and fate                   | Phase II Physical-chemical properties and fate | Phase II Physical-chemical properties and fate                                                                                                                                                                                                                                                               | Phase II Physical-chemical properties and fate                                                                                                                                                                                                                                                               | Phase II Physical-chemical properties and fate                                                                                                                                                                                                                                                               | Phase II Physical-chemical properties and fate                                                                                                                              |
| Study type                                                       | Test protocol                                  | Results                                                                                                                                                                                                                                                                                                      | Results                                                                                                                                                                                                                                                                                                      | Results                                                                                                                                                                                                                                                                                                      | Remarks                                                                                                                                                                     |
| Adsorption-Desorption                                            | OECD 106                                       | 4 soils KFOCads = 749 L/kg (Sandy clay loam) KFOCads = 4230 L/kg (Clay loam) KFOCads = 1250 L/kg (Loamy sand) KFOCads = 29500 L/kg (Loamy sand) 1 sludge                                                                                                                                                     | 4 soils KFOCads = 749 L/kg (Sandy clay loam) KFOCads = 4230 L/kg (Clay loam) KFOCads = 1250 L/kg (Loamy sand) KFOCads = 29500 L/kg (Loamy sand) 1 sludge                                                                                                                                                     | 4 soils KFOCads = 749 L/kg (Sandy clay loam) KFOCads = 4230 L/kg (Clay loam) KFOCads = 1250 L/kg (Loamy sand) KFOCads = 29500 L/kg (Loamy sand) 1 sludge                                                                                                                                                     | Medium to very high potential for binding to soil; low potential for binding to sludge; degree of irreversibility to the adsorption.                                        |
| Ready Biodegradability Test                                      | OECD 301                                       | Mean O2 consumption Day 19: 10%                                                                                                                                                                                                                                                                              | Mean O2 consumption Day 19: 10%                                                                                                                                                                                                                                                                              | Mean O2 consumption Day 19: 10%                                                                                                                                                                                                                                                                              | Not readily biodegradable                                                                                                                                                   |
| Aerobic and Anaerobic Transformation in Aquatic Sediment systems | OECD 308                                       | Empirical 20 ºC DT 50 , water = 1.1-1.2 days DT 50 , sediment = 20-111 days DT 50 , system = 1.2-1.3 days Empirical 12 ºC DT 50 , water = 2.3-2.5 days DT 50 , sediment = 42.5-235.8 days DT 50 , system = 2.5-2.8 days Metabolites: Polar component: 15.2 %AR Component 2: 12.7 %AR %shifting to sediment = | Empirical 20 ºC DT 50 , water = 1.1-1.2 days DT 50 , sediment = 20-111 days DT 50 , system = 1.2-1.3 days Empirical 12 ºC DT 50 , water = 2.3-2.5 days DT 50 , sediment = 42.5-235.8 days DT 50 , system = 2.5-2.8 days Metabolites: Polar component: 15.2 %AR Component 2: 12.7 %AR %shifting to sediment = | Empirical 20 ºC DT 50 , water = 1.1-1.2 days DT 50 , sediment = 20-111 days DT 50 , system = 1.2-1.3 days Empirical 12 ºC DT 50 , water = 2.3-2.5 days DT 50 , sediment = 42.5-235.8 days DT 50 , system = 2.5-2.8 days Metabolites: Polar component: 15.2 %AR Component 2: 12.7 %AR %shifting to sediment = | Mirabegron is very persistent. The trigger value of 10% exceeded - a sediment-water Chironomid Toxicity test triggered. Transformation products are potentially persistent. |
| Phase IIa Effect studies                                         | Phase IIa Effect studies                       | Phase IIa Effect studies                                                                                                                                                                                                                                                                                     | Phase IIa Effect studies                                                                                                                                                                                                                                                                                     | Phase IIa Effect studies                                                                                                                                                                                                                                                                                     | Phase IIa Effect studies                                                                                                                                                    |
| Study type                                                       | Test protocol                                  | Endpoint                                                                                                                                                                                                                                                                                                     | value                                                                                                                                                                                                                                                                                                        | Unit                                                                                                                                                                                                                                                                                                         | Remarks                                                                                                                                                                     |
| Algae, Growth Inhibition Test/ Species                           | OECD 201                                       | NOEC                                                                                                                                                                                                                                                                                                         | 4.34                                                                                                                                                                                                                                                                                                         | µg/L                                                                                                                                                                                                                                                                                                         | Pseudokirchneriell a subcapitata                                                                                                                                            |
| Daphnia sp . Reproduction Test                                   | OECD 211                                       | NOEC                                                                                                                                                                                                                                                                                                         | 1.01                                                                                                                                                                                                                                                                                                         | µg/L                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                             |
| Fish, Early Life Stage Toxicity Test/ Species                    | OECD 210                                       | NOEC                                                                                                                                                                                                                                                                                                         | 10.1                                                                                                                                                                                                                                                                                                         | µg/L                                                                                                                                                                                                                                                                                                         | Pimephales promelas                                                                                                                                                         |
| Activated Sludge, Respiration Inhibition Test                    | OECD 209                                       | EC                                                                                                                                                                                                                                                                                                           | 100                                                                                                                                                                                                                                                                                                          | µg/L                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                             |
| Phase IIb Studies                                                | Phase IIb Studies                              | Phase IIb Studies                                                                                                                                                                                                                                                                                            | Phase IIb Studies                                                                                                                                                                                                                                                                                            | Phase IIb Studies                                                                                                                                                                                                                                                                                            | Phase IIb Studies                                                                                                                                                           |
| Sediment dwelling organism                                       | OECD218                                        | NOEC LOEC NOEC OC10                                                                                                                                                                                                                                                                                          | 1092 4368                                                                                                                                                                                                                                                                                                    | mg/ kg dry                                                                                                                                                                                                                                                                                                   | Chironomus riparius                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

| sedi men t weig ht   |
|----------------------|

## 2.5.5. Discussion on non-clinical aspects

Two juvenile animal studies (2-week DRF and 13-week pivotal) were conducted to support the new indication in paediatric population.

In terms of potential effects on hormonal plasma levels, the results after 2 weeks of treatment showed variation of corticosterone levels (increased) in males in the 30 and 100 mg/kg groups. Also, mirabegron decreased plasma leptin concentration throughout the dosing period and dose-dependently (in the 30 and 100 mg/kg groups). Findings reported in the juvenile animal studies were discussed by the applicant, concluding that most of them are also reported in adult animals (not juvenile specific) and reversible, and in most cases at systemic exposures above the human systemic exposure projected for children. No effects were reported in developmental milestones, mating ability or embryo-foetal development.

Conclusions from the juvenile toxicity study and conclusions from leptin study (178-TX-061) (reduced plasma leptin levels in rats) as well as conclusions from the juvenile toxicity study (Study 178-TX-055) and results with regards to gonadotropic hormones (Study 178-TX-059) in adult rats has also been added to section 5.3 of the SmPC. Mirabegron had no discernible effect on gonadotropic or sex steroid hormone levels.

Analysis of the samples from the 13-week study in juvenile animals (PND 10), showed an initial decrease in exposure values reported until day 12 of treatment (PND 21), followed by an increase of exposure levels noted on days 36 and 91, indicating an effect of weaning in juvenile animals. The Applicant notes that this effect may be caused at least in part by age-related changes in drug metabolizing enzymes such as CYP 3A in the rat liver between prior to and after weaning. No effect on physical development or sexual maturation was shown. Mirabegron administration from weaning through sexual maturation had no effect on mating ability, fertility or embryofoetal development. Mirabegron administration increased lipolysis and food consumption in juvenile rats. This has been added to 5.3 of the SmPC.

## Environmental Risk Assessment

Based on the updated environmental risk assessment in this report, the introduction of a new population will not lead to a significant increase in environmental exposure.

Updated ERA does not modify the conclusions obtained in the initial application.

## 2.5.6. Conclusion on the non-clinical aspects

The data submitted in the non-clinical part of the dossier are acceptable for this type of application and no concerns are raised from a non-clinical perspective. The updated environmental risk assessment is accepted and it is it is considered that the use in the new indication will not lead to a significant increase in environmental exposure of mirabegron. Considering the above data, mirabegron is not expected to pose a risk to the environment.

<div style=\"page-break-after: always\"></div>

## 2.6. Clinical aspects

## 2.6.1. Introduction

## GCP aspects

The Clinical trials were performed in accordance with GCP as claimed by the MAH.

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

## · Tabular overview of clinical studies

| Type of Study and Study Identifier   | Objective(s) of the Study                                                                                                                                                                                                                                                                                                                                                                                                                                          | Study Design and Type of Control                                                                                                                                                                                       | Test Product(s); Dosage Regimen; Route of Administration                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Number of Subjects                                           | Healthy Subjects or Diagnosis of Patients                                             | Duratio n of Treatme nt                                                    | Study Status; Type of Report   |
|--------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------|---------------------------------------------------------------------------------------|----------------------------------------------------------------------------|--------------------------------|
| Phase 1 Studies                      | Phase 1 Studies                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Phase 1 Studies                                                                                                                                                                                                        | Phase 1 Studies                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Phase 1 Studies                                              | Phase 1 Studies                                                                       | Phase 1 Studies                                                            | Phase 1 Studies                |
| Relative bioavailabilit y 178-CL-201 | Primary: • To assess the bioavailability of 50 mg mirabegron oral suspension formulation A relative to that of the 50 mg mirabegron modified release tablet when dosed under fasted conditions. Secondary: • To assess the effect of food on the pharmacokinetic s of 50 mg mirabegron oral suspension formulation A. • To evaluate the safety and tolerability of single doses of 50 mg mirabegron oral suspension formulation A under fed and fasted conditions. | This was a phase 1, openlabel, randomized, single dose, 4period crossover clinical study. Subjects were randomized to 1 of the 4 treatment sequences. Treatments were separated by at least 14 days of washout period. | Treatment A: 50 mg mirabegron oral suspension formulation A (2 mg/mL) administered under fasted conditions. Treatment B: 50 mg mirabegron oral suspension formulation A (2 mg/mL) administered under fed conditions. Treatment C: 50 mg mirabegron modified release tablets administered under fasted conditions. Treatment D: 50 mg mirabegron modified release tablets administered under fed conditions. For assessment of the food effect, subjects received a standardized light breakfast (dosing 30 minutes after completion of the light breakfast) and a light lunch 2 h after dosing rather than a high fat breakfast because for mirabegron tablets, the impact of a light breakfast on the exposure was shown to have been larger than that of a high fat breakfast | Enrolled: 25 adults Treated: 25 adults Complet ed: 22 adults | Healthy adult subjects (young male and female subjects aged 18 to less than 26 years) | A single dose on 4 occasio ns separated by at least 14-day washout periods | Complet e; [Full]              |

<div style=\"page-break-after: always\"></div>

| Type of Study and Study Identifier                 | Objective(s) of the Study                                                                                                                                                                                                                                                                                                                                                                       | Study Design and Type of Control                                                                                                                                                                                                                                                                                                                                                                          | Test Product(s); Dosage Regimen; Route of Administration                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Number of Subjects                                                                                                                               | Healthy Subjects or Diagnosis of Patients                                                                                                          | Duratio n of Treatme nt   | Study Status; Type of Report   |
|----------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------|--------------------------------|
|                                                    |                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                           | Oral administration                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                  |                                                                                                                                                    |                           |                                |
| Single ascending dose Pharmacokine tics 178-CL-202 | Primary: • To evaluate the pharmacokinetic s of mirabegron prolongedreleas e tablets after single-dose administration at different dose levels in children and adolescents with NDO or OAB. Secondary: • To evaluate the safety and tolerability of mirabegron prolongedreleas e tablets after single-dose administration at different dose levels in children and adolescents with NDO or OAB. | This was a phase 1, multicenter, open-label, single ascending dose study in pediatric patients with NDO/OAB. 5 cohorts, 2 dose groups (low-dose [cohort 1 adolescents and cohort 2 children] and highdose [cohort 3 adolescents and cohort 4 and 5 in children]) with targeted exposures equivalent to 25 and 50 mg in adults at steady state. Doses were administere d after a washout period of 12 days | Cohort 1: male and female adolescents (12 to less than 18 years); low dose, fed. Cohort 2: male and female children (5 to less than 12 years); low dose, fed. Cohort 3: male and female adolescents (12 to less than 18 years); high dose, fed Cohort 4: male and female children (5 to less than 12 years); high dose, fed Cohort 5: male and female children (5 to less than 12 years); high dose, fasted Low dose: Cohort 1 (adolescents) and Cohort 2 (children): 25 mg tablet (body weight between 20.0 to < 55.0 kg 50 mg tablet (body weight ≥ 55.0 kg) High dose: Cohort 3 (adolescents), Cohorts 4 and 5 (children): 50 mg tablet (body weight 20.0 to < 40.0 kg) 75 mg tablet (body weight ≥ 40.0 kg) For food-effect assessment, the first 4 cohorts were dosed under fed conditions i.e., within 1 h after completion of the light breakfast. The last cohort was dosed under fasting conditions | Enrolled: 34 (15 adole scents and 19 childr en) Treated: 34 (15 adole scents and 19 childr en) Complet ed: 34 (15 adole scents and 19 childr en) | Male and female adolescen ts aged 12 to less than 18 years with NDO or OAB. Male and female children aged 5 to less than 12 years with NDO or OAB. | Single dose               | Complet e; [Full]              |
| Single dose Pharmacokine tics 178-CL-203           | Primary: • To evaluate the pharmacokinetic s of mirabegron                                                                                                                                                                                                                                                                                                                                      | This was a phase 1, multicenter, open-label, single-dose                                                                                                                                                                                                                                                                                                                                                  | Mirabegron oral suspension formulation B (2 mg/mL).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Enrolled: 9 childre n                                                                                                                            | Male and female children aged 3 to less than                                                                                                       | Single dose               | Complet e; [Full]              |

<div style=\"page-break-after: always\"></div>

| Type of Study and Study Identifier   | Objective(s) of the Study                                                                                                                                                                                                                                                                                                                                                            | Study Design and Type of Control                                                                                                                                                                                        | Test Product(s); Dosage Regimen; Route of Administration                                                                                                                                                                                                                                                                                             | Number of Subjects                                           | Healthy Subjects or Diagnosis of Patients                             | Duratio n of Treatme nt                                                        | Study Status; Type of Report   |
|--------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------|-----------------------------------------------------------------------|--------------------------------------------------------------------------------|--------------------------------|
|                                      | oral suspension after single dose administration in children with NDO or OAB. Secondary: • To evaluate the safety and tolerability of mirabegron oral suspension after single dose administration in children with NDO or OAB. • To evaluate the acceptability and palatability of mirabegron oral suspension after single dose administration in children with                      | study in pediatric patients with NDO or OAB.                                                                                                                                                                            | Single doses were administered according to each patient's weight, to achieve a target exposure equivalent to that following 50 mg prolonged release tablets given once daily to adults at steady state. Oral administration                                                                                                                         | Treated: 9 childre n Complet ed: 9 childre n                 | 12 years with NDO or OAB.                                             |                                                                                |                                |
| Bioavailabilit y 178-CL-208          | NDO or OAB. Primary: • To assess the bioavailability of 88 mg mirabegron oral suspension (8 mg/mL) relative to that of 88 mg mirabegron oral suspension (2 mg/mL) when dosed under fasted conditions. Secondary: • To assess the effect of food on the pharmacokinetic s of 88 mg mirabegron oral suspension (8 mg/mL). • To evaluate the safety and tolerability of single doses of | This was a phase 1, openlabel, randomized, single dose, 3period crossover clinical study. Subjects were randomized to 1 of the 6 treatment sequences. Treatments were separated by washout periods of at least 14 days. | Treatment A: 88 mg mirabegron oral suspension formulation C (8 mg/mL) administered under fasted conditions. Treatment B: 88 mg mirabegron oral suspension formulation B (2 mg/mL) administered under fasted conditions. Treatment C: 88 mg mirabegron oral suspension formulation C (8 mg/mL) administered under fed conditions. Oral administration | Enrolled: 24 adults Treated: 24 adults Complet ed: 24 adults | Healthy adult subjects (male and female subjects aged 18 to 45 years) | A single dose on 3 occasio ns separated by washout periods of at least 14 days | Complet e; [Full]              |

<div style=\"page-break-after: always\"></div>

| Type of Study and Study Identifier   | Objective(s) of the Study                                                                                                                                                                                                                                                                                                                                               | Study Design and Type of Control                                                                                    | Test Product(s); Dosage Regimen; Route of Administration                                                                                                                                                                                                                                                                                                                                                                          | Number of Subjects                                                                                                                             | Healthy Subjects or Diagnosis of Patients                                                                                                                                                                            | Duratio n of Treatme nt   | Study Status; Type of Report    |
|--------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------|---------------------------------|
|                                      | 88 mg mirabegron oral suspension.                                                                                                                                                                                                                                                                                                                                       |                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                |                                                                                                                                                                                                                      |                           |                                 |
| Phase 3 Study                        | Phase 3 Study                                                                                                                                                                                                                                                                                                                                                           | Phase 3 Study                                                                                                       | Phase 3 Study                                                                                                                                                                                                                                                                                                                                                                                                                     | Phase 3 Study                                                                                                                                  | Phase 3 Study                                                                                                                                                                                                        | Phase 3 Study             | Phase 3 Study                   |
| Efficacy/safet y 178-CL-206A         | Primary: • To evaluate the efficacy of mirabegron after multiple-dose administration in the pediatric population. Secondary: • To evaluate the safety and tolerability of mirabegron after multiple-dose administration in the pediatric population. • To evaluate the pharmacokinetic s of mirabegron after multiple- dose administration in the pediatric population. | This was a phase 3, multicenter, openlabel, baseline controlled dosetitration study in pediatric patients with NDO. | Mirabegron tablets, strengths 25 mg and 50 mg. Mirabegron oral suspension formulation C (8 mg/mL). The initial dose of mirabegron was based on the patient's weight, and was targeted to achieve steady-state exposures similar to those of adults administered the mirabegron 25 mg tablet once daily (PED25). At week 2, 4 or 8, patients were uptitrated to PED50 based on given dose titration criteria. Oral administration. | Enrolled: 91 (56 children and 35 adolesce nts)/ Treated: 86 (55 children and 31 adolesce nts) Complet ed: 70 (43 children and 27 adolesce nts) | Male and female children aged 3 to less than 12 years with NDO on clean intermitte nt catheteriz ation. Male and female adolescen ts aged 12 to less than 18 years with NDO on clean intermitte nt catheteriz ation. | 52 weeks                  | Complete, [Full] [Amendme nt 1] |

In the mirabegron NDO pediatric development program, efficacy and safety were assessed in a phase 3 study (178-CL-206A) in which 86 pediatric patients with NDO using CIC received daily doses of mirabegron, as oral suspension or prolonged-release tablets, for up to 52 weeks. Supportive exposure and safety data were obtained from 4 phase 1 single-dose studies in 17 pediatric patients with NDO and 26 pediatric patients with OAB (178-CL-202 and 178-CL-203) and 49 healthy adult subjects (178-CL-201 and 178-CL-208).

## 2.6.2. Clinical pharmacology

## 2.6.2.1. Pharmacokinetics

## Absorption

After oral administration of mirabegron in healthy volunteers, mirabegron is absorbed to reach peak plasma concentrations (Cmax) between 3 and 4 hours. The absolute bioavailability increased from 29% at a dose of 25 mg to 35% at a dose of 50 mg. Mean Cmax and AUC increased more than dose proportionally over the dose range. In the overall population of males and females, a 2-fold increase in dose from 50 mg to 100 mg mirabegron increased Cmax and AUCtau by approximately 2.9- and 2.6-fold, respectively, whereas a 4-fold increase in dose from 50 mg to 200 mg mirabegron increased Cmax and AUCtau by approximately 8.4- and

<div style=\"page-break-after: always\"></div>

6.5-fold. Steady state concentrations are achieved within 7 days of once daily dosing with mirabegron. After once daily administration, plasma exposure of mirabegron at steady state is approximately double that seen after a single dose.

Co-administration of a 50 mg tablet with a high-fat meal reduced mirabegron Cmax and AUC by 45% and 17%, respectively. A low-fat meal decreased mirabegron Cmax and AUC by 75% and 51%, respectively. In the phase 3 studies, mirabegron was administered with or without food and demonstrated both safety and efficacy. Therefore, mirabegron can be taken with or without food at the recommended dose.

## Distribution

Mirabegron volume of distribution was relatively large and increased with increasing body weight in accordance with allometric principles based on population pharmacokinetic analysis. Age, sex and patient population had no impact on volume of distribution after accounting for potential differences in body weight. In general, the individual predictions showed that relative to adolescents, children had smaller Vz/F values due to smaller body weight; however, the individual predictions for Vz/F were also influenced by the dose and formulation effects on relative bioavailability.

## Elimination

Mirabegron clearance was predicted to increase with increasing body weight in accordance with allometric principles. Mirabegron clearance was also predicted to increase in patients with OAB relative to patients with NDO. The apparent clearance parameter was impacted significantly by dose, formulation and food effects on relative bioavailability. Values of apparent clearance were highly variable but generally similar between children and adolescents, despite body weight differences, because of these effects on bioavailability.

Metabolism of mirabegron has been studied in vitro and in healthy human subjects.

## Pharmacokinetic data analysis

To support the new paedriatic formulation application, the applicant has submitted two bioavailabity studies for Betmiga comparing different formulations of the oral suspension and the oral suspension against the already approved prolonged release tablets. The mirabegron oral suspension of formulation C is the proposed formulation for commercialization. The prolonged-release granules of formulation C, are reconstituted with water to prepare an oral suspension with a concentration of 8 mg/mL.

Furthermore, the Applicant has performed comparative dissolution profiles between the different new formulations.

The following relative bioavailability studies and the influence of food have been performed with the new intended to commercialise formulations for paediatric population:

- Study 178-CL-201: To assess the bioavailability of 50 mg mirabegron oral suspension formulation A relative to that of the 50 mg mirabegron modified release tablet when dosed under fasted conditions.

This was a phase 1, single dose, 4-period crossover study to assess the bioavailability of a mirabegron oral suspension relative to the mirabegron prolonged release tablet and to assess the effect of food on the pharmacokinetics of mirabegron oral suspension in healthy young male and female subjects with a washout period of 14 days.

- o Treatment A: 50 mg mirabegron oral suspension administered under fasted conditions.
- o Treatment B: 50 mg mirabegron oral suspension administered under fed conditions.

<div style=\"page-break-after: always\"></div>

- o Treatment C: 50 mg mirabegron modified release tablets administered under fasted conditions.
- o Treatment D: 50 mg mirabegron modified release tablets administered under fed conditions.

In all subjects, 22 blood samples were drawn at the following time points: pre-dose, 0.50, 1.00, 1.50, 2.00, 2.50, 3.00, 4.00, 5.00, 6.00, 8.00, 12.00, 16.00, 24.00, 36.00, 48.00, 72.00, 96.00, 120.00, 144.00, 192.00 and 240.00 hours after drug administration.

A total of 25 healthy subjects (11 male and 14 female) were included in this clinical study as per the inclusion and exclusion criteria. Seven subjects were randomized to treatment sequence ACBD and 6 subjects were randomized to each of the remaining 3 treatment sequences (BADC, CDAB and DBCA).

A summary of mirabegron pharmacokinetic parameters for both formulations (oral suspension of formulation A and prolonged-release tablet) and fasted/fed conditions is reported:

|                                       | n=23                             | n=23         | n=23              | n=23             | n=23           |
|---------------------------------------|----------------------------------|--------------|-------------------|------------------|----------------|
| Treatment                             | tmax (h)                         | Cmax (ng/mL) | AUClast (ng-h/mL) | AUCinf (ng-h/mL) | t1/2 (h)       |
| Oral Suspension FormulationAt)-Fasted | 4.080 (2.00 - 5.33)12.19 (9.328) |              | 166.5 (82.76)     | 185.2 (87.47)    | 47.89 (14.15)  |
| Oral Suspension (FormulationAt)-Fed   | 3.000 (1.03 -12.0)2.540 (1.239)  |              | 56.55 (24.22)     | 76.37 (27.80)§   | 46.25 (17.12)s |
| Tablet-Fasted                         | 4.020 (1.98 -5.03)35.15 (16.26)  |              | 370.1 (150.8)     | 391.3 (151.9)    | 50.30 (12.01)  |
| Tablet-Fed                            | 3.020 (1.98  6.00)15.45 (9.682)  |              | 154.5 (82.23)     | 172.3 (83.92)    | 50.02 (17.60)  |

Statistical assessment of the bioavailability between the oral suspension A compared with the prolonged-release tablets is reported below:

| Parameter        |   GeometrieLS Mean for SuspensionFasted |   Geometrie L.S Mlean for Tablets Fasted |   Geometrie LS Mean Ratio (%)t | 90%CIofRatio (%)t   |
|------------------|-----------------------------------------|------------------------------------------|--------------------------------|---------------------|
| AUCinr (ng*h/mL) |                                 169.7   |                                    353.9 |                          47.95 | (40.91, 56.21)      |
| AUCisi (ng*h/mL) |                                 151.4   |                                    336   |                          45.06 | (38.46, 52.80)      |
| (ng/mL)          |                                   9.903 |                                     32.2 |                          30.76 | (23.76, 39.81)      |

The statistical effect of food is described in the following table:

| Parameter        |   GeometrieLS Mean for Suspension Fed |   GeometrieL.S Mean for Suspension Fasted |   GeometrieLS Mean Ratio (%)t | 90%CIofRatio (%)t   |
|------------------|---------------------------------------|-------------------------------------------|-------------------------------|---------------------|
| AUCint (ng*h/mL) |                                68.07  |                                   169.7   |                         40.12 | (33.95,47.41)       |
| AUCist (ng*h/mL) |                                50.79  |                                   151.4   |                         33.54 | (28.68, 39.23)      |
| (ng/mL)          |                                 2.218 |                                     9.903 |                         22.4  | (17.35,28.92)       |

<div style=\"page-break-after: always\"></div>

The statistical analysis shows that the bioavailability of the oral suspension A was lower than the prolonged-release tablet under fasted conditions and that the oral suspension A under fed conditions relative to fasted conditions was decreased which is considered acceptable as the efficacy was demonstrated for both formulations in the phase III study 178-CL-203.

The safety profile of both products seems to be comparable although the design was not powered to compare the safety profile. No difference in the safety profile can be anticipated.

- Study 178-CL-208: To assess the bioavailability of 88 mg mirabegron oral suspension (8 mg/mL) relative to that of 88 mg mirabegron oral suspension (2 mg/mL) when dosed under fasted conditions.

This was a phase 1, single dose, 3-period crossover study to assess the bioavailability of a mirabegron oral suspension of 8 mg/mL mirabegron (88 mg) relative to the oral suspension of 2 mg/mL mirabegron and to assess the effect of food on the pharmacokinetics of the oral suspension of 8 mg/mL mirabegron (88 mg) in healthy male and female adult subjects with a washout period of 14 days.

As Study 178-CL-201 revealed that the relative bioavailability of the 2 mg/mirabegron oral suspension was 46% of the tablet under fasted conditions. To compensate for the 46% relative bioavailability of the oral suspension, the dose needed to be almost doubled. The available population-pharmacokinetic-model predicted that a dose of 88 mg oral suspension under fasted conditions would result in an exposure comparable to that following a dose of a 50 mg tablet.

- Treatment A: 88 mg mirabegron oral suspension (8 mg/mL) administered under fasted conditions.
- Treatment B: 88 mg mirabegron oral suspension (2 mg/mL) administered under fasted conditions.
- Treatment C: 88 mg mirabegron oral suspension (8 mg/mL) administered under fed conditions.

In all subjects, 22 blood samples were drawn at the following time points: pre-dose, 0.50, 1.00, 1.50, 2.00, 2.50, 3.00, 4.00, 5.00, 6.00, 8.00, 12.00, 16.00, 24.00, 36.00, 48.00, 72.00, 96.00, 120.00, 144.00, 192.00 and 240.00 hours after drug administration

## Identity of Investigational products (YM178)

Mirabegron oral suspension 8 mg/mL: Batch number: BX1006391. Expiration date: Mar 2017.

Mirabegron oral suspension 2 mg/mL: Batch number: BX1006355. Expiration date: Mar 2017.

A total of 24 healthy subjects (13 male and 11 female) were included in this clinical study as per the inclusion and exclusion criteria. Four subjects were randomized to each treatment sequence ABC, ACB, BAC, BCA, CAB and CBA.

Statistical assessment of the bioavailability between the oral suspension 8 mg/mL in fasted state compared with oral suspension 2 mg/mL is reported below:

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Parameter         | ReferenceFormulation (2 mg/mL)   | ReferenceFormulation (2 mg/mL)   | TestFormulation (8 mg/mL)   | TestFormulation (8 mg/mL)   | Geometric LS Mean Ratio   | 90% CI of       |
|-------------------|----------------------------------|----------------------------------|-----------------------------|-----------------------------|---------------------------|-----------------|
|                   | n                                | Geometric LS Mean                | n                           | Geometric LS Mean           | (%)t                      | Ratiot          |
| AUCunr (ng-h/mL)  | 23                               | 251                              | 24                          | 253                         | 100.58                    | (90.92, 111.25) |
| AUCiast (ng-h/mL) | 23                               | 232                              | 24                          | 234                         | 100.94                    | (90.63,112.42)  |
| Cmx (ng/mL)       | 23                               | 11.3                             | 24                          | 12.1                        | 106.74                    | (84.24, 135.24) |

The statistical effect of food for the 8 mg/mL oral suspension is described in the following table:

<!-- image -->

| Parameter        | ReferenceFormulation (8 mg/mL Fasted)   | ReferenceFormulation (8 mg/mL Fasted)   | TestFormulation (8 mg/mL Fed)   | TestFormulation (8 mg/mL Fed)   | Geometric LS Mean Ratio (%)t   | 90% CI of      |
|------------------|-----------------------------------------|-----------------------------------------|---------------------------------|---------------------------------|--------------------------------|----------------|
|                  | n                                       | Geometric LS Mean                       | n                               | Geometric LS Mean               |                                | Ratio (%)t     |
| AUCinf ng*h/mL)  | 24                                      | 253                                     | 24                              | 138                             | 54.83                          | (49.64, 60.55) |
| AUCiust ng-h/mL) | 24                                      | 234                                     | 24                              | 120                             | 51.19                          | (46.04, 56.91) |
| mx (ng/mL)       | 24                                      | 12.1                                    | 24                              | 4.46                            | 36.91                          | (29.23, 46.61) |

The comparison between 8 mg/mL and 2 mg/mirabegron oral suspensions under fasted conditions based, on the ratio of geometric means showed that the AUCinf and AUClast of the 8 mg/mL mirabegron oral suspension amounted to 100.58% and 100.94% of the corresponding AUCs estimated for the 2 mg/mL mirabegron oral suspension. Estimated 90% CIs of the ratio were (90.92%, 111.25%) for AUCinf and (90.63%, 112.42%) for AUClast. The relative bioavailability of the 8 mg/mL mirabegron oral suspension in terms of Cmax was 106.74% of the 2 mg/mL mirabegron oral suspension with estimated 90% CIs of the ratio equal to (84.24%, 135.24%). The range of individual values for AUCinf, AUClast and Cmax for the 2 formulations overlapped. The 2 treatments also shared a similar time to peak tmax) as well as similar elimination trends (t½, CL/F, Vz/F).

The effect of food was demonstrated for 8 mg/mL oral suspension obtaining a higher bioavailability when administered without food that could be observed for Cmax, AUCinf and AUClast. This food effect was already known from mirabegron and is in line with the food effects observed for the 50 mg prolonged release tablets.

## Pharmacokinetics in target population

## Final population PK model

Parameters for the covariate model (i.e., base model plus the effect of OAB on CL/F) were generally estimated with good precision, however, a key exception was the exponent parameter for the effect of dose on relative bioavailability ( θ11). The relative standard error was 64%. It was hypothesized that the dose range included in these pediatric studies may not have been wide enough to fully characterize this component of the model. As such, this parameter was fixed to the previously identified value for the effect of dose on F in adult patients receiving mirabegron [178-PK-204]. Fixing this parameter to the value obtained in adults had no meaningful impact on the objective function value further supporting this hypothesis.

<div style=\"page-break-after: always\"></div>

Patient population (OAB, relative to the typical patient with NDO) was tested on clearance and central volume of distribution in the pediatric population pharmacokinetic model. OAB on clearance resulted in a statistically significant improvement and was added to the base model, which included body weight.

Compared to a reference subject (patient with NDO weighing 50 kg and receiving a 50 mg once daily tablet dose in the fed state), a patient with OAB at the same weight, fed state, formulation and dose was predicted to have a 30.7% reduction in steady-state AUCtau and a 21.2% reduction in Cmax.

Table 1 - Parameter Estimates for Best Model

| Parameter                                       | Notation                 | Estimate                 | Standard Error           |
|-------------------------------------------------|--------------------------|--------------------------|--------------------------|
| FixedEffects                                    |                          |                          |                          |
| TransitRateConstant(ktr)[1/hr]                  | 01                       | 4.10                     | 0.341                    |
| Apparent Clearance（CL/F)[L/hr]                  | 02                       | 234                      | 197                      |
| Apparent CentralVolumeofDistribution（Vc/F)[L]   | θ3                       | 7240                     | 977                      |
| ApparentPeripheralVolumeofDistribution(Vp/F)[L] | 04                       | 6060                     | 890                      |
| ApparentIntercompartmental Clearance(Q/F)[L/lr] | 05                       | 273                      | 81.7                     |
| SuspensionFormulationonF                        |                          | -0.846                   | 0.122                    |
| Fasted Meal Status on F                         | 08                       | 0.806                    | 0.215                    |
| Doseon F                                        | 011                      | 0.459                    | FIXED                    |
| Population=OABon CL/F                           | 012                      | 0.367                    | 0.105                    |
| Tablecontinuedonnextpage                        | Tablecontinuedonnextpage | Tablecontinuedonnextpage | Tablecontinuedonnextpage |

IIV=interindividual variability.CV=coefficient ofvariation,F=relative bioavailability

| Parameter                    | Notation   | Estimate   | Standard Error   |
|------------------------------|------------|------------|------------------|
| InterindividualVariability   |            |            |                  |
| IIVktr                       |            | 0.178      | 0.0491           |
| Covariance（IIVktr,IIVCL/F)   | Cov（@1,2)  | 0.00622    | 0.0341           |
| IIVCL/F                      |            | 0.302      | 0.0470           |
| Covariance（IIVktr,IIVVc/F)   | Cov（1,3）   | 0.218      | 0.104            |
| Covariance（IIVCL/F,IIVVc/F)  | Cov（2,3)   | 0.342      | 0.0751           |
| IIVVe/F                      |            | 0.965      | 0.255            |
| ResidualVariability          |            |            |                  |
| ResidualError[approximateCV] | 06         | 0.366      | 0.0165           |

The condition number for the Best Model evaluated was 120 suggesting a stable model. Eta shrinkage was 33.0%, 4.65%, and 19.9% for ktr, CL, and Vc, respectively, and indicates that individual predicted PK parameters would be suitable for subsequent exposure-response analyses.

<div style=\"page-break-after: always\"></div>

Figure 1 - Best Model Goodness-of-fit Diagnostics

<!-- image -->

Caption:Solid Blue Line is a Loess Smoothor Gaussian Kemel Density

<div style=\"page-break-after: always\"></div>

Figure 2 - Visual Predictive Check by Study and Age Group

<!-- image -->

Note:Solidredline(pinkshadedregion)is theobservedmedian(90%predictioninterval).The solidbluelines (blue shadedregion) are theobserved1oand90percentiles(90%prediction intervals).

<div style=\"page-break-after: always\"></div>

Figure 3 - Visual Predictive Check by Study and Body Weight Group

<!-- image -->

Note:Solidred line (pink shaded region)is the observedmedian (9o%prediction interval).The solid bluelines (blue shadedregion)are the observed 1oand90percentiles(90%predictions intervals).

A numerical summary of the influence of covariates on steady-state Cmax and AUC(0-tau) is provided in Table 2. The predicted typical values for Cmax and AUC(0-tau) for a particular univariate test condition were compared to the typical values for the reference condition. The reference subject was a 50 kg NDO patient that received a 50 mg once-daily mirabegron tablet with food.

<div style=\"page-break-after: always\"></div>

Table 2 - Numerical Comparison of Covariate Effects on Steady-State Cmax and AUC(o-tau)

|                         | Steady-StateCmax(ng/mL)       | Steady-StateCmax(ng/mL)       | Steady-StateAUC(o-tau)(ng*h/mL)   | Steady-StateAUC(o-tau)(ng*h/mL)   |
|-------------------------|-------------------------------|-------------------------------|-----------------------------------|-----------------------------------|
| Condition               | Test/Reference Ratio (90%6CI) | Percentage Difference (90%C1) | Test/Reference Ratio (90%CI)      | Percentage Difference (90%C1)     |
| Reference\"              | 1 (1.1)                       | 0 (0.0)                       | 1 (1.1)                           | 0 (0.0）                           |
| BodyWeight=15kg         | 2.74 (2.71,2.77)              | 174 (171,177)                 | 2.47 (2.47.2.47)                  | 147 (147,147)                     |
| BodyWeight=35kg         | 1.35 (1.34,1.35)              | 34.5 (34.0,34.9)              | 1.31 (1.31,1.31)                  | 30.7 (30.7.30.7)                  |
| BodyWeight=70kg         | 0.757 (0.755,0.760)           | -24.3 (-24.5,-24.0)           | 0.777 (0.777,0.777)               | -22.3 (-22.3.-22.3)               |
| Formulation= Suspension | 0.429 (0.353.0.528)           | -57.1 (-64.7,-47.2)           | 0.429 (0.353.0.528)               | -57.1 (-64.7,-47.2)               |
| Food=Fasted             | 2.24 (1.56.3.18)              | 124 (56.2.218)                | 2.24 (1.56.3.18)                  | 124 (56.2.218)                    |
| Population=OAB          | 0.788 (0.709.0.878)           | -21.2 (-29.1,-12.2)           | 0.693 (0.584.0.822）               | -30.7 (-41.6,-17.8)               |

## 2.6.2.2. Pharmacodynamics

## Mechanism of action, Primary and Secondary pharmacology

No data / information about primary pharmacology related to the indication neurogenic detrusor overactivity or secondary pharmacology have been submitted.

## 2.6.3. Discussion on clinical pharmacology

Mirabegron is a potent and selective agonist for the human beta 3-adrenoceptor that is being developed as prolonged-release granules for oral suspension for the treatment of neurogenic detrusor overactivity (NDO) in paediatric patients aged 3 to less than 18 years.

To support the new pediatric formulation application, the applicant has submitted two bioavailabity studies for Betmiga comparing different formulations of the oral suspension and the oral suspension against the already approved prolonged release tablets. The mirabegron oral suspension of formulation C is the proposed formulation for commercialization. The prolonged-release granules of formulation C, are reconstituted with water to prepare an oral suspension with a concentration of 8 mg/mL.

Furthermore, the Applicant has performed comparative dissolution profiles between the different new formulations.

The non-compartmental analysis revealed differences in overall exposure due to formulation-, dose- and type of population-effects. Specifically, results from study 178-CL-201 showed 53-55% lower AUCinf and AUClast and 70% for Cmax when formulated as 50 mg oral suspension compared to 50 mg tablet formulation under fasted conditions. When fed conditions were evaluated, the results were slightly greater (60% lower for AUCinf, 67% lower for AUClast and 78% lower for Cmax of the 50 mg oral suspension compared to 50 mg tablet formulation). Due to the effect of the formulation on the overall bioavailability, study 178-CL-208 was

<div style=\"page-break-after: always\"></div>

conducted with a higher oral suspension dose (88 mg) compared to the tablet formulation (50 mg). This study aimed to evaluate the bioequivalence between 8 mg/mL and 2 mg/mL formulations. The results indicated that no clinically relevant differences in exposure were observed between both oral suspensions in fasted state conditions. The impact of fed state reduced by 45, 49, and 64% the AUCinf, AUClast and Cmax. Betmiga granules for prolonged-release oral suspension are to be administered with food as mentioned in 4.2 and 5.2 of the SmPC.

The base population PK model established a different mathematical framework, especially regarding the characterization of the absorption process, compared to previously used population PK model for dose selection in adult healthy volunteers and pediatric clinical trials. A two-compartment structural model with first-order absorption and first-order elimination with eight transit compartments was assumed. The use of a two-compartment model to characterize the disposition of mirabegron is adequate based on the experimental evidence available. However, a previously developed population PK model using experimental information from studies 178-CL-201, 178-CL-202 and 178-CL-203 was formulated including two peripheral compartments and a first-order and zero-order absorption processes, which clearly differs in the structural definition with the current population PK model proposed. The very sparse (or absence) data above 50 hours in Study 202 and 203 does not allow to accept or discard the presence of the second peripheral compartment. Although the current population PK model is able to describe pediatric data, uncertainties remain regarding the adequacy of CL and V1, which may be biased by the absence of a second peripheral compartment. Therefore, the current population PK model should be considered with caution for the extrapolation of exposure in pediatric patients below 2 years of age or additional scenarios that lack of experimental information. However, as the claimed indication is above the age of 3 years this issues is not further pursued.

The characterization of the delayed absorption process through the use of transit compartments is also acknowledged. The overall assessment of the model ability to describe the observed data suggests an adequate performance of the final population PK model, but discrepancies could be detected around the Cmax area from the VPC plots, which was confirmed in the GOF plots. The simulation-based analysis on Cmax across the different age cohorts (adolescents and children) and food conditions (fed and fasted) demonstrates an under-prediction of Cmax at high dose regimen in fed and fasted conditions. Only data from study 203 (children high-dose fed) seems to be captured by the population PK model. Although the model misspecification may not be relevant in terms of dose selection so far, a bias on Cmax has been demonstrated, which impedes to use the current population PK model as the unique strategy for a prospective dose-selection or response-related (efficacy/safety) scenario justification based on predicted Cmax levels in pediatric patients without experimental evidence. The impact of body weight on the exposure of mirabegron (Cmax and AUCtau) was clinically relevant in paediatric patients weighting less than 35 kg or greater than 70 kg. The dose recommendation in pediatric patients has been established according to different body weight bands: 11-22 kg, 22-35 kg and &gt;=35 kg. The dose levels selected have been evaluated in terms of equivalence of exposure (AUC0-tau) to the adult population. A large proportion of pediatric patients (&gt;25%) with body weight less than 22 kg are expected to show higher AUCtau levels than the 90% of adult patients but according to the SmPC lower dose levels could be selected for patients with lower body weight to provide similar exposure as the adult patients which is acceptable. Furthermore, the recommended dose of Betmiga granules for prolonged-release oral suspension is determined based on patient weight at the recommended starting dose and may be increased to the lowest effective dose as outlined in 4.2 of the SmPC.

The impact of renal and hepatic impairment on mirabegron exposure in adult patients has been fully extrapolated to paediatric patients with renal or hepatic impairment. The dose recommendation based on the

<div style=\"page-break-after: always\"></div>

different body weight bands proposed by the Applicant includes an initial dose in paediatric patients with mild/moderate renal impairment or mild hepatic impairment between 24 to 48 mg of mirabegron which can be increased up to 48-80 mg of the oral suspension. Paediatric patients with severe renal or moderate hepatic impairment do not have dose increase of mirabegron, with an initial dose range from 24 to 48 mg based on the body weight.  Mirabegron is not indicated in paediatric patients with ESRD or severe hepatic impairment. This approach was considered acceptable by the CHMP.

## 2.6.4. Conclusions on clinical pharmacology

The pharmacokinetics of mirabegron in paediatric patients have been characterized through a noncompartmental analysis in healthy adult volunteers and the development of a population PK model including paediatric patients with NDO or OAB. The characterization of PK properties for dose selection in paediatric patients is endorsed.

## 2.6.5. Clinical efficacy

## 2.6.5.1. Dose response study(ies)

The approach for defining the dosing recommendations considers the available data in adult patients with overactive bladder (OAB) across the dose range of 25 mg to 200 mg once daily across the phase 2 and 3 adult program to support the paediatric NDO program. The general approach was to define paediatric exposures that correlated with the 2 approved adult doses of 25 mg and 50 mg mirabegron once daily.

In Study 178-CL-206A, either mirabegron oral suspension 8 mg/mL (patients with a body weight &lt; 35 kg) or mirabegron tablets (patients with a body weight ≥ 35 kg; patients unable or unwilling to take tablets could take the suspension) was administered. Therefore, the dosing table used for this study was adopted for commercial use with a single modification: the recommended maximum suspension dose in patients ≥ 35 kg was adjusted from 11 mL to 10 mL (80 mg) for pragmatic purposes. The final proposed doses, to be administered in the fed state, are shown in Table 3.

Table 3 - Recommended Doses of Mirabegron Oral Suspension of Formulation C and Prolonged-release Tablet for Pediatric Patients With NDO (Fed State)

| RecommendedDose          | BodyWeight Range (kg)   | TabletDose (mg)   | SuspensionVolume (mL)*   |
|--------------------------|-------------------------|-------------------|--------------------------|
| Recommended startingdose | 11to<22                 |                   | 3                        |
| Recommended startingdose | 22to<35                 |                   | 4                        |
| Recommended startingdose | ≥35                     | 25                | 6                        |
| Recommendedmaximumdose   | 11to<22                 |                   | 6                        |
| Recommendedmaximumdose   | 22 to<35                |                   | 8                        |
| Recommendedmaximumdose   | ≥35                     | 50                | 10t                      |

<div style=\"page-break-after: always\"></div>

## 2.6.5.2. Main study(ies)

An Open-label, Baseline-controlled, Multicenter, Phase 3 Dose titration Study Followed by a Fixed-dose Observation Period to Evaluate Efficacy, Safety and Pharmacokinetics of Mirabegron in Children and Adolescents From 3 to Less Than 18 Years of Age with Neurogenic Detrusor Overactivity (NDO) on Clean Intermittent Catheterization (CIC)

This was a phase 3, open-label, baseline-controlled, multicenter study in children and adolescents from 3 to &lt; 18 years of age with NDO on CIC.

The study consisted of 3 investigational periods:

- Pretreatment period: for a maximum of 28 days before baseline, including screening, washout (if applicable) and baseline
- Efficacy treatment period: beginning the day after baseline and continuing to week 24
- Long-term safety period: beginning after week 24 and continuing to week 52 (end of study/treatment).

Patients who were receiving oral drug treatment to manage their NDO or received any other prohibited medication underwent a 2-week washout period. After the screening visit, a training e-diary had to be completed by the patients, which had to be confirmed at visit 2. Patients started to complete the 7-day baseline e-diary before the baseline visit (visit 3).

## Methods

## · Study Participants

Patients were male or female from 3 to &lt; 18 years of age with body weight of ≥ 11 kg. Eligible patients suffered from NDO confirmed by urodynamic investigation at baseline. The diagnosis of NDO was confirmed by the presence of ≥ 1 involuntary detrusor contraction &gt; 15 cm H2O from baseline detrusor pressure, and/or a decrease in bladder compliance leading to an increase in baseline detrusor pressure of &gt; 20 cm H2O. Patients had been using CIC for ≥ 4 weeks prior to screening and had current indication for drug therapy to manage NDO. Patients were excluded from participation if had a known genitourinary condition (other than NDO) that could cause overactive contractions or incontinence (e.g., bladder extrophy, urinary tract obstruction, urethral diverticulum or fistula) or kidney/bladder stones or another persistent local pathology that may cause urinary symptoms. Patients suffering from a symptomatic UTI at baseline (symptomatic was defined as pain, fever, hematuria, new onset foul-smelling urine), established hypertension, resting pulse rate &gt; 99 th  percentile, had risk of QT prolongation, were also excluded.

## · Treatments

The initial dose of mirabegron was selected to achieve plasma concentrations equivalent to the steady-state exposures expected with 25 mg mirabegron administered once daily in adults (PED25). The dose had to be increased to the paediatric equivalent dose to mirabegron 50 mg (PED50) in all patients at week 2, 4 or 8, unless the investigator considered the patient to be effectively treated with PED25 or there were safety or tolerability issues with PED25. Dose down-titration to PED25 could be performed at any time if there was a safety issue.

<div style=\"page-break-after: always\"></div>

## · Objectives

The primary objective was to evaluate the efficacy of mirabegron after multiple-dose administration in the paediatric population.

The secondary objectives were to evaluate the safety and tolerability of mirabegron after multipledose administration in the paediatric population and to evaluate the pharmacokinetics of mirabegron after multiple-dose administration in the paediatric population.

## · Outcomes/endpoints

The primary efficacy endpoint was the change from baseline in maximum cystometric capacity (MCC) after 24 weeks of treatment (based on filling urodynamics).

The following secondary efficacy endpoints were assessed:

a) Change from baseline in urodynamic measures at weeks 4 and 24:

- -MCC (week 4 only)
- -Bladder compliance (change in volume/change in pressure)
- -Number of overactive detrusor contractions (&gt; 15 cm H2O) until end of filling
- -Detrusor pressure at end of filling
- -Filling volume until first overactive detrusor contraction (&gt; 15 cm H2O)

b) Change from baseline in bladder volume and leakage measures at weeks 2, 4, 8, 12, 24, 36 and 52:

- -Average catheterized volume per catheterization
- -Maximum catheterized volume
- -Maximum catheterized daytime volume
- -Average morning catheterized volume (based on first catheterization after patient woke up)
- -Mean number of leakage episodes per day (day and night time)
- -Number of dry (leakage-free) days/7 days (day and night time)

c) Patient- or clinician-reported questionnaires at weeks 24 and 52:

- -Change from baseline in Pediatric Incontinence Questionnaire (PIN-Q)
- -Change from baseline in Patient Global Impression of Severity Scale (PGI-S)
- -Clinician Global Impression of Change (CGI-C)
- -Acceptability (also at week 4)
- -The following safety endpoints were assessed:

## · Sample size

The primary endpoint was the change from baseline in MCC after 24 weeks of mirabegron treatment.

<div style=\"page-break-after: always\"></div>

A study with 44 evaluable patients who had valid (as by the central reviewer's assessment) nonmissing MCC measurements at week 24 and at baseline would have had a 90% power to detect a statistically significant change from baseline, if the real change from baseline in the patient population was ≥ 52 mL and the real SD for change from baseline was ≤ 103 mL. The power calculation was done assuming a paired t-test with 2-sided significance level of 0.05. Assuming 30% of enrolled patients discontinued or not evaluable for the primary endpoint, a total of approximately 63 patients were needed to be enrolled so that 44 patients were evaluable in total.

## · Randomisation and Blinding (masking)

It was an open label study. Only one treated cohort was studied.

## · Statistical methods

A patient was considered being evaluable if the patient had a nonmissing maximum cystometric capacity (MCC) measurement at baseline and at a postbaseline visit.

All statistical comparisons were made using a 2-sided test at α = 0.05 significance level unless specifically stated otherwise.

## Analysis Sets

## Analysis sets of interest were:

All Allocated Set consisted of all allocated patients, i.e., all those patients with a nonmissing registration date at baseline. This set was used to summarize disposition of patients who were allocated to mirabegron treatment.

Full Analysis Set (FAS) consisted of all patients who took ≥ 1 dose of study drug and provided both valid (as by the central reviewer ' s assessment) nonmissing MCC measurements at baseline and at a postbaseline visit for the primary efficacy endpoint. The FAS was used for primary analyses of efficacy data, for sensitivity and subgroup analyses.

Per Protocol Set (PPS) included all patients of the FAS who fulfilled the protocol in terms of their eligibility, interventions and outcome assessments, and for whom valid MCC measurements at baseline and at week 24 were reported. The PPS was used for secondary analyses of efficacy data.

Safety Analysis Set (SAF) consisted of all patients who took ≥ 1 dose of study drug. The SAF was used for summaries of demographic and baseline characteristics and all safety- and tolerabilityrelated variables.

## Efficacy

## Primary Variable:

The primary analysis of the primary variable imputed missing MCC observations at week 24 using last observation carried forward (LOCF) on the FAS. This analysis was also performed on the PPS. In accordance with the definition of the estimand, the primary analysis of the primary efficacy endpoint of change from baseline in MCC after 24 weeks of treatment (based on filling urodynamics) was a paired t-test using the UNIVARIATE procedure in SAS. The following hypotheses were tested at the 2-sided significance level 0.05; no adjustment for multiplicity was made:

- H0: Mean change from baseline in MCC at week 24 is equal to zero

<div style=\"page-break-after: always\"></div>

- H1: Mean change from baseline in MCC at week 24 in MCC is not equal to zero

Secondary and sensitivity analyses of the primary efficacy endpoint included analyses without data imputation, a baseline observation carried forward approach, repeated measures analysis of covariance (ANCOVA), nonparametric Wilcoxon signed-rank test.

## Secondary Variables:

The change from baseline for secondary endpoints based on urodynamic assessments, the patient's e-diary (including bladder diary) and questionnaires were summarized and analyzed using similar primary statistical methods as for the primary endpoint, where appropriate. CGI-C and acceptability results were tabulated per timepoint of assessment.

## Results

## · Participant flow

<!-- image -->

NDO: neurogenic detrusor overactivity; QTcB: QT interval corrected by Bazett's formula. † Included 19 screen failures, 1 withdrawal by patient, 1 withdrawal by parent/guardian, and 1 for other reasons. ‡ Included 3 cases of no signs of NDO on

<div style=\"page-break-after: always\"></div>

baseline urodynamic assessment as per central review, 1 case of not meeting inclusion/exclusion criteria (registered in error), and 1 case of not meeting inclusion criterion 12 (not able to comply with the study requirements). § Included 4 cases of no signs of NDO on baseline urodynamic assessment after central review, 7 cases of technical issues with baseline urodynamic assessment, and 2 cases of withdrawal due to QTcB prolongation at baseline after central review.

## · Recruitment

This study was conducted at 32 sites that enrolled patients in a total of 19 countries in 4 geographic regions including Europe (Belgium, Croatia, Denmark, Latvia, Lithuania, Norway, Poland, Romania, Serbia, Slovakia), Asia and Pacific (Australia, Malaysia, Philippines, South Korea, Taiwan), Middle East (Israel, Jordan, Turkey), and North America (Mexico).

Study Initiation Date (Date of First Enrollment): 17 Jun 2016

Study Completion Date (Date of Last Evaluation): 06 May 2019

## · Conduct of the study

The original protocol for this study was dated 09 Dec 2015. There was 1 amendment, which was substantial (02 Nov 2016)

- The age range of the patients was updated to include children from 3 to &lt; 18 years of age.
- Mirabegron oral suspension (8 mg/mL) was added to the protocol as a second study drug formulation to enable dosing of the younger patients.
- The weight range for inclusion of patients in the study was lowered to ≥ 11 kg.
- Additional self-blood pressure measurement were included at weeks 1 and 2 after the start of dosing and after a dose escalation.

These protocol changes were implemented after enrolment of 38 patients.

Protocol deviation (PD)

Overall, 11 (12.1%) patients had PDs. The most frequently reported PD (6.6% of all patients) was PD4 (patient received excluded concomitant treatment). PD2 (developed withdrawal criteria during the study and was not withdrawn) was not reported for any patients.

## · Baseline data

A total of 86 patients received study drug and were included in the SAF, 55 children aged 3 to &lt; 12 years and 31 adolescents aged 12 to &lt; 18 years. Of these, 70 patients completed treatment through week 52 (43 children and 27 adolescents) and 68 patients (43 children and 25 adolescents) had adequate urodynamic measurements for evaluation of efficacy (FAS).

Across all patients in the SAF, there was an equal distribution across sexes (45.3% boys and 54.7% girls). Most patients were White (72.1%), with 23.3% Asian. Three patients were Hispanic or Latino. At screening the mean age was 10.1 years and ranged from 3 to 17 years (Table 4)

<div style=\"page-break-after: always\"></div>

Table 4 - Summary of Demographics and Baseline Characteristics (SAF)

| Parameter Category/ Statistics   | Children (3 to <12 Years) n=55   | Adolescents (12 to < 18 Years) n=31   | All Patients (3 to < 18 Years) n=86   |
|----------------------------------|----------------------------------|---------------------------------------|---------------------------------------|
| Sex, n (%)                       |                                  |                                       |                                       |
| Male                             | 22 (40.0%)                       | 17 (54.8%)                            | 39 (45.3%)                            |
| Female                           | 33 (60.0%)                       | 14 (45.2%)                            | 47 (54.7%)                            |
| Age, yearst                      |                                  |                                       |                                       |
| Mean (SD)                        | 7.9 (2.5)                        | 14.0 (1.7)                            | 10.1 (3.7)                            |
| Median                           | 9.0                              | 14.0                                  | 10.0                                  |
| Min - Max                        | 3 - 11                           | 12 - 17                               | 3 - 17                                |
| Race, n (%)                      |                                  |                                       |                                       |
| White                            | 40 (72.7%)                       | 22 (71.0%)                            | 62 (72.1%)                            |
| Black/African American           | 0                                | 0                                     | 0                                     |
| Asian                            | 13 (23.6%)                       | 7 (22.6%)                             | 20 (23.3%)                            |
| American Indian/Alaska Native    | 0                                | 1 (3.2%)                              | 1 (1.2%)                              |
| Native Hawaiian/Pacific Islander | 0                                | 0                                     | 0                                     |
| Other                            | 2 (3.6%)                         | 1 (3.2%)                              | 3 (3.5%)                              |
| Ethnicity,n (%)                  |                                  |                                       |                                       |
| Hispanic or Latino               | 1 (1.8%)                         | 2 (6.5%)                              | 3 (3.5%)                              |
| Not Hispanic or Latino           | 54 (98.2%)                       | 29 (93.5%)                            | 83 (96.5%)                            |
| Weight, kg+                      |                                  |                                       |                                       |
| n1                               | 55                               | 31                                    | 86                                    |
| Mean (SD)                        | 29.83 (13.41)                    | 50.96 (13.78)                         | 37.45 (16.90)                         |
| Median                           | 28.00                            | 47.50                                 | 35.85                                 |
| Min -Max                         | 12.6-69.7                        | 28.2-78.5                             | 12.6-78.5                             |
| Height, cmt                      |                                  |                                       |                                       |
| n1                               | 55                               | 31                                    | 86                                    |
| Mean (SD)                        | 124.77 (18.69)                   | 152.91 (12.06)                        | 134.91 (21.40)                        |
| Median                           | 128.00                           | 152.00                                | 138.75                                |
| Min -Max                         | 92.1- 160.0                      | 120.0-178.0                           | 92.1 - 178.0                          |
| BMI, kg/m²t                      |                                  |                                       |                                       |
| nn                               | 55                               | 31                                    | 86                                    |
| Mean (SD)                        | 18.18 (3.94)                     | 21.96 (6.02)                          | 19.55 (5.10)                          |
| Median                           | 17.10                            | 19.80                                 | 18.35                                 |
| Min - Max                        | 11.9-27.2                        | 10.5-33.3                             | 10.5-33.3                             |

All patients who received ≥ 1 dose of study drug (SAF).

BMI: body mass index; eCRF: electronic case report form; Max: maximum; Min: minimum; SAF: safety analysis set.

† Age at screening was calculated as (date of last informed consent given at screening - date of birth +1)/365.25. If the date of birth was not given, the age at screening was equal to the value recorded on the demographics page of the eCRF (an integer number of years) plus 0.5.

‡ BMI = weight (kg)/[height (m2)]. Height and weight were assessed at screening.

The mean duration of NDO disease was 7.11 years (range 0.1 to 15.9 years). For children, the duration was 5.80 years (range 0.3 to 11.9 years) and for adolescents 9.44 years (range 0.1 to 15.9 years).

<div style=\"page-break-after: always\"></div>

Per protocol, all patients started at PED25, with approximately half (54.7%) starting on tablets (19 children and 28 adolescents) and the remainder (45.3%) on suspension (36 children and 3 adolescents). The per-protocol dose increase to PED50 by week 8 occurred in all but 4 patients. There were no dose increases or decreases from week 8 onwards. Between weeks 8 and 52, dose interruptions due to TEAEs or dosing noncompliance were recorded in the clinical database for 12 patients. On average, treatment compliance exceeded 95% across age groups and formulations.

## Prior and Concomitant Therapy

All patients reported CIC or other terms describing CIC.  Previous NDO medication was used by 76 (88.4%) patients , and non-NDO medication was used by 68 (79.1%) patients.

Table 5 - Overview of NDO Therapies Prior to Study Drug Administration (SAF)

<!-- image -->

| Parameter Category/Statisties                         | Children (3 to < 12 Years) n=55                       | Adolescents (12 to < 18 Years) n =31                  | All Patients (3 to < 18 Years)  =86                   |
|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|
| NDO Nonmedication Therapy,n (%6)                      | NDO Nonmedication Therapy,n (%6)                      | NDO Nonmedication Therapy,n (%6)                      | NDO Nonmedication Therapy,n (%6)                      |
| sa1                                                   | 55 (100.0%)                                           | 31 (100.0%)                                           | 86 (100.0%)                                           |
| \"CIC\"\"                                                | 28 (50.9%)                                            | 15 (48.4%)                                            | 43 (50.0%)                                            |
| Other term describing CICt                            | 26 (47.3%)                                            | 15 (48.4%)                                            | 41 (47.7%)                                            |
| \"Intermittent Cathrization\"                           | 0                                                     | 1 (3.2%)                                              | 1 (1.2%)                                              |
| \"Urinary Catheterization\"                             | 1 (1.8%)                                              | 0                                                     | 1 (1.2%)                                              |
| Duation of Nonmedication Therapy at Screening (Years) | Duation of Nonmedication Therapy at Screening (Years) | Duation of Nonmedication Therapy at Screening (Years) | Duation of Nonmedication Therapy at Screening (Years) |
|                                                       | 55                                                    | 31                                                    | 86                                                    |
| Mean (SD)                                             | 4.43 (3.47)                                           | 9.09 (5.32)                                           | 6.11 (4.77)                                           |
| Median                                                | 3.55                                                  | 10.17                                                 | 5.44                                                  |
| Min -Max                                              | 0.1 - 11.2                                            | 0.1 - 16.1                                            | 0.1 - 16.1                                            |
| Any NDO Medieation Therapy, n (%)                     | Any NDO Medieation Therapy, n (%)                     | Any NDO Medieation Therapy, n (%)                     | Any NDO Medieation Therapy, n (%)                     |
|                                                       | 48 (87.3%)                                            | 28 (90.3%)                                            | 76 (88.4%)                                            |
| Most Frequently Used (> 5% patients in any age group) | Most Frequently Used (> 5% patients in any age group) | Most Frequently Used (> 5% patients in any age group) | Most Frequently Used (> 5% patients in any age group) |
| Botulinum Toxin Type A                                | 1 (1.8%)                                              | 2 (6.5%)                                              | 3 (3.5%)                                              |
| Fesoterodine                                          | 0                                                     | 3 (9.7%)                                              | 3 (3.5%)                                              |
| Mirabegron                                            | 3 (5.5%)                                              | 3 (9.7%)                                              | 6(7.0%)                                               |
| Oxybutynin                                            | 21 (38.2%)                                            | 7 (22.6%)                                             | 28 (32.6%)                                            |
| Propiverine                                           | 3 (5.5%)                                              | 2 (6.5%)                                              | 5 (5.8%)                                              |
| Solifenacin                                           | 11 (20.0%)                                            | 8 (25.8%)                                             | 19 (22.1%)                                            |
| Tolterodine                                           | 3 (5.5%)                                              | 1 (3.2%)                                              | 4 (4.7%)                                              |
| Trospium                                              | 3 (5.5%)                                              | 1 (3.2%)                                              | 4 (4.7%)                                              |

All patients who received ≥ 1 dose of study drug (SAF).

CIC: clean intermittent catheterization; Max: maximum; Min: minimum; NDO: neurogenic detrusor activity; n: number of patients; SAF: safety analysis set.

† Other verbatim to describe CIC.

<div style=\"page-break-after: always\"></div>

## · Numbers analysed

Table 6 - Patient Disposition and Analysis Sets

| Parameter                                 | Children (3 to < 12 Year's) n=55   | Adolescents (12 to < 18 Year's) n=31   | All Patients (3 to < 18 Year's) n =86   |
|-------------------------------------------|------------------------------------|----------------------------------------|-----------------------------------------|
| Disposition [n (%)] (SAF)                 |                                    |                                        |                                         |
| Completed treatment                       | 43 (78.2%)                         | 27 (87.1%)                             | 70 (81.4%)                              |
| Study drug discontinuationt               | 12 (21.8%)                         | 4 (12.9%)                              | 16 (18.6%)                              |
| Adverse event                             | 3 (5.5%)                           | 0                                      | 3 (3.5%)                                |
| Death                                     | 0                                  | 0                                      | 0                                       |
| Lack of efficacy                          | 0                                  | 0                                      | 0                                       |
| Lost to follow-up                         | 0                                  | 0                                      | 0                                       |
| Protocol deviation                        | 0                                  | 0                                      | 0                                       |
| Withdrawal by patient                     | 0                                  | 0                                      | 0                                       |
| Withdrawal by parent/guardian             | 0                                  | 0                                      | 0                                       |
| Noncompliance with study drug             | 0                                  | 0                                      | 0                                       |
| Other                                     | 9 (16.4%)                          | 4 (12.9%)                              | 13 (15.1%)                              |
| Analysis Set [n (%o)] (All Allocated Set) |                                    |                                        |                                         |
| All allocated sett                        | 56 (100.0%)                        | 35 (100.0%)                            | 91 (100.0%)                             |
| Safety analysis sets                      | 55 (98.2%)                         | 31 (88.6%)                             | 86 (94.5%)                              |
| Full analysis set                         | 43 (76.8%)                         | 25 (71.4%)                             | 68 (74.7%)                              |
| Per protocol setit                        | 38 (67.9%)                         | 22 (62.9%)                             | 60 (65.9%)                              |
| Pharmacokinetics analysis sett+           | 43 (76.8%)                         | 23 (65.7%)                             | 66 (72.5%)                              |

Note: Percentage of patients with nonmissing registration date at baseline are shown.

FAS: full analysis set; MCC: maximum cystometric capacity; SAF: safety analysis set.

† Only the primary reason for discontinuation was collected.

‡ All patients with a nonmissing registration date at visit 3 (baseline).

## · Outcomes and estimation

## Primary Efficacy Endpoint

After 24 weeks of treatment using LOCF, all age groups had a statistically significant increase in MCC compared with baseline (P &lt; 0.001) (primary analysis of primary endpoint) (Table 7). The statistically significant improvement in MCC was evident at week 4 (55.53 mL) and sustained across the 24-week treatment period (Table 8).

Secondary, sensitivity and subgroup analyses of the primary endpoint (including the primary analysis in the PPS, to week 24 observed values and using BOCF) support the results from the primary analysis.

<div style=\"page-break-after: always\"></div>

Table 7 - Primary Analysis of Change from Baseline in Maximum Cystometric Capacity (mL) at Week 24 (LOCF) (FAS)

| Statistic                  | Children (3to<12Yeal's) 11=43   | Children (3to<12Yeal's) 11=43   | Adolescents (12 to<18 Yeal's) n=25   | Adolescents (12 to<18 Yeal's) n=25   | All Patients (3 t0<18 Yeal's) n=68   | All Patients (3 t0<18 Yeal's) n=68   |
|----------------------------|---------------------------------|---------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|
| Baseline. n 1Mean (SD)     | 43                              | 158.64 (94.50)                  | 25                                   | 238.92 (99.14)                       | 68                                   | 188.16 (103.15)                      |
| Week 24 LOCF, n  Mean (SD) | 43                              | 230.73 (129.19)                 | 25                                   | 352.13 (125.23)                      | 68                                   | 275.36 (139.85)                      |
| ChangefromBaseline,nt      | 43                              | 43                              | 25                                   | 25                                   | 68                                   | 68                                   |
| Mean (SD)                  | 72.09 (87.09)                   | 72.09 (87.09)                   | 113.21 (82.99)                       | 113.21 (82.99)                       | 87.20 (87.30)                        | 87.20 (87.30)                        |
| 95% CI                     | (45.28, 98.89)s                 | (45.28, 98.89)s                 | (78.95, 147.47)s                     | (78.95, 147.47)s                     | (66.07, 108.33)§                     | (66.07, 108.33)§                     |
| P valuet                   | <0.001                          | <0.001                          | <0.001                               | <0.001                               | <0.001                               | <0.001                               |

Secondary Efficacy Endpoints

After 24 weeks of treatment, statistically significant improvement from baseline in most secondary urodynamic endpoints was observed, generally for all 3 age groups (Table 8).

Table 8 - Analyses of Secondary Endpoints - Urodynamic, Bladder Volume and Leakage Measures (FAS)

|                                                                                                   |                                                                                                   | Children (3 to < 12 Years) n=43                                                                   | Children (3 to < 12 Years) n=43                                                                   | Adolescents (12 to < 18 Year's) n=25                                                              | Adolescents (12 to < 18 Year's) n=25                                                              | All Patients (3 to < 18 Years) n =68                                                              | All Patients (3 to < 18 Years) n =68                                                              |
|---------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|
| Maximum Cystometric Capacity at Week 4 (mL)                                                       | Maximum Cystometric Capacity at Week 4 (mL)                                                       | Maximum Cystometric Capacity at Week 4 (mL)                                                       | Maximum Cystometric Capacity at Week 4 (mL)                                                       | Maximum Cystometric Capacity at Week 4 (mL)                                                       | Maximum Cystometric Capacity at Week 4 (mL)                                                       | Maximum Cystometric Capacity at Week 4 (mL)                                                       | Maximum Cystometric Capacity at Week 4 (mL)                                                       |
|                                                                                                   | Baseline, n | Mean (SD)                                                                           | 43                                                                                                | 158.64 (94.50)                                                                                    | 25                                                                                                | 238.92 (99.14)                                                                                    | 68                                                                                                | 188.16 (103.15)                                                                                   |
|                                                                                                   | Week 4, n  Mean (SD)                                                                              | 41                                                                                                | 203.94 (125.23)                                                                                   | 23                                                                                                | 311.04 (114.34)                                                                                   | 64                                                                                                | 242.43 (131.17)                                                                                   |
| Change from Baseline,nt                                                                           | Change from Baseline,nt                                                                           | 41                                                                                                | 41                                                                                                | 23                                                                                                | 23                                                                                                | 64                                                                                                | 64                                                                                                |
| Mean (SD)                                                                                         | Mean (SD)                                                                                         | 41.36 (71.64)                                                                                     | 41.36 (71.64)                                                                                     | 80.78 (96.15)                                                                                     | 80.78 (96.15)                                                                                     | 55.53 (82.76)                                                                                     | 55.53 (82.76)                                                                                     |
| 95% CI                                                                                            | 95% CI                                                                                            | (18.75, 63.97)                                                                                    | (18.75, 63.97)                                                                                    | (39.20, 122.36)                                                                                   | (39.20, 122.36)                                                                                   | (34.85, 76.20)                                                                                    | (34.85, 76.20)                                                                                    |
| P valuef                                                                                          | P valuef                                                                                          | <0.001                                                                                            | <0.001                                                                                            | <0.001                                                                                            | <0.001                                                                                            | <0.001                                                                                            | <0.001                                                                                            |
| Bladder Compliance at Week 24 (mL/cm H2O)                                                         | Bladder Compliance at Week 24 (mL/cm H2O)                                                         | Bladder Compliance at Week 24 (mL/cm H2O)                                                         | Bladder Compliance at Week 24 (mL/cm H2O)                                                         | Bladder Compliance at Week 24 (mL/cm H2O)                                                         | Bladder Compliance at Week 24 (mL/cm H2O)                                                         | Bladder Compliance at Week 24 (mL/cm H2O)                                                         | Bladder Compliance at Week 24 (mL/cm H2O)                                                         |
|                                                                                                   | Baseline, n | Mean (SD)                                                                           | 40                                                                                                | 14.53 (50.75)                                                                                     | 24                                                                                                | 11.02 (10.05)                                                                                     | 64                                                                                                | 13.21 (40.42)                                                                                     |
|                                                                                                   | Week 24, n I Mean (SD)                                                                            | 35                                                                                                | 29.63 (52.81)                                                                                     | 22                                                                                                | 23.89 (15.35)                                                                                     | 57                                                                                                | 27.41 (42.30)                                                                                     |
| Change from Baseline, nf                                                                          | Change from Baseline, nf                                                                          | 33                                                                                                | 33                                                                                                | 21                                                                                                | 21                                                                                                | 54                                                                                                | 54                                                                                                |
| Mean (SD)                                                                                         | Mean (SD)                                                                                         | 14.62 (42.09)                                                                                     | 14.62 (42.09)                                                                                     | 13.59 (15.02)                                                                                     | 13.59 (15.02)                                                                                     | 14.22 (33.99)                                                                                     | 14.22 (33.99)                                                                                     |
| 95% CI                                                                                            | 95% CI                                                                                            | (-0.31, 29.54)                                                                                    | (-0.31, 29.54)                                                                                    | (6.75, 20.42)                                                                                     | (6.75, 20.42)                                                                                     | (4.94, 23.49)                                                                                     | (4.94, 23.49)                                                                                     |
| P valuef                                                                                          | P valuef                                                                                          | 0.055                                                                                             | 0.055                                                                                             | <0.001                                                                                            | <0.001                                                                                            | 0.003                                                                                             | 0.003                                                                                             |
| Number of Overactive Detrusor Contractions at Week 24 (> 15 cim H2O) Until End of Bladder-filling | Number of Overactive Detrusor Contractions at Week 24 (> 15 cim H2O) Until End of Bladder-filling | Number of Overactive Detrusor Contractions at Week 24 (> 15 cim H2O) Until End of Bladder-filling | Number of Overactive Detrusor Contractions at Week 24 (> 15 cim H2O) Until End of Bladder-filling | Number of Overactive Detrusor Contractions at Week 24 (> 15 cim H2O) Until End of Bladder-filling | Number of Overactive Detrusor Contractions at Week 24 (> 15 cim H2O) Until End of Bladder-filling | Number of Overactive Detrusor Contractions at Week 24 (> 15 cim H2O) Until End of Bladder-filling | Number of Overactive Detrusor Contractions at Week 24 (> 15 cim H2O) Until End of Bladder-filling |
|                                                                                                   | Baseline, n | Mean (SD)                                                                           | 42                                                                                                | 3.07 (3.88)                                                                                       | 24                                                                                                | 2.04 (2.97)                                                                                       | 66                                                                                                | 2.70 (3.59)                                                                                       |
|                                                                                                   | Week 24, n Mean (SD)                                                                              | 37                                                                                                | 1.08 (2.23)                                                                                       | 23                                                                                                | 1.48 (2.35)                                                                                       | 60                                                                                                | 1.23 (2.27)                                                                                       |
| Change from Baseline, n↑                                                                          | Change from Baseline, n↑                                                                          | 36                                                                                                | 36                                                                                                | 22                                                                                                | 22                                                                                                | 58                                                                                                | 58                                                                                                |
| Mean (SD)                                                                                         | Mean (SD)                                                                                         | -1.86 (4.16)                                                                                      | -1.86 (4.16)                                                                                      | -0.77 (3.87)                                                                                      | -0.77 (3.87)                                                                                      | -1.45 (4.05)                                                                                      | -1.45 (4.05)                                                                                      |
| 95% CI                                                                                            | 95% CI                                                                                            | (-3.27,-0.45)                                                                                     | (-3.27,-0.45)                                                                                     | (-2.49, 0.94)                                                                                     | (-2.49, 0.94)                                                                                     | (-2.51, -0.38)                                                                                    | (-2.51, -0.38)                                                                                    |
| P valuet                                                                                          | P valuet                                                                                          | 0.011                                                                                             | 0.011                                                                                             | 0.359                                                                                             | 0.359                                                                                             | 0.009                                                                                             | 0.009                                                                                             |

<div style=\"page-break-after: always\"></div>

| Statistic                                                                                                   | Children n=43                                                                                               | (3 to < 12 Years)                                                                                           |                                                                                                             | Adolescents (12 to ≤ 18 Years) n=25                                                                         | All Patients (3 to < 18 Years)  =68                                                                         |                                                                                                             |
|-------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|
| Detrusor Pressure at End of Bladder Filling at Week 24 (em HO)                                              | Detrusor Pressure at End of Bladder Filling at Week 24 (em HO)                                              | Detrusor Pressure at End of Bladder Filling at Week 24 (em HO)                                              | Detrusor Pressure at End of Bladder Filling at Week 24 (em HO)                                              | Detrusor Pressure at End of Bladder Filling at Week 24 (em HO)                                              | Detrusor Pressure at End of Bladder Filling at Week 24 (em HO)                                              | Detrusor Pressure at End of Bladder Filling at Week 24 (em HO)                                              |
| Baseline, n I Mean (SD)                                                                                     | 42                                                                                                          | 42.25 (26.27)                                                                                               | 24                                                                                                          | 38.65 (17.97)                                                                                               | 66                                                                                                          | 40.94 (23.51)                                                                                               |
| Week 24, n I Mean (SD)                                                                                      | 37                                                                                                          | 25.66 (21.24)                                                                                               | 23                                                                                                          | 27.84 (18.92)                                                                                               | 60                                                                                                          | 26.50 (20.24)                                                                                               |
| Changefrom Baseline,nt                                                                                      |                                                                                                             | 36                                                                                                          |                                                                                                             | 22                                                                                                          |                                                                                                             | 58                                                                                                          |
| Mean (SD)                                                                                                   |                                                                                                             | -18.11 (19.97)                                                                                              |                                                                                                             | -13.19 (19.91)                                                                                              |                                                                                                             | -16.24 (19.92)                                                                                              |
| 10 %56                                                                                                      |                                                                                                             | (-24.87, -11.35)                                                                                            |                                                                                                             | (-22.02, -4.36)                                                                                             |                                                                                                             | (-21.48, -11.01)                                                                                            |
| P valuet                                                                                                    |                                                                                                             | ≤0.001                                                                                                      |                                                                                                             | 0.005                                                                                                       |                                                                                                             | ≤0.001                                                                                                      |
| Bladder Volume until First Detrusor Contraction >15 cm HgO at Week 24 (mL)                                  | Bladder Volume until First Detrusor Contraction >15 cm HgO at Week 24 (mL)                                  | Bladder Volume until First Detrusor Contraction >15 cm HgO at Week 24 (mL)                                  | Bladder Volume until First Detrusor Contraction >15 cm HgO at Week 24 (mL)                                  | Bladder Volume until First Detrusor Contraction >15 cm HgO at Week 24 (mL)                                  | Bladder Volume until First Detrusor Contraction >15 cm HgO at Week 24 (mL)                                  | Bladder Volume until First Detrusor Contraction >15 cm HgO at Week 24 (mL)                                  |
| Baseline, n§                                                                                                |                                                                                                             | 28                                                                                                          |                                                                                                             | 13                                                                                                          |                                                                                                             | 41                                                                                                          |
| Median (Ql -- Q3)                                                                                           |                                                                                                             | 63.50 (42.00 -99.00)                                                                                        |                                                                                                             | 81.00 (53.00- 186.00)                                                                                       |                                                                                                             | 68.00 (44.70 - 100.30)                                                                                      |
| Week 24,n§                                                                                                  |                                                                                                             | 13                                                                                                          |                                                                                                             | 8                                                                                                           |                                                                                                             | 21                                                                                                          |
| Median (Ql - Q3)                                                                                            |                                                                                                             | 68.00(32.00-110.00)                                                                                         |                                                                                                             | 62.00 (4.00-95.15)                                                                                          |                                                                                                             | 68.00(20.00-98.00)                                                                                          |
| P value                                                                                                     |                                                                                                             | 0.002                                                                                                       |                                                                                                             | 0.039                                                                                                       |                                                                                                             | 0.001                                                                                                       |
| Maximum Catheterized Volume per Catheterization at Week 24 (mL)                                             | Maximum Catheterized Volume per Catheterization at Week 24 (mL)                                             | Maximum Catheterized Volume per Catheterization at Week 24 (mL)                                             | Maximum Catheterized Volume per Catheterization at Week 24 (mL)                                             | Maximum Catheterized Volume per Catheterization at Week 24 (mL)                                             | Maximum Catheterized Volume per Catheterization at Week 24 (mL)                                             | Maximum Catheterized Volume per Catheterization at Week 24 (mL)                                             |
| Baseline, n Mean (SD)                                                                                       | 43                                                                                                          | 302.41 (107.29)                                                                                             | 24                                                                                                          | 364.63 (111.27)                                                                                             | 67                                                                                                          | 324.69 (112.00)                                                                                             |
| Week 24, n I Mean (SD)                                                                                      | 41                                                                                                          | 353.95 (104.47)                                                                                             |                                                                                                             | 449.98 (146.62)                                                                                             | 65                                                                                                          | 389.41 (129.34)                                                                                             |
| Changefrom Baseline,nt                                                                                      |                                                                                                             | 41                                                                                                          |                                                                                                             | 23                                                                                                          |                                                                                                             | 64                                                                                                          |
| Mean (SD)                                                                                                   |                                                                                                             | 49.88 (103.70)                                                                                              |                                                                                                             | 84.39 (121.98)                                                                                              |                                                                                                             | 62.28 (110.91)                                                                                              |
| 95% CI                                                                                                      |                                                                                                             | (17.1, 82.6)                                                                                                |                                                                                                             | (31.6, 137.1)                                                                                               |                                                                                                             | (34.6, 90.0)                                                                                                |
| P valuet                                                                                                    |                                                                                                             | 0.004                                                                                                       |                                                                                                             | 0.003                                                                                                       |                                                                                                             | ≤0.001                                                                                                      |
| Arerage Catheterized Volume per Catheterization at Week 24 (mL)                                             | Arerage Catheterized Volume per Catheterization at Week 24 (mL)                                             | Arerage Catheterized Volume per Catheterization at Week 24 (mL)                                             | Arerage Catheterized Volume per Catheterization at Week 24 (mL)                                             | Arerage Catheterized Volume per Catheterization at Week 24 (mL)                                             | Arerage Catheterized Volume per Catheterization at Week 24 (mL)                                             | Arerage Catheterized Volume per Catheterization at Week 24 (mL)                                             |
| Baseline, n I Mean (SD)                                                                                     | 43                                                                                                          | 236.73 (70.52)                                                                                              | 24                                                                                                          | 278.98 (91.96)                                                                                              | 67                                                                                                          | 251.87 (80.80)                                                                                              |
| Week 24, n  Mean (SD)                                                                                       | 41                                                                                                          | 279.74 (71.86)                                                                                              | 24                                                                                                          | 335.13 (97.89)                                                                                              | 65                                                                                                          | 300.19 (86.01)                                                                                              |
| Change from Baseline,nt                                                                                     |                                                                                                             | 41                                                                                                          |                                                                                                             | 23                                                                                                          |                                                                                                             | 64                                                                                                          |
| Mean (SD)                                                                                                   |                                                                                                             | 41.63 (58.03)                                                                                               |                                                                                                             | 59.31 (82.22)                                                                                               |                                                                                                             | 47.99 (67.62)                                                                                               |
| 95% CI                                                                                                      |                                                                                                             | (23.3, 60.0)                                                                                                |                                                                                                             | (23.8, 94.9)                                                                                                |                                                                                                             | (31.1, 64.9)                                                                                                |
| P valuet                                                                                                    |                                                                                                             | ≤0.001                                                                                                      |                                                                                                             | 0.002                                                                                                       |                                                                                                             | ≤0.001                                                                                                      |
| Maximum Catheterized Daytime Volume at Week 24 (mL)                                                         | Maximum Catheterized Daytime Volume at Week 24 (mL)                                                         | Maximum Catheterized Daytime Volume at Week 24 (mL)                                                         | Maximum Catheterized Daytime Volume at Week 24 (mL)                                                         | Maximum Catheterized Daytime Volume at Week 24 (mL)                                                         | Maximum Catheterized Daytime Volume at Week 24 (mL)                                                         | Maximum Catheterized Daytime Volume at Week 24 (mL)                                                         |
| Baseline, n  Mean (SD)                                                                                      | 43                                                                                                          | 300.16 (105.71)                                                                                             | 24                                                                                                          | 367.52 (119.03)                                                                                             | 67                                                                                                          | 324.29 (114.49)                                                                                             |
| Week 24, n Mean (SD)                                                                                        | 41                                                                                                          | 345.91 (84.61)                                                                                              | 24                                                                                                          | 449.98 (146.62)                                                                                             | 65                                                                                                          | 384.34 (121.50)                                                                                             |
| Changefrom Baseline,nt                                                                                      |                                                                                                             | 41                                                                                                          |                                                                                                             | 23                                                                                                          |                                                                                                             | 64                                                                                                          |
| Mean (SD)                                                                                                   |                                                                                                             | 44.20 (98.31)                                                                                               |                                                                                                             | 81.37 (117.77)                                                                                              |                                                                                                             | 57.56 (106.32)                                                                                              |
| 10 %56                                                                                                      |                                                                                                             | (13.2, 75.2)                                                                                                |                                                                                                             | (30.4, 132.3)                                                                                               |                                                                                                             | (31.0, 84.1)                                                                                                |
| Pvaluet                                                                                                     |                                                                                                             | 0.006                                                                                                       |                                                                                                             | 0.003                                                                                                       |                                                                                                             | 0.001                                                                                                       |
| Arerage Mforning Catheterized Volume (based on first catheterization after patient woke up) at Week 24 (mL) | Arerage Mforning Catheterized Volume (based on first catheterization after patient woke up) at Week 24 (mL) | Arerage Mforning Catheterized Volume (based on first catheterization after patient woke up) at Week 24 (mL) | Arerage Mforning Catheterized Volume (based on first catheterization after patient woke up) at Week 24 (mL) | Arerage Mforning Catheterized Volume (based on first catheterization after patient woke up) at Week 24 (mL) | Arerage Mforning Catheterized Volume (based on first catheterization after patient woke up) at Week 24 (mL) | Arerage Mforning Catheterized Volume (based on first catheterization after patient woke up) at Week 24 (mL) |
| Baseline, n I Mean (SD)                                                                                     | 42                                                                                                          | 272.23 (102.40)                                                                                             | 23                                                                                                          | 305.00 (102.40)                                                                                             | 65                                                                                                          | 283.82 (102.82)                                                                                             |
| Week 24, n Mean (SD)                                                                                        | 36                                                                                                          | 311.35 (82.33)                                                                                              | 22                                                                                                          | 384.87 (135.46)                                                                                             | 58                                                                                                          | 339.24 (110.53)                                                                                             |
| Changefrom Baseline, nt                                                                                     |                                                                                                             | 36                                                                                                          |                                                                                                             | 20                                                                                                          |                                                                                                             | 56                                                                                                          |
| Mean (SD)                                                                                                   |                                                                                                             | 40.76 (116.41)                                                                                              |                                                                                                             | 86.66 (96.55)                                                                                               |                                                                                                             | 57.15 (111.07)                                                                                              |
| 95% CI                                                                                                      |                                                                                                             | (1..4, 80.2)                                                                                                |                                                                                                             | (41.5, 131.8)                                                                                               |                                                                                                             | (27.4, 86.9)                                                                                                |
| P valuet                                                                                                    |                                                                                                             | 0.043                                                                                                       |                                                                                                             | ≤0.001                                                                                                      |                                                                                                             | ≤0.001                                                                                                      |

<div style=\"page-break-after: always\"></div>

|                                                                                                                                            |                                                                                                                                            | Children (3 to < 12 Years) n=43                                                                                                            | Children (3 to < 12 Years) n=43                                                                                                            | Adolescents (12 to <18 Years) n=25                                                                                                         | Adolescents (12 to <18 Years) n=25                                                                                                         | All Patients (3 to <18 Years) n =68                                                                                                        | All Patients (3 to <18 Years) n =68                                                                                                        |
|--------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| Number of Dry (Leakage-free) Days per 7 Days (Day and Night Time) at Week 24                                                               | Number of Dry (Leakage-free) Days per 7 Days (Day and Night Time) at Week 24                                                               | Number of Dry (Leakage-free) Days per 7 Days (Day and Night Time) at Week 24                                                               | Number of Dry (Leakage-free) Days per 7 Days (Day and Night Time) at Week 24                                                               | Number of Dry (Leakage-free) Days per 7 Days (Day and Night Time) at Week 24                                                               | Number of Dry (Leakage-free) Days per 7 Days (Day and Night Time) at Week 24                                                               | Number of Dry (Leakage-free) Days per 7 Days (Day and Night Time) at Week 24                                                               | Number of Dry (Leakage-free) Days per 7 Days (Day and Night Time) at Week 24                                                               |
|                                                                                                                                            | Baseline, n Mean (SD)                                                                                                                      | 43                                                                                                                                         | 0.83 (2.08)                                                                                                                                | 24                                                                                                                                         | 1.56 (2.41)                                                                                                                                | 67                                                                                                                                         | 1.09 (2.21)                                                                                                                                |
|                                                                                                                                            | Week 24, nMean (SD)                                                                                                                        | 41                                                                                                                                         | 2.22 (2.54)                                                                                                                                | 25                                                                                                                                         | 3.58 (3.17)                                                                                                                                | 66                                                                                                                                         | 2.73 (2.85)                                                                                                                                |
| Change from Baseline, n↑                                                                                                                   | Change from Baseline, n↑                                                                                                                   | 41                                                                                                                                         | 41                                                                                                                                         | 24                                                                                                                                         | 24                                                                                                                                         | 65                                                                                                                                         | 65                                                                                                                                         |
| Mean (SD)                                                                                                                                  | Mean (SD)                                                                                                                                  | 1.34 (2.18)                                                                                                                                | 1.34 (2.18)                                                                                                                                | 2.17 (2.38)                                                                                                                                | 2.17 (2.38)                                                                                                                                | 1.65 (2.27)                                                                                                                                | 1.65 (2.27)                                                                                                                                |
| 95% CI                                                                                                                                     | 95% CI                                                                                                                                     | (0.7,2.0)                                                                                                                                  | (0.7,2.0)                                                                                                                                  | (1.2,3.2)                                                                                                                                  | (1.2,3.2)                                                                                                                                  | (1.1, 2.2)                                                                                                                                 | (1.1, 2.2)                                                                                                                                 |
| P valuet                                                                                                                                   | P valuet                                                                                                                                   | ≤0.001                                                                                                                                     | ≤0.001                                                                                                                                     | <0.001                                                                                                                                     | <0.001                                                                                                                                     | <0.001                                                                                                                                     | <0.001                                                                                                                                     |
| Mean Number of Leakage Episodes per Day (Day and Night Time) at Week 24: Ad-hoc Analysis With Imputation*                                  | Mean Number of Leakage Episodes per Day (Day and Night Time) at Week 24: Ad-hoc Analysis With Imputation*                                  | Mean Number of Leakage Episodes per Day (Day and Night Time) at Week 24: Ad-hoc Analysis With Imputation*                                  | Mean Number of Leakage Episodes per Day (Day and Night Time) at Week 24: Ad-hoc Analysis With Imputation*                                  | Mean Number of Leakage Episodes per Day (Day and Night Time) at Week 24: Ad-hoc Analysis With Imputation*                                  | Mean Number of Leakage Episodes per Day (Day and Night Time) at Week 24: Ad-hoc Analysis With Imputation*                                  | Mean Number of Leakage Episodes per Day (Day and Night Time) at Week 24: Ad-hoc Analysis With Imputation*                                  | Mean Number of Leakage Episodes per Day (Day and Night Time) at Week 24: Ad-hoc Analysis With Imputation*                                  |
|                                                                                                                                            | Baseline, n  Mean (SD)                                                                                                                     | 39                                                                                                                                         | 4.54 (12.32)                                                                                                                               | 20                                                                                                                                         | 1.93 (1.66)                                                                                                                                | 59                                                                                                                                         | 3.65 (10.10)                                                                                                                               |
|                                                                                                                                            | Week 24, n |Mean (SD)                                                                                                                      | 31                                                                                                                                         | 5.00 (23.05)                                                                                                                               | 15                                                                                                                                         | 1.63 (1.19)                                                                                                                                | 46                                                                                                                                         | 3.90 (18.90)                                                                                                                               |
| Changefrom Baseline,n                                                                                                                      | Changefrom Baseline,n                                                                                                                      | 31                                                                                                                                         | 31                                                                                                                                         | 14                                                                                                                                         | 14                                                                                                                                         | 45                                                                                                                                         | 45                                                                                                                                         |
| Mean (SD)                                                                                                                                  | Mean (SD)                                                                                                                                  | 0.18 (10.05)                                                                                                                               | 0.18 (10.05)                                                                                                                               | -0.75 (1.28)                                                                                                                               | -0.75 (1.28)                                                                                                                               | -0.11 (8.34)                                                                                                                               | -0.11 (8.34)                                                                                                                               |
| 95% CI                                                                                                                                     | 95% CI                                                                                                                                     | (-3.5,3.9)                                                                                                                                 | (-3.5,3.9)                                                                                                                                 | (-1.5,0.0)                                                                                                                                 | (-1.5,0.0)                                                                                                                                 | (-2.6,2.4)                                                                                                                                 | (-2.6,2.4)                                                                                                                                 |
| P valuet                                                                                                                                   | P valuet                                                                                                                                   | 0.922                                                                                                                                      | 0.922                                                                                                                                      | 0.047                                                                                                                                      | 0.047                                                                                                                                      | 0.929                                                                                                                                      | 0.929                                                                                                                                      |
| Mean Number of Leakage Episodes per Day (Day and Night Time) at Week 24: Ad-hoc Analysis With Imputation, Without Data From l Patient*t.** | Mean Number of Leakage Episodes per Day (Day and Night Time) at Week 24: Ad-hoc Analysis With Imputation, Without Data From l Patient*t.** | Mean Number of Leakage Episodes per Day (Day and Night Time) at Week 24: Ad-hoc Analysis With Imputation, Without Data From l Patient*t.** | Mean Number of Leakage Episodes per Day (Day and Night Time) at Week 24: Ad-hoc Analysis With Imputation, Without Data From l Patient*t.** | Mean Number of Leakage Episodes per Day (Day and Night Time) at Week 24: Ad-hoc Analysis With Imputation, Without Data From l Patient*t.** | Mean Number of Leakage Episodes per Day (Day and Night Time) at Week 24: Ad-hoc Analysis With Imputation, Without Data From l Patient*t.** | Mean Number of Leakage Episodes per Day (Day and Night Time) at Week 24: Ad-hoc Analysis With Imputation, Without Data From l Patient*t.** | Mean Number of Leakage Episodes per Day (Day and Night Time) at Week 24: Ad-hoc Analysis With Imputation, Without Data From l Patient*t.** |
|                                                                                                                                            | Baseline, n Mean (SD)                                                                                                                      | 38                                                                                                                                         | 2.64 (3.51)                                                                                                                                | 20                                                                                                                                         | 1.93 (1.66)                                                                                                                                | 58                                                                                                                                         | 2.40 (3.00)                                                                                                                                |
|                                                                                                                                            | Week 24, n Mean (SD)                                                                                                                       | 30                                                                                                                                         | 0.87 (1.35)                                                                                                                                | 15                                                                                                                                         | 1.63 (1.19)                                                                                                                                | 45                                                                                                                                         | 1.12 (1.34)                                                                                                                                |
| Changefrom Baseline,n                                                                                                                      | Changefrom Baseline,n                                                                                                                      | 30                                                                                                                                         | 30                                                                                                                                         | 14                                                                                                                                         | 14                                                                                                                                         | 44                                                                                                                                         | 44                                                                                                                                         |
| Mean (SD)                                                                                                                                  | Mean (SD)                                                                                                                                  | -1.57 (2.63)                                                                                                                               | -1.57 (2.63)                                                                                                                               | -0.75 (1.28)                                                                                                                               | -0.75 (1.28)                                                                                                                               | -1.31 (2.30)                                                                                                                               | -1.31 (2.30)                                                                                                                               |
| 95% CI                                                                                                                                     | 95% CI                                                                                                                                     | (-2.5,-0.6)                                                                                                                                | (-2.5,-0.6)                                                                                                                                | (-1.5, 0.0)                                                                                                                                | (-1.5, 0.0)                                                                                                                                | (-2.0,-0.6)                                                                                                                                | (-2.0,-0.6)                                                                                                                                |
| P valuet                                                                                                                                   | P valuet                                                                                                                                   | 0.003                                                                                                                                      | 0.003                                                                                                                                      |                                                                                                                                            |                                                                                                                                            | <0.001                                                                                                                                     | <0.001                                                                                                                                     |

All patients who received ≥ 1 dose of study drug and had both a valid nonmissing baseline measurement and

≥ 1 postbaseline measurement for the primary efficacy endpoint (maximum cystometric capacity) (FAS). During urodynamic assessments, the bladder was filled until voiding/leakage began, or until the patient experienced pain or discomfort, or because dangerous high detrusor pressure, or 135% of maximum catheterized volume for age had been reached.

CI: confidence interval; FAS: full analysis set; Q1: first quartile; Q3: third quartile

† The number of patients with a nonmissing change from baseline to week 4 or 24.

‡ From a 2-sided paired t-test, testing the null hypothesis that change from baseline is equal to 0.

§ If no detrusor contraction of &gt; 15 cm H2O occurred, the bladder volume was imputed with maximum cystometric capacity.

¶ From a Wilcoxon signed rank test, testing the null hypothesis that week 24 median is equal to baseline median.

†† Patients who did not report any leakage episode during the visit were imputed with a '0' for that visit.

‡‡ Data from 1 child are excluded because this child erroneously reported the weight of the leakage instead of the number of leakage episodes.

## Secondary Patient- or Clinician-reported Questionnaire Endpoints

The PIN-Q measures the emotional impact that urinary incontinence has on a child. It is based on ediary records and the score ranges from 0 (no effect) to 80 (worst effect). No impact of the treatment was observed in children and the changes were not significant in adolescents. With respect to the global impression of the treatment a clinicians reported the conditions as much improved or very much improved in &gt;70% of patients while modest improvement was reported from the patients' perspective.

<div style=\"page-break-after: always\"></div>

## Patient e-Diary Endpoints of Bladder Volume at Week 52

## · Average Catheterized Volume Per Catheterization

Figure 4 - Change From Baseline in Average Catheterized Volume per Catheterization (mL) by Study Week (FAS): All Patients (3 to &lt; 18 years of age)

Age Group = All Subjects (Aged 3 years to Less than 18 Years)

<!-- image -->

All patients who received ≥ 1 dose of study drug and had both a valid nonmissing baseline measurement and ≥ 1 postbaseline measurement for the primary efficacy endpoint (maximum cystometric capacity) (full analysis set, FAS).

Mean change from baseline with 95% confidence interval is shown.

- # Change from baseline is statistically significantly not equal to 0 at the 0.05 level (t-test).
- Maximum Catheterized Volume per Catheterization

Figure 5 - Change From Baseline in Maximum Catheterized Volume per Catheterization (mL) by Study Week (FAS): All Patients (3 to &lt; 18 years of age)

Age Group = All Subjects (Aged 3 years to Less than 18 Years)

<!-- image -->

All patients who received ≥ 1 dose of study drug and had both a valid nonmissing baseline measurement and

<div style=\"page-break-after: always\"></div>

- ≥ 1 postbaseline measurement for the primary efficacy endpoint (maximum cystometric capacity) (full analysis set, FAS).

Mean change from baseline with 95% confidence interval is shown.

- # Change from baseline is statistically significantly not equal to 0 at the 0.05 level (t-test).
- Maximum Catheterized Daytime Volume

Figure 6 - Change From Baseline in Maximum Catheterized Daytime Volume (mL) by Study Week (FAS): All Patients (3 to &lt; 18 years of age)

Age Group = All Subjects (Aged 3 years to Less than 18 Years)

<!-- image -->

All patients who received ≥ 1 dose of study drug and had both a valid nonmissing baseline measurement and ≥ 1 postbaseline measurement for the primary efficacy endpoint (maximum cystometric capacity) (full analysis set, FAS).

Mean change from baseline with 95% confidence interval is shown.

- # Change from baseline is statistically significantly not equal to 0 at the 0.05 level (t-test).
- Average Morning Catheterized Volume

Figure 7 - Change From Baseline in Average Morning Catheterized Volume (mL) by Study Week (FAS): All Patients (3 to &lt; 18 years of age)

Age Group = All Subjects (Aged 3 years to Less than 18 Years)

<!-- image -->

All patients who received ≥ 1 dose of study drug and had both a valid nonmissing baseline measurement and ≥ 1 postbaseline measurement for the primary efficacy endpoint (maximum cystometric capacity) (full analysis

<div style=\"page-break-after: always\"></div>

set, FAS). Mean change from baseline with 95% confidence interval is shown. # Change from baseline is statistically significantly not equal to 0 at the 0.05 level (t-test).

## · Ancillary analyses

Subgroup Analysis

## Sex

A statistically significant (P &lt; 0.001) increase in MCC from baseline to week 24 LOCF was observed for both sexes in all age groups for the FAS using an ANCOVA model including sex and age group as fixed effects, sex by age group as interaction term and baseline value as a covariate. The impact of sex on the primary endpoint was limited.

## Race

The increase from baseline to week 24 LOCF in MCC was larger in white than in Asian patients. However, the subgroup for Asian race was limited in size and definitive conclusions as a function of race are limited.

## Formulation

Both formulation subgroups, tablets and suspension, showed statistically significant (P &lt; 0.001) MCC increase from baseline, for all analyses, including the ANCOVA model and the Wilcoxon signed-rank test. At week 24 LOCF, the mean (SD) increase from baseline in MCC was 121.61 (14.60) mL for the tablet formulation and 50.71 (15.08) mL for the suspension formulation.

The formulation subgroup analyses may be confounded by age. In general, adolescents took tablets, and children took the suspension formulation more frequently than the tablet formulation.

## · Summary of main efficacy results

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

<div style=\"page-break-after: always\"></div>

Table 9 - Summary of Efficacy for Trial 178-CL-206A

| Title: An Open-label, Baseline-controlled, Multicenter, Phase 3 Dose-titration Study Followed by a Fixed-dose Observation Period to Evaluate Efficacy, Safety and Pharmacokinetics of Mirabegron in Children and Adolescents From 3 to Less Than 18 Years of Age with Neurogenic Detrusor Overactivity (NDO) on Clean Intermittent Catheterization (CIC)   | Title: An Open-label, Baseline-controlled, Multicenter, Phase 3 Dose-titration Study Followed by a Fixed-dose Observation Period to Evaluate Efficacy, Safety and Pharmacokinetics of Mirabegron in Children and Adolescents From 3 to Less Than 18 Years of Age with Neurogenic Detrusor Overactivity (NDO) on Clean Intermittent Catheterization (CIC)   | Title: An Open-label, Baseline-controlled, Multicenter, Phase 3 Dose-titration Study Followed by a Fixed-dose Observation Period to Evaluate Efficacy, Safety and Pharmacokinetics of Mirabegron in Children and Adolescents From 3 to Less Than 18 Years of Age with Neurogenic Detrusor Overactivity (NDO) on Clean Intermittent Catheterization (CIC)                                                            |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study Identifier                                                                                                                                                                                                                                                                                                                                           | 178-CL-206A,EudraCT 2015-002876-25                                                                                                                                                                                                                                                                                                                         | 178-CL-206A,EudraCT 2015-002876-25                                                                                                                                                                                                                                                                                                                                                                                  |
| Design                                                                                                                                                                                                                                                                                                                                                     | open-label, baseline-controlled, multicenter                                                                                                                                                                                                                                                                                                               | open-label, baseline-controlled, multicenter                                                                                                                                                                                                                                                                                                                                                                        |
|                                                                                                                                                                                                                                                                                                                                                            | DurationofMainPhase: Duration of Run-in Phase: Duration of Extension Phase:                                                                                                                                                                                                                                                                                | 24 weeks maximum of 28 daysbeforebaseline 28 weeks, beginning after week 24 and continuing to week 52                                                                                                                                                                                                                                                                                                               |
| Hypothesis Treatment                                                                                                                                                                                                                                                                                                                                       | Superiority                                                                                                                                                                                                                                                                                                                                                | Superiority                                                                                                                                                                                                                                                                                                                                                                                                         |
| Groups                                                                                                                                                                                                                                                                                                                                                     | Children                                                                                                                                                                                                                                                                                                                                                   | Male and female children from 3 to < 12 years of age. The initial dose of oral mirabegron was based on the patient's weight and was targeted to achieve steady-state exposures similar to those of adults administered the mirabegron 25 mg tablet once daily (PED25). At week 2, 4 or 8, patients were uptitrated to PED50 based on given dose titration criteria. Duration of treatment: 52 weeks n = 56 enrolled |
|                                                                                                                                                                                                                                                                                                                                                            | Adolescents                                                                                                                                                                                                                                                                                                                                                | Male and female adolescents from 12 to < 18 years of age. The initial dose of oral mirabegron was based on the patient's weight (PED25). At week 2, 4 or 8, patients were uptitrated to PED50 based on given dose titration criteria. Duration of treatment: 52 weeks n = 35 enrolled                                                                                                                               |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                           | All Patients                             |                                                                                  | Male and female children and adolescents from 3 to < 18 years of age. The initial dose of oral mirabegron was based on the patient's weight (PED25). At week 2, 4 or 8, patients were uptitrated to PED50 based on given dose titration criteria. Durationoftreatment:52weeks n=91enrolled                                                                                                                         |
|---------------------------|------------------------------------------|----------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Endpoints and Definitions | Primary Endpoint                         | Maximum Cystometric Capacity (MCC) at Week 24                                    | Change from baseline in MCC (mL) after 24 weeks of treatment (based on filling urodynamics)                                                                                                                                                                                                                                                                                                                        |
| Endpoints and Definitions | Select Secondary MCC at Week 4 Endpoints |                                                                                  | Change from baseline in MCC (mL) after 4 weeks of treatment (based on filling urodynamics)                                                                                                                                                                                                                                                                                                                         |
| Endpoints and Definitions | Select Secondary MCC at Week 4 Endpoints | Bladder Compliance at Week 24                                                    | Change from baseline in bladder compliance (change in volume/change in pressure [mL/cm H2O]) after 24 weeks of treatment                                                                                                                                                                                                                                                                                           |
| Endpoints and Definitions | Select Secondary MCC at Week 4 Endpoints | No. of Overactive Detrusor Contractions Until End of Bladder- filling at Week 24 | Change from baseline in number of overactivedetrusor contractions (> 15 cm H2O) until end ofbladder filling after 24 weeks of treatment                                                                                                                                                                                                                                                                            |
| Endpoints and Definitions | Select Secondary MCC at Week 4 Endpoints | Detrusor Pressure at End of Bladder Filling at Week 24                           | Change from baseline in detrusor pressure (cm HzO) at end of bladder filling after 24 weeks of treatment                                                                                                                                                                                                                                                                                                           |
| Endpoints and Definitions | Select Secondary MCC at Week 4 Endpoints | Bladder Volume until First Detrusor Rank Test                                    | Change from baseline in filling volume (mL) until first overactive detrusor Contraction at Week contraction (> 15 cm H2O) until end of 24: Wilcoxon Signedbladder filling after 24 weeks of treatment using a Wilcoxon signed rank test to test the null hypothesis that week 24 median was equal to baseline median. If no detrusor contraction of > 15 cm H2O occurred, the bladder yolume was imputed with MCC. |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| BladderVolume until First Detnusor Contraction at Week 24: Paired t-test                                                                                                   | Change ffrom baseline in filling volume (mL) until first overactive detnusor contraction (> 15 cm HO) until end of bladder filling after 24 weeks of treatment using a 2-sided paired t-test to test the null hypothesis that change from baseline was equal to O. If no detrusor contraction of> 15 cm H2O occunred, the bladder volume was imputed with MCC.                                                                                                                                                                                                                                                      |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Maximum per Catheterization at Week 24 Average per Catheterization at Week 24                                                                                              | Change from baseline in maximum Catheterized Volumecatheterized volume (mL) per catheterization after 24 weeks of treatment Change from baseline in average Catheterized Volumecatheterized volume (mL) per catheterization after 24 weeks of treatment                                                                                                                                                                                                                                                                                                                                                             |
| Maximum Catheterized Daytime Volume at Week 24                                                                                                                             | Change ffrom baseline in maximum catheterized daytime volume (mL) after 24 weeks of treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Average Moming at Week 24                                                                                                                                                  | Change from baseline in average Catheterized Volumemorming catheterized volume (mL) based on first catheterization after patient woke up) after 24 weeks of treatment                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| No. ofDry Days/7 Days at Week 24                                                                                                                                           | Change from baseline in number of dry (leakage-ffee) days per 7 days (day and might time) after 24 weeks of treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Mean No. of Leakage Episodes Der Day at Week 24: Ad-hoc Analysis With Imputation Mean No. of Leakage Episodes per Day at Week 24: Ad-hoc Analysis With Data From 1 Patient | Change from baseline in mean number of leakage episodes per day (day and might time) after 24 weeks of treatment. Patients who did not report any leakage episode during the visit were imputed with a 'O' for that visit. Change from baseline in mean number ofleakage episodes per day (day and might time) after 24 weeks of treatment. Patients who did not report any leakage episode during the visit were imputed Imputation, Without with a 'O' for that visit. Data fom 1 child are excluded because this child erroneously reported the weight of the leakage instead of the number of leakage episodes. |

<div style=\"page-break-after: always\"></div>

| Database Lock                                   | 01 JUL2019                                                                                                                                                                                                                                   | 01 JUL2019                                                                                                                                                                                                                                   | 01 JUL2019                                                                                                                                                                                                                                   | 01 JUL2019                                                                                                                                                                                                                                   | 01 JUL2019                                                                                                                                                                                                                                   |
|-------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Results and Analysis                            | Results and Analysis                                                                                                                                                                                                                         | Results and Analysis                                                                                                                                                                                                                         | Results and Analysis                                                                                                                                                                                                                         | Results and Analysis                                                                                                                                                                                                                         | Results and Analysis                                                                                                                                                                                                                         |
| Analysis                                        |                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                              |
| Description                                     | Primary Analysis                                                                                                                                                                                                                             | Primary Analysis                                                                                                                                                                                                                             | Primary Analysis                                                                                                                                                                                                                             | Primary Analysis                                                                                                                                                                                                                             | Primary Analysis                                                                                                                                                                                                                             |
| Analysis Population and Time Point              | Full Analysis Set (All patients who received ≥ 1 dose of study drug and had both a valid nonmissing baseline measurement and ≥ 1 postbaseline measurement for the primary efficacy endpoint [MCC]) Week 24 (last observation caried forward) | Full Analysis Set (All patients who received ≥ 1 dose of study drug and had both a valid nonmissing baseline measurement and ≥ 1 postbaseline measurement for the primary efficacy endpoint [MCC]) Week 24 (last observation caried forward) | Full Analysis Set (All patients who received ≥ 1 dose of study drug and had both a valid nonmissing baseline measurement and ≥ 1 postbaseline measurement for the primary efficacy endpoint [MCC]) Week 24 (last observation caried forward) | Full Analysis Set (All patients who received ≥ 1 dose of study drug and had both a valid nonmissing baseline measurement and ≥ 1 postbaseline measurement for the primary efficacy endpoint [MCC]) Week 24 (last observation caried forward) | Full Analysis Set (All patients who received ≥ 1 dose of study drug and had both a valid nonmissing baseline measurement and ≥ 1 postbaseline measurement for the primary efficacy endpoint [MCC]) Week 24 (last observation caried forward) |
| Description Descriptive                         | Treatment Group                                                                                                                                                                                                                              | Children                                                                                                                                                                                                                                     | Adolescents                                                                                                                                                                                                                                  | Adolescents                                                                                                                                                                                                                                  | All Patients                                                                                                                                                                                                                                 |
| Statistics                                      | No. of Patients                                                                                                                                                                                                                              | 43                                                                                                                                                                                                                                           | 25                                                                                                                                                                                                                                           | 25                                                                                                                                                                                                                                           | 68                                                                                                                                                                                                                                           |
| and Estimate                                    | MCC at Week 24 (Mean [SD])                                                                                                                                                                                                                   | 72.09 (87.09)                                                                                                                                                                                                                                | 113.21 (82.99)                                                                                                                                                                                                                               | 113.21 (82.99)                                                                                                                                                                                                                               | 87.20 (87.30)                                                                                                                                                                                                                                |
| Variability                                     | 95% CI                                                                                                                                                                                                                                       | (45.28, 98.89)                                                                                                                                                                                                                               | (78.95, 147.47)                                                                                                                                                                                                                              | (78.95, 147.47)                                                                                                                                                                                                                              | (66.07, 108.33)                                                                                                                                                                                                                              |
|                                                 | P value                                                                                                                                                                                                                                      | ≤0.001                                                                                                                                                                                                                                       | ≤0.001                                                                                                                                                                                                                                       | ≤0.001                                                                                                                                                                                                                                       | <0.001                                                                                                                                                                                                                                       |
| Analysis Description                            | Select Secondary Analyses                                                                                                                                                                                                                    | Select Secondary Analyses                                                                                                                                                                                                                    | Select Secondary Analyses                                                                                                                                                                                                                    | Select Secondary Analyses                                                                                                                                                                                                                    | Select Secondary Analyses                                                                                                                                                                                                                    |
| Descriptive Statistics and Estimate Variability | MCC at Week 4                                                                                                                                                                                                                                | Treatment Group                                                                                                                                                                                                                              | Children                                                                                                                                                                                                                                     | AdolescentsAll Patients                                                                                                                                                                                                                      | AdolescentsAll Patients                                                                                                                                                                                                                      |
|                                                 | MCC at Week 4                                                                                                                                                                                                                                | No. of Patients                                                                                                                                                                                                                              | 41                                                                                                                                                                                                                                           | 23                                                                                                                                                                                                                                           | 64                                                                                                                                                                                                                                           |
|                                                 | MCC at Week 4                                                                                                                                                                                                                                | Mean (SD)                                                                                                                                                                                                                                    | 41.36 (71.64)                                                                                                                                                                                                                                | 80.78 (96.15)                                                                                                                                                                                                                                | 55.53 (82.76)                                                                                                                                                                                                                                |
|                                                 | MCC at Week 4                                                                                                                                                                                                                                | I0 %56                                                                                                                                                                                                                                       | (18.75, 63.97)                                                                                                                                                                                                                               | (39.20, 122.36)                                                                                                                                                                                                                              | (34.85, 76.20)                                                                                                                                                                                                                               |
|                                                 | MCC at Week 4                                                                                                                                                                                                                                | P value (2-sided paired t-test)                                                                                                                                                                                                              | 0.001                                                                                                                                                                                                                                        | <0.001                                                                                                                                                                                                                                       | ≤0.001                                                                                                                                                                                                                                       |
|                                                 | Bladder Compliance at Week 24                                                                                                                                                                                                                | Treatment Group                                                                                                                                                                                                                              | Children                                                                                                                                                                                                                                     | Adolescents                                                                                                                                                                                                                                  | All Patients                                                                                                                                                                                                                                 |
|                                                 |                                                                                                                                                                                                                                              | No. of Patients                                                                                                                                                                                                                              | 33                                                                                                                                                                                                                                           | 21                                                                                                                                                                                                                                           | 54                                                                                                                                                                                                                                           |
|                                                 |                                                                                                                                                                                                                                              | Mean (SD)                                                                                                                                                                                                                                    | 14.62 (42.09)                                                                                                                                                                                                                                | 13.59 (15.02)                                                                                                                                                                                                                                | 14.22 (33.99)                                                                                                                                                                                                                                |
|                                                 |                                                                                                                                                                                                                                              | 95% CI                                                                                                                                                                                                                                       | (-0.31,29.54)(6.75, 20.42)(4.94, 23.49)                                                                                                                                                                                                      |                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                              |
|                                                 | No. of Overactive                                                                                                                                                                                                                            | P value (2-sided paired t-test) Treatment Group                                                                                                                                                                                              | 0.055                                                                                                                                                                                                                                        | <0.001                                                                                                                                                                                                                                       | 0.003                                                                                                                                                                                                                                        |
|                                                 |                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                              | Children                                                                                                                                                                                                                                     | Adolescents                                                                                                                                                                                                                                  | All Patients                                                                                                                                                                                                                                 |
|                                                 |                                                                                                                                                                                                                                              | No. of Patients                                                                                                                                                                                                                              | 36                                                                                                                                                                                                                                           | 22                                                                                                                                                                                                                                           | 58                                                                                                                                                                                                                                           |
|                                                 | Detnsor                                                                                                                                                                                                                                      | Mean (SD)                                                                                                                                                                                                                                    | -1.86 (4.16)                                                                                                                                                                                                                                 | -0.77 (3.87)                                                                                                                                                                                                                                 | -1.45 (4.05)                                                                                                                                                                                                                                 |
|                                                 | Contractions Until End of                                                                                                                                                                                                                    | 10 %56                                                                                                                                                                                                                                       | (-3.27, -0.45)(-2.49, 0.94)                                                                                                                                                                                                                  |                                                                                                                                                                                                                                              | (-2.51, - 0.38)                                                                                                                                                                                                                              |
|                                                 | Bladder-filling atP value (2-sided Week 24                                                                                                                                                                                                   | paired t-test)                                                                                                                                                                                                                               | 0.011                                                                                                                                                                                                                                        | 0.359                                                                                                                                                                                                                                        | 0.009                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

| Detnsor                                                                                                                  | Treatment Group                                        | Children                      | AdolescentsAll Patients         |                                  |
|--------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|-------------------------------|---------------------------------|----------------------------------|
| Pressure at End of Bladder Filling at Week 24                                                                            | No. of Patients                                        | 36                            | 22                              | 58                               |
| Pressure at End of Bladder Filling at Week 24                                                                            | Mean (SD)                                              | -18.11 (19.97)                | -13.19 (19.91)                  | -16.24 (19.92)                   |
| Pressure at End of Bladder Filling at Week 24                                                                            | 95% CI                                                 | (-24.87, -11.35)              | (-22.02, 4.36)                  | (-21.48, -11.01)                 |
| Pressure at End of Bladder Filling at Week 24                                                                            | P value (2-sided paired t-test)                        | 0.001                         | 0.005                           | ≤ 0.001                          |
| Bladder Volume umtil First Detnusor Contraction at Week 24: Rank Test Bladder Volume until First Detnusor Contraction at | Treatment Group No. of Patients                        | Children                      | Adolescents                     | All Patients                     |
| Bladder Volume umtil First Detnusor Contraction at Week 24: Rank Test Bladder Volume until First Detnusor Contraction at |                                                        | 38                            | 24                              | 62                               |
| Bladder Volume umtil First Detnusor Contraction at Week 24: Rank Test Bladder Volume until First Detnusor Contraction at | Median (Q1, Q3)                                        | 76.00 (32.00, 147.20)         | 78.45 (26.00, 176.50)           | 77.50 (32.00, 174.00)            |
| Bladder Volume umtil First Detnusor Contraction at Week 24: Rank Test Bladder Volume until First Detnusor Contraction at | Wilcoxon SignedP value (Wilcoxon Signed Rank Test)     | 0.001                         | <0.001                          | <0.001                           |
| Week 24: Paired 95% CI t-test                                                                                            | Treatment Group                                        | Children                      | Adolescents                     | All Patients                     |
|                                                                                                                          | No. of Patients Mean (SD)                              | 38                            | 24                              | 62                               |
|                                                                                                                          |                                                        | 93.09 (88.14) (64.12, 122.06) | 121.33 (159.84) (53.84, 134.64) | 104.02 (120.57) (73.40, 188.82)  |
| Maximum Catheterized Volume per Catheterization at Week 24                                                               | Treatment Group No. of Patients                        | Children                      | 23                              | 64                               |
| Maximum Catheterized Volume per Catheterization at Week 24                                                               | P value (2-sided paired t-test)                        | c0.001                        | 0.001                           | <0.001                           |
|                                                                                                                          |                                                        |                               | AdolescentsAll Patients         |                                  |
|                                                                                                                          | Mean (SD)                                              | 41 49.88 (103.70)             | 84.39 (121.98)                  | 62.28 (110.91)                   |
| Average Catheterized Volume per                                                                                          | 95% CI P value (2-sided paired t-test) Treatment Group | (17.1, 82.6) 0.004            | (31.6,137.1) (34.6, 90.0) 0.003 | <0.001                           |
| Catheterization at Week 24                                                                                               | No. of Patients                                        | Children                      | Adolescents                     | All Patients                     |
| Catheterization at Week 24                                                                                               |                                                        | 41                            | 23                              | 64                               |
| Catheterization at Week 24                                                                                               | Mean (SD)                                              | 41.63 (58.03)                 | 59.31 (82.22)                   | 47.99 (67.62)                    |
| Catheterization at Week 24                                                                                               | 10 %56                                                 | (23.3, 60.0)                  | (23.8, 94.9)(31.1, 64.9) 0.002  | ≤0.001                           |
| Maximum                                                                                                                  | P value (2-sided paired t-test)                        | ≤0.001                        |                                 |                                  |
| Catheterized Daytime Volume Mean (SD) at Week 24                                                                         | Treatment Group No. of Patients                        | Children 41                   | Adolescents 23                  | SAll Patients 64                 |
| Catheterized Daytime Volume Mean (SD) at Week 24                                                                         |                                                        | 44.20 (98.31)                 | 81.37 (117.77)                  | 57.56 (106.32)                   |
| Catheterized Daytime Volume Mean (SD) at Week 24                                                                         | 95% CI                                                 | (13.2, 75.2)                  |                                 |                                  |
| Catheterized Daytime Volume Mean (SD) at Week 24                                                                         |                                                        | 0.006                         | 0.003                           | (30.4, 132.3)(31.0, 84.1) <0.001 |
| Catheterized Daytime Volume Mean (SD) at Week 24                                                                         | P value (2-sided paired t-test)                        |                               |                                 |                                  |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|       | Average Moming Catheterized Volume at Week 24                                                                                                                                                                                                                        | Treatment Group                                                                                                                                                                                                                                                      | Children                                                                                                                                                                                                                                                             | Adolescents                                                                                                                                                                                                                                                          | All Patients                                                                                                                                                                                                                                                         |
|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|       | Average Moming Catheterized Volume at Week 24                                                                                                                                                                                                                        | No. of Patients                                                                                                                                                                                                                                                      | 36                                                                                                                                                                                                                                                                   | 20                                                                                                                                                                                                                                                                   | 56                                                                                                                                                                                                                                                                   |
|       | Average Moming Catheterized Volume at Week 24                                                                                                                                                                                                                        | Mean (SD)                                                                                                                                                                                                                                                            | 40.76 (116.41)                                                                                                                                                                                                                                                       | 86.66 (96.55)                                                                                                                                                                                                                                                        | 57.15 (111.07)                                                                                                                                                                                                                                                       |
|       | Average Moming Catheterized Volume at Week 24                                                                                                                                                                                                                        | 95% CI                                                                                                                                                                                                                                                               | (1.4, 80.2)                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                      | (41.5, 131.8) (27.4, 86.9)                                                                                                                                                                                                                                           |
|       | Average Moming Catheterized Volume at Week 24                                                                                                                                                                                                                        | P value (2-sided paired t-test)                                                                                                                                                                                                                                      | 0.043                                                                                                                                                                                                                                                                | <0.001                                                                                                                                                                                                                                                               | <0.001                                                                                                                                                                                                                                                               |
|       | No. of Dry Days/7 Days at Week 24                                                                                                                                                                                                                                    | Treatment Group                                                                                                                                                                                                                                                      | Children                                                                                                                                                                                                                                                             | Adolescents                                                                                                                                                                                                                                                          | All Patients                                                                                                                                                                                                                                                         |
|       | No. of Dry Days/7 Days at Week 24                                                                                                                                                                                                                                    | No. of Patients                                                                                                                                                                                                                                                      | 41                                                                                                                                                                                                                                                                   | 24                                                                                                                                                                                                                                                                   | 65                                                                                                                                                                                                                                                                   |
|       | No. of Dry Days/7 Days at Week 24                                                                                                                                                                                                                                    | Mean (SD)                                                                                                                                                                                                                                                            | 1.34 (2.18)                                                                                                                                                                                                                                                          | 2.17 (2.38)                                                                                                                                                                                                                                                          | 1.65 (2.27)                                                                                                                                                                                                                                                          |
|       | No. of Dry Days/7 Days at Week 24                                                                                                                                                                                                                                    | 95% CI                                                                                                                                                                                                                                                               | (0.7, 2.0)                                                                                                                                                                                                                                                           | (1.2,3.2)                                                                                                                                                                                                                                                            | (1.1,2.2)                                                                                                                                                                                                                                                            |
|       | No. of Dry Days/7 Days at Week 24                                                                                                                                                                                                                                    | P value (2-sided paired t-test)                                                                                                                                                                                                                                      | ≤0.001                                                                                                                                                                                                                                                               | <0.001                                                                                                                                                                                                                                                               | < 0.001                                                                                                                                                                                                                                                              |
|       | Mean No. of Leakage Episodes per Day at Week 24: Ad-hoc Analysis with Imputation Mean No. of Leakage Episodes per Day at Week 24:                                                                                                                                    | Treatment Group                                                                                                                                                                                                                                                      | Children                                                                                                                                                                                                                                                             | Adolescents                                                                                                                                                                                                                                                          | All Patients                                                                                                                                                                                                                                                         |
|       | Mean No. of Leakage Episodes per Day at Week 24: Ad-hoc Analysis with Imputation Mean No. of Leakage Episodes per Day at Week 24:                                                                                                                                    | No. of Patients                                                                                                                                                                                                                                                      | 27                                                                                                                                                                                                                                                                   | 21                                                                                                                                                                                                                                                                   | 48                                                                                                                                                                                                                                                                   |
|       | Mean No. of Leakage Episodes per Day at Week 24: Ad-hoc Analysis with Imputation Mean No. of Leakage Episodes per Day at Week 24:                                                                                                                                    | Mean (SD)                                                                                                                                                                                                                                                            | -2.34 (3.66)                                                                                                                                                                                                                                                         | 0.98 (1.08)                                                                                                                                                                                                                                                          | -1.75 (2.89)                                                                                                                                                                                                                                                         |
|       | Mean No. of Leakage Episodes per Day at Week 24: Ad-hoc Analysis with Imputation Mean No. of Leakage Episodes per Day at Week 24:                                                                                                                                    | 95% CI                                                                                                                                                                                                                                                               | (-3.8, -0.9)                                                                                                                                                                                                                                                         | (-1.5,-0.5)                                                                                                                                                                                                                                                          | (-2.6,-0.9)                                                                                                                                                                                                                                                          |
|       | Mean No. of Leakage Episodes per Day at Week 24: Ad-hoc Analysis with Imputation Mean No. of Leakage Episodes per Day at Week 24:                                                                                                                                    | P value (2-sided paired t-test)                                                                                                                                                                                                                                      | 0.003                                                                                                                                                                                                                                                                | <0.001                                                                                                                                                                                                                                                               | ≤0.001                                                                                                                                                                                                                                                               |
|       |                                                                                                                                                                                                                                                                      | Treatment Group                                                                                                                                                                                                                                                      | Children                                                                                                                                                                                                                                                             | Adolescents                                                                                                                                                                                                                                                          | All Patients                                                                                                                                                                                                                                                         |
|       |                                                                                                                                                                                                                                                                      | No. ofPatients                                                                                                                                                                                                                                                       | 26                                                                                                                                                                                                                                                                   | 21                                                                                                                                                                                                                                                                   | 47                                                                                                                                                                                                                                                                   |
|       |                                                                                                                                                                                                                                                                      | Mean (SD)                                                                                                                                                                                                                                                            | -1.97 (3.17)                                                                                                                                                                                                                                                         | 0.98 (1.08)                                                                                                                                                                                                                                                          | -1.53 (2.49)                                                                                                                                                                                                                                                         |
|       |                                                                                                                                                                                                                                                                      | 95% CI                                                                                                                                                                                                                                                               | (-3.2, -0.7)                                                                                                                                                                                                                                                         | (-1.5, -0.5)                                                                                                                                                                                                                                                         | (-2.3,-0.8)                                                                                                                                                                                                                                                          |
|       |                                                                                                                                                                                                                                                                      | Ad-hoc Analysis P value (2-sided with Imputation, paired t-test) Without Data                                                                                                                                                                                        | 0.004                                                                                                                                                                                                                                                                | < 0.001                                                                                                                                                                                                                                                              | <0.001                                                                                                                                                                                                                                                               |
| Notes | From 1 Patient During urodymamic assessments, the bladder was filled until voiding/leakage began, or until the patient experienced pain or discomfort, or because dangerous high detrusor pressure, or 135% of maximum catheterized volume for age had been reached. | From 1 Patient During urodymamic assessments, the bladder was filled until voiding/leakage began, or until the patient experienced pain or discomfort, or because dangerous high detrusor pressure, or 135% of maximum catheterized volume for age had been reached. | From 1 Patient During urodymamic assessments, the bladder was filled until voiding/leakage began, or until the patient experienced pain or discomfort, or because dangerous high detrusor pressure, or 135% of maximum catheterized volume for age had been reached. | From 1 Patient During urodymamic assessments, the bladder was filled until voiding/leakage began, or until the patient experienced pain or discomfort, or because dangerous high detrusor pressure, or 135% of maximum catheterized volume for age had been reached. | From 1 Patient During urodymamic assessments, the bladder was filled until voiding/leakage began, or until the patient experienced pain or discomfort, or because dangerous high detrusor pressure, or 135% of maximum catheterized volume for age had been reached. |

## 2.6.6. Discussion on clinical efficacy

The evidence of efficacy of mirabegron in the treatment of Neurogenic Detrusor Overactivity (NDO) in children and adolescents consisted of one Phase III clinical trial (Study 178-CL-206A). This study forms the basis for the application for both the prolonged-release granules (line extension) and the new indication for mirabegron tablets (type II variation).

## Design and conduct of clinical studies

Study 178-CL-206A is a Phase III, open-label, baseline-controlled, multicenter study in children and adolescents from 3 to &lt; 18 years of age with NDO on Clean Intermittent Catheterization. The study had a pre-treatment period for up to 28 days before baseline, an efficacy treatment period from the day after baseline to week 24 and a long-term safety period after week 24 and continuing to week 52. The duration of the study appears sufficient; i.e. 6 months for efficacy purposes, 12 months for long safety evaluation. This study was agreed with the PDCO and the design is in line with the recommendations provided in the EMA

<div style=\"page-break-after: always\"></div>

guideline on incontinence (CPMP/EWP/18/01/Rev. 1) on NDO. Paediatric subjects older than 3 years with confirmed diagnosis of NDO (determined by urodynamic criteria) who were on Clean Intermittent Catheterization were eligible for the study. Originally planned for subjects ≥5 years the study was modified to lower the low age cut-off from 5 to 3 years. Both naïve and pre-treated paediatric patients could be included but the treatment for NDO previously received was not maintained during the study. For entry patients were required to have indication for drug therapy to manage NDO. The need for drug therapy to manage NDO was determined by the treating investigator based on patient medical history, clinical judgment, and appropriate prior testing.

A total of 113 paediatric patients were screened, of whom 91 were enrolled and 86 took at least 1 dose of mirabegron and were included in the safety analysis set (55 children and 31 adolescents). A total of 70 subjects (43 children and 27 adolescents) completed the study. The main reasons for discontinuation during the Efficacy Treatment Period were the lack of signs of NDO on baseline urodynamic assessment or technical issues during the urodynamic study. One patient discontinued during the Long-term Safety Period due to an adverse event.

A total of 52 patients were recruited in Europe (60.5%), followed by 21 from Asia and Pacific (24.4%), 10 patients from Middle East (11.6%) and 3 from North America (Mexico, [3.5%]). The population is considered as representative of EU.

Females represented 54.7% of the population. The overall mean age was 10.1 years (7.9 years for children, 14.0 for adolescents). Most of the patients (72.1%) were White. The mean weight was 29.83 kg for children (ranging from 12.6 to 69.7 kg) and 50.96 kg for adolescents (from 28.2 to 78.5 kg).

The duration of the disease was about 7 years (children 5.8 years; adolescents 9.4 years). The most common aetiologies were congenital central nervous system anomaly (children 54.5%; adolescents 48.4%), meningomyelocele (children 27.3%; adolescents 19.4%) and spina bifida (children 10.9%; adolescents 12.9%). Other conditions were reported by a limited number of patients. Half of subjects (51.2%) showed an overactive urethral sphincter.

In addition to CIC, most of patients (88.4%) were on treatment before starting the study. Only 10 patients did not report NDO medication at screening/start of washout period. Antimuscarinics (oxybutinin 32.6%, solifenacin 22.1%) were the most frequently used. Three patients were on botulinum toxin and of note 6 patients (7.0%) were on treatment with mirabegron.

All patients received mirabegron during the phase III trial. Considering that Clean Intermittent Catheterization was one of the requisites for entering the trial a placebo control arm could have been an option in line with the EMA Guideline recommendation. Alternatively, an active comparator could have been an option given that pharmacotherapy (mainly based on antimuscarinics) is considered as first line therapy and several antimuscarinics (oxybutinin, solifenacin) have been approved for this indication. They are probably preferable to other alternatives such as botulinum toxin due to its (minimally) invasive administration and the inherent difficulties for masking.

The finally conducted one single arm is also considered as an acceptable design and it was agreed with the PDCO. It should also be taken into account that the primary endpoint (MCC) is a cystometric measure less prone to bias.

The doses selected for children and adolescents intended to obtain similar exposures to 25 mg and 50 mg as in adults. The dose was titrated during the study and after an initial low dose (equivalent to 25 mg in adults; PED25) all patients were uptitrated to the high dose (equivalent to 50 mg in adults; PED50). Most of patients

<div style=\"page-break-after: always\"></div>

(80.2%) uptitrated to the high dose during the study. It should be noted that, mirabegron is not approved in NDO in adults and the dose for treating NDO in adults is still not established However, in the published studies of mirabegron for the treatment of adults with NDO the doses administered were those recommended for OAB (in adults). Thus, it could be expected that the equivalent dose could also work in children with NDO. Since the efficacy of mirabegron in adults with NDO has not been evaluated yet the uncertainty exists, although these studies provide some support and it is accepted that the dose used for treating OAB in adults has been used as reference.

Mirabegron was administered as extended release formulation once daily on a body weight basis. A new formulation in granules was developed for subjects weighting &lt;35 kg. The selection of the dose for this formulation has been based on predictions from PK/PD modelling (see Clinical Pharmacology section).

Treatment compliance was very high, 96.24% with the tablets and 97.33% with the oral solution. Of note, 39 subjects received the oral solution and 46 patients received the tablets.

The evaluation of efficacy mainly relies on the assessment of the lower urinary tract function during the storage phase of the bladder (capacity of the bladder, compliance and detrusor activity). It was based on the urodynamic assessment performed at baseline and week 24. The lack of a placebo arm represents a limitation in order to conclude on the efficacy. The evaluation of the response based on pharmacodynamic examination and the fact that two independent reviewers performed the assessment may partially reduce the risk of bias.

Urodynamic studies are part of the diagnosis and follow up of children and adolescents with neurogenic bladder dysfunction 11 . They assess if storage function of the bladder remains at pressures low enough for upper urinary tract safety. They also determine sphincter reactivity to bladder emptying and evaluate the adequacy of treatment of detrusor overactivity. The International Children's Continence Society guideline on the standards for applying and reporting the urodynamic studies in children 12,13  has been followed.

The primary efficacy endpoint was the change from baseline to week 24 in maximum cystometric capacity (MCC) defined as maximum bladder capacity reached during filling cystometry before either voiding/leakage begins, or pain or discomfort or dangerous high detrusor pressure occurs, or 135% of expected bladder capacity is reached. It is in line with the EMA Guideline recommendations and has been studied in several studies conducted in the field. This also applies for the selected secondary endpoints. 14,15   Other relevant aspects for the patients such as specific patients questionnaires (PIN-Q) measuring the impact of the treatment on the subject and patient/clinicians impressions on the global effect of the treatment are also evaluated.

No urodynamic assessment is performed beyond 6 months of treatment so that the evaluation of the maintenance of the effect is limited.

The primary analysis was based on change from baseline in the MCC at 26 weeks. It was performed on the full analysis set including patients with a baseline and a postbaseline measurement and using LOCF for missing values. This approach was also followed in the secondary analyses.

11  Stain R et al. Neurourology and Urodynamics. 2020;39:45-57.

12  Bauer SB et al. Neurourology and Urodynamics. 2015;34:640-647.

13  Austin PF et al. Neurourology and Urodynamics. 2016;35:471-481

14  Franco I et al. Journal of Pediatric Urology (2020) 16, 180.e1e180.e8

15  Franco I, Horowitz M, Grady R, Adams RC, de Jong TPVM, Lindert K, et al. J Urol 2005;173:221e5.

<div style=\"page-break-after: always\"></div>

## Efficacy data and additional analyses

After 24 weeks of treatment a statistically significant increase in Maximum Cystometric Capacity  (mean [SD]) was shown in children aged 3 to 12 years  of 72.09 (87.09) ml and in adolescents aged 12 to 18 years of 87.20 (87.30) ml, compared to the baseline values (both p &lt; 0.001). This improvement was also observed for the global population, with an increase of 87.20 (87.30) ml compared to baseline values (p &lt; 0.001). Per Protocol and sensitivity analyses conducted were consistent with the primary analysis.

The treatment effect exceed the 52 ml estimated in the sample size calculation and is in line with published studies conducted with antimuscarinics 17,16,17   Franco et al  (2005) analysed 2 age groups (1 to 5 years and 6 to 15 years) and reported mean (SD) MCC changes from baseline of 71.5 (88) mL and 75.4 (102.7) mL, respectively, after 24 weeks treatment with oxybutynin. Goessl et al (2000) reported an increase of 52.8 ml after 3 months of treatment with tolterodine. Franco et al (2020) reported an increase 37.0 mL in patients aged 6 months-5 years and 57.2 ml in patients 5-18 years after 6 months of treatment with solifenacine.

The increase in Maximum Cystometric Capacity was observed at Week 4 in both groups: 41.36 (71.64) ml in children and 80.78 (96.15) ml in adolescents (both p &lt; 0.001).

At the end of the 24-week period of treatment patients improved bladder compliance in 14.22 (33.99) mL/cm H2O and reduced detrusor activity. A significantly lower number of detrusor contractions (-1.45 [4.05]) and reduced detrusor pressure at the end of filling was measured with respect to baseline levels. The bladder capacity until first contraction was also increased.

With respect to clinical parameters such as the frequency of leakage the overall results are disappointing. Statistical significance (in comparison to baseline) has only been reached at 'borderline' level for adolescents, and for children only after exclusion of an outlier . As for the number of CICs per day, the mean change from baseline to week 24 in was -0.12. The clinical impact of these results appears very low. It is unknown whether a more evident clinical benefit could be achieved at a latter timepoint.

With respect to the voided volumes recorded in the bladder diaries, the treatment with mirabegron increased the volumes catheterized during the day (maximum daytime volume), during the night (average morning volume) and the average volume per catheterization.

It is acknowledged that high detrusor pressure in NDO has been associated with endangering the upper urinary tract in the long term. A lowering of the detrusor leak point pressure below 40 cmH2O has been advocated to be associated with protection of the upper urinary based on literature 18 ,  19 . Reduction of detrussor pressure was observed at the end of the efficacy period for all studied cut-off points (&lt; 40 cm H20, &lt; 30 cm H20 and &lt; 20 cm H20).  No additional information on the protection of the upper urinary tract in NDO pediatric patients treated with mirabegron has been provided. In this regard, another potentially useful marker, namely bladder compliance below the thresholds 12.5 ml/cm H2O and 20 ml/cm H2O was provided the results at Day 180. An increase in bladder compliance was observed for both thresholds by Week 24 with respect to baseline. A bladder compliance of at least 12.5 ml/cm H2O was achieved between 51% and 73% of

16 Goessl C, Sauter T, Michael T, Bergé B, Staehler M, Miller K. Urology. 2000 Mar;55(3):414-8.

17 Franco I, Hoebeke P, Baka-Ostrowska M, Bolong D, Davies LN, Dahler E, Snijder R, Stroosma O, Verheggen F, Newgreen D, Bosman B, Vande Walle J. J Pediatr Urol. 2020 Apr;16(2):180.e1-180.e8.

18  Tarcan T, Sekerci CA, Akbal C, Tinay I, Tanidir Y, Sahan A, Sahin B, Top T, Simsek F. Is 40 cm H2O detrusor leak point pressure cut-off reliable for upper urinary tract protection in children with myelodysplasia? Neurourol Urodyn. 2017;36:759-63

19  Kurzrock EA, Polse S. Renal deterioration in myelodysplastic children: urodynamic evaluation and clinical correlates. J Urol. 1998;159:1657-61

<div style=\"page-break-after: always\"></div>

patients, depending on age, compared to baseline values ( 10% in children and 25% in adolescents) and between 34% and 50% of patients, depending on age, achieve bladder compliance of at least 20 mL/cm H20 by week 24 versus 5% and 12.5% at baseline, in children and adolescents, respectively. Without allowing sound conclusions, these data suggest a positive trend in this respect.

The PIN-Q measures the emotional impact that urinary incontinence has on a child. It is based on e-diary records and the score ranges from 0 (no effect) to 80 (worst effect). No impact of the treatment was observed in children and the changes were not significant in adolescents. With respect to the global impression of the treatment a clinicians reported the conditions as much improved or very much improved in &gt; 70% of patients while modest improvement was reported from the patients' perspective.

No urodynamic studies were performed beyond 6 months of treatment. Efficacy at Week 52 is based only on results of catheterized volumes from e-diaries. Looking at figures a reduction of the effect is observed with respect to that achieved at Week 26, being numerically lower for the most of the measures (especially in adolescents and all the patient groups). This decrease in volume between 24 and 52 weeks was not statistically significant but caution is advised in interpreting the data because of the small number of subjects, the lack of a control arm, and absence of urodynamic measures at later time points.  At Day 180 the MAH presented further results of catheterized volumes at Week 52 using baseline MCC volume values for correction for bladder volume. This approach shows no relevant differences between volumes measured at Week 24 and those measured at Week 52, which partially alleviates this uncertainty. 5.1 of the SmPC outlines that there is a lack of data on maintenance of the effect beyond 6 months of treatment as measured by urodynamic evaluation which is acceptable.

## 2.6.7. Conclusions on the clinical efficacy

Mirabegron has shown an effect with respect to baseline status on the control of detrusor activity and bladder capacity assessed by urodynamic outcomes and voiding volumes measured with Clean Intermittent Catheterization in a population with an established condition and who required pharmacological treatment. This effect was observed after 26 weeks of treatment. The perception of the patients on improvement of the condition and on the impact of treatment on the quality of life was less evident.

The maintenance of the effect of mirabegron beyond 6-month treatment is based on the CIC volumes recorded in the e-bladder diaries since no urodynamic studies were performed at the end of the study.

Whereas with the available data there is no a strong signal questioning the long-term efficacy of mirabegron in this population the reduced number of patients studied and the lack of control arm does not allow for concluding on this issue. The lack of data on maintenance of the effect beyond 6 months of treatment as measured by urodynamic evaluation is mentioned in the SmPC for information of the prescriber which is acceptable.

## 2.6.8. Clinical safety

Betmiga (mirabegron) is a first-in-class, selective human beta-3 adrenoceptor agonist. The requested indication is the treatment of neurogenic detrusor overactivity (NDO) in paediatric patients aged 3 to less than 18 years.

The sources of safety information concerning this application are the data collected from 129 pediatric patients with NDO or OAB during the pediatric development program.

<div style=\"page-break-after: always\"></div>

The primary source of safety data is the phase 3 study conducted in 86 pediatric patients with NDO using clean intermittent catheterization (CIC) (study 178-CL-206A). Of the 91 patients enrolled in the study, 86 took ≥ 1 dose of mirabegron and were included in the safety analysis set (SAF). In the SAF, among all patients combined (age 3 to less than 18 years), approximately half were female (54.7%); most were White (72.1%) and 3 (3.5%) patients were Hispanic or Latino. The mean age (SD) was 10.1 (3.7) years and the mean weight (SD) was 37.45 (16.90) kg.

All patients in the SAF (55 children and 31 adolescents) entered the 24 week dose-titration period, 71 patients (44 [80.0%] children and 27 [87.1%] adolescents) entered the 28 week fixed dose assessment period and 70 (43 [78.2%] children and 27 [87.1%] adolescents) completed treatment.

16 patients discontinued study drug, 12 (21.8%) children and 4 (12.9%) adolescents. The main reason for discontinuation was 'Other', which included 4 cases of no signs of NDO on baseline urodynamic assessment after central review, 7 cases of technical issues with baseline urodynamic assessment, and 2 cases of withdrawal due to QTcB prolongation at baseline after central review.

The mirabegron oral suspension formulation proposed for commercialization was used in this study for patients weighting less than 35 kg or with problems to swallow; the rest of patients took tablets of mirabegron.

Supportive sources of safety data are 2 phase 1 single-dose studies in 17 pediatric patients with NDO and 26 pediatric patients with OAB, using tablets (Study 178-CL-202) or oral suspension (Study 178-CL-203).

Results are presented at the study level, by age group (aged 3 to less than 12 years; aged 12 to less than 18 years) and overall. No pooling across studies was performed. The SAF of each study comprised all patients who received at least 1 dose of mirabegron.

Table 10 - Overview of Clinical Pharmacokinetic, Efficacy and Safety Pediatric Studies

| Study Number   | Sludy Phase   | Study Population (Study Type)                                                | Sludy Design                                   | Treatment Regimen                                                                                                                                                                                                                                                                                                                                                                                                                            | Sludy Status   | Patientsin Safety Analysis Set      |
|----------------|---------------|------------------------------------------------------------------------------|------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|-------------------------------------|
| 178-CL- 202    |               | NDO or OAB (Phamacokinetics [food effect], safety)                           | Open-label, single ascending dose              | Low dose:Cohort 1(adolescents)and Cohort 2(children): 25 mg tablet (body weight between 20.0 to<55.0 kg) 50mgtablet (body weight≥55.0kg) High dose:Cohort 3（adolescents),Cohorts 4 and 5(children): 75mg: 1 x 25 mg tablet and 1 x 50 mg tablet(body weight≥40.0 kg) Forfood-effectassessment,thefirst 4cohortsweredosedunderfed conditionsi.e.,within1haflercompletionofthelightbreakfast.Thelast cohort was dosed under fasting conditions | Completed      | 34 (15 adolescents and 19 children) |
| 178-CL- 203    | 1             | NDO orOAB (Phamacokinetics [food effect], safety)                            | Open-label, single-dose                        | Mirabegron oral suspension formulationB (prolonged-release granules Were reconstitutedwith water toprepare a suspensionwitha concentrationof2mg/mL) Single doses were administered according to each patient's weight, to achieve a target exposure equivalent to that following 50 mg prolonged- release tabletsgiven once daily to adults atsteady-state.                                                                                  | Completed      | 9 children                          |
| 178-CL- 206A   | 3             | NDO on clean intermittent catheterization (Efficacy/safety/ phamacokinetics) | Open-label, baseline controlled dose-titration | Mirabegron tablets, strengths 25 mg and 50 mg. Mirabegron oral suspension formulation C(prolonged-release granules Were reconstituted with water to prepare a suspension with a concentration of 8mg/mL) Initial dose, ie., PED25, was weight-based. At week2.4or 8.patientswereuptitrated toPED50based ongiven dose titration criteria.                                                                                                     | Completed      | 86 (55 children and 31 adolescents) |

NDO:neurogenic detrusoroveractivity;OAB:overactive bladder;PED25:pediatricdose targeted to achieve steady-state exposures similarto those ofadultsadministered the

<div style=\"page-break-after: always\"></div>

## Safety assessment

Safety assessments included incidence and severity of treatment-emergent adverse events (TEAEs), clinical laboratory evaluations, vital signs, 12-lead electrocardiogram (ECG), upper urinary tract ultrasound assessment and estimated glomerular filtration rate (eGFR). In addition, effects on growth and development were assessed in Study 178-CL-206A.

The following safety parameters are presented in the CSRs for each study:

- Extent of exposure
- Summary of TEAEs
- Summaries of serious TEAEs and TEAEs leading to discontinuation, and a summary of TEAEs of special interest
- Summary of changes in laboratory parameters including hematology, biochemistry and urinalysis. For Study 178-CL-206A: summary of eGFR.
- Summary of vital signs.
- Summary of ECGs. Cardiac monitoring over 24 hours with a 6-lead Holter was captured in phase 1 Studies 178-CL-202 and 178-CL-203.
- Summary of body weight, height and body mass index (BMI), only for study 178-CL-206A.
- Summary of upper urinary tract ultrasound, only for study 178-CL-206A.
- Summary of postvoid residual volume (PVR), for studies 178-CL-202 and 178-CL-203.

Drug-induced liver injury was assessed in all studies per the FDA's Guidance for Industry Drug-Induced Liver Injury: Premarketing Clinical Evaluation (Jul 2009). These assessments included frequency of elevated liver parameters and analyses of liver transaminases and total bilirubin.

TEAEs considered of interest in the safety monitoring plan of the pediatric studies were selected because they are important identified/potential risks in adults taking mirabegron for OAB.

The following safety endpoints were assessed:

- Incidence, relationship and severity of treatment-emergent adverse events (TEAEs)
- Change from baseline in vital signs (clinic measurements): systolic blood pressure (SBP), diastolic blood pressure (DBP), pulse rate and temperature at weeks 4, 12, 24 and 52 (EoT/EoS)
- Change from baseline in vital signs (self-blood pressure measurement [SBPM]): SBP, DBP, pulse rate at weeks 2, 4, 8, 12, 24, 36 and 52 (EoT/EoS) and on 2 consecutive days at around 1 and 2 weeks after start of dosing with the pediatric equivalent dose to mirabegron 25 mg (PED25) (day 1) and after up-titration to the pediatric equivalent dose to mirabegron 50 mg (PED50) (weeks 2, 4 or 8), if not already covered by the scheduled week 2 and/or week 4 SBPM
- Change from baseline in hematology and biochemistry tests at weeks 12 and 52 (EoT/EoS) and urinalysis tests at weeks 4, 12, 24 and 52 (EoT/EoS)
- Change from baseline in 12-lead electrocardiogram (ECG) parameters at weeks 4, 12, 24 and 52 (EoT/EoS)

<div style=\"page-break-after: always\"></div>

- Change from baseline to week 52 (EoT/EoS) in upper urinary tract ultrasound assessment
- Change from baseline in estimated glomerular filtration rate (eGFR) at weeks 12 and 52 (EoT/EoS)

## 2.6.8.1. Patient exposure

Across the 3 paediatric studies in the mirabegron paediatric development program, the patients received mirabegron in any of its formulations. Patients who received multiple doses received daily doses of up to 50 mg for up to 52 weeks.

As it is stated, only data on the chronic administration of mirabegron in paediatric patients is coming from the single phase 3 study (178-CL-206A). In this study, the mean duration of treatment was approximately 300 days and was longer in adolescents (318.55 days) than in children (293.65 days). Overall, the mean duration of treatment was 302.63 days.

Table 11 - Paediatric Studies in the Mirabegron Paediatric NDO Development Program

| PatientIndication Age Group         | Number of Patients Dosed WithMirabegron   | Number of Patients Dosed WithMirabegron   | Number of Patients Dosed WithMirabegron   |
|-------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|
| Study                               | Single dose                               | Multiple Dose                             | Any Dose                                  |
| PediatricpatientswithNDO or OAB     | 43                                        | 86                                        | 129                                       |
| Pediatric patients with NDO         | 17                                        | 86                                        | 103                                       |
| Children (3 to < 12 years)          | 12                                        | 55                                        | 67                                        |
| Phase 3 Study 178-CL-206A           |                                           | 55                                        | 55                                        |
| Supportivephase 1 Study 178-CL-202  | 6                                         |                                           | 6                                         |
| Supportive phase 1 Study 178-CL-203 | 6                                         |                                           | 6                                         |
| Adolescents （12 to <18 years)       | 5                                         | 31                                        | 36                                        |
| Phase3Study 178-CL-206A             |                                           | 31                                        | 31                                        |
| Supportive phase 1 Study 178-CL-202 | 5                                         |                                           | 5                                         |
| Supportive phase 1 Study 178-CL-203 | 0                                         |                                           | 0                                         |
| Pediatric patients with OAB         | 26                                        |                                           | 26                                        |
| Children (3 to <12 years)           | 16                                        |                                           | 16                                        |
| Supportive phase 1 Study 178-CL-202 | 13                                        |                                           | 13                                        |
| Supportive phase 1 Study 178-CL-203 | 3                                         |                                           | 3                                         |
| Adolescents (12 to < 18 years)      | 10                                        |                                           | 10                                        |
| Supportivephase 1 Study 178-CL-202  | 10                                        |                                           | 10                                        |
| Supportive phase 1 Study 178-CL-203 | 0                                         |                                           | 0                                         |

All patients who received at least 1 dose of mirabegron prolonged-release tablets or mirabegron oral suspension. Note: Study 178-CL-206 was not conducted and data from Study 178-CL-206A will support the pediatric NDO population. The protocols of each study were similar as they were originally designed to be identical; therefore. Study 178-CL-206A encompasses Study 178-CL-206.

-: not applicable; NDO: neurogenic detrusor overactivity; OAB: overactive bladder

<div style=\"page-break-after: always\"></div>

Study period:

- 178-CL-202: single dose study, from 2Q 2014 to 3Q 2015
- 178-CL-203: single dose study, from 3Q 2015 to 2Q 2016
- 178-CL-206A: from 17 th  Jun 2016 to 6 th  May 2019

The protocol of the Study 178-CL-206A, stated that all patients must start at the paediatric dose targeted to achieve steady-state exposures similar to those of adults administered the mirabegron 25 mg tablet once daily (PED25), with 54.7% starting on tablets and the remaining 45.3% on oral suspension. By week 4, 77.9% of patients received the paediatric dose targeted to achieve steady-state exposures similar to those of adults administered the mirabegron 50 mg tablet once daily (PED50) and 7.0% continued PED25. The protocol-specified dose increase to PED50 by week 8 occurred in all but 4 (4.7%) patients, or 80.2%. These doses remained unchangeable from week 8 onwards, but some dose interruptions due to TEAEs or dosing noncompliance were recorded in the clinical database for 12 patients.

Study drug compliance exceeded 95% across age groups and formulations.

## 2.6.8.2. Adverse events

## TEAEs

Both formulations of mirabegron were well-tolerated by paediatric patients and no new safety concerns were identified compared with the known safety profile of mirabegron in adults.

In the study 178-CL-206A, during 52 weeks of treatment, TEAEs were reported by 51 (59.3%) patients (33 [60.0%] children and 18 [58.1%] adolescents), while drug-related TEAEs were reported in 14 (16.3%) patients (8 [14.5%] children and 6 [19.4%] adolescents).

Serious TEAEs were reported in 14 (16.3%) patients (9 [16.4%] children and 5 [16.1%] adolescents) but there were no drug-related serious TEAEs.

Between the 2 age groups, the proportions of patients were similar for those experiencing at least 1 TEAE or drug related TEAE.

In Study 178-CL-202, the most common TEAEs were ECG QT prolonged in 1 child in cohort 2 (14.3%) and 1 adolescent in cohort 3 (12.5%), and vomiting in 1 child in cohort 5 (16.7%) and 1 adolescent in cohort 1 (14.3%).

In Study 178-CL-203, 1 child patient reported a TEAE of pyrexia (11.1%).

The majority of TEAEs were not considered related to study drug among 3 studies.

In the main study, TEAEs reported by 37 (43.0%) patients were not considered related to study drug. TEAEs were considered possible or probably related in 13 (15.1%) and 1 (1.2%) patients, respectively.

A similar trend was observed for children and adolescents.

In Study 178-CL-202, 1 patient (1 adolescent in cohort 3 [12.5%]) reported a drug-related TEAE (ECG QT prolonged).

No drug-related TEAEs were reported during Study 178-CL-203.

<div style=\"page-break-after: always\"></div>

The majority of TEAEs were of mild intensity in the 3 studies.

Across all patients in the main study (178-CL-206A), TEAEs reported by 31 (36.0%) patients were of mild intensity. TEAEs were moderate and severe in 16 (18.6%) and 4 (4.7%) patients, respectively.

Adolescents reported more frequently moderate (7 [22.6%] patients) and severe TEAEs (3 [9.7%] patients) than children (moderate: 9 [16.4%] patients, severe: 1 [1.8%] patients).

None of these severe TEAEs were considered related to study drug.

Table 12 - Overview Of TEAEs and Death (SAF); Study 178-CL-206A

|                                                      | Children (3 to < 12 Years) n=55   | Children (3 to < 12 Years) n=55   | Adolescents (12 to <18 Years) n=31   | Adolescents (12 to <18 Years) n=31   | All Patients (3 to <18 Years) n=86   | All Patients (3 to <18 Years) n=86   |
|------------------------------------------------------|-----------------------------------|-----------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|
| Incidenceof TEAE/Number of TEAE                      | n (%)                             | Events                            | (%) u                                | Events                               | n (%)                                | Events                               |
| TEAE                                                 | 33 (60.0)                         | 78                                | 18 (58.1)                            | 61                                   | 51 (59.3)                            | 139                                  |
| Drug-relatedt TEAE                                   | 8 (14.5)                          | 12                                | 6 (19.4)                             | 8                                    | 14 (16.3)                            | 20                                   |
| Serious TEAEt                                        | 9 (16.4)                          | 10                                | 5 (16.1)                             | 9                                    | 14 (16.3)                            | 19                                   |
| Drug-relatedt Serious TEAEt                          | 0                                 | 0                                 | 0                                    | 0                                    | 0                                    | 0                                    |
| TEAE Leading to Death                                | 0                                 | 0                                 | 0                                    | 0                                    | 0                                    | 0                                    |
| Drug-relatedTEAE Leading to Death                    | 0                                 | 0                                 | 0                                    | 0                                    | 0                                    | 0                                    |
| TEAE Leading to Permanent Discontinuation            | 3 (5.5)                           | 3                                 | 0                                    | 0                                    | 3 (3.5)                              | 3                                    |
| Drug-relatedTEAE Leading toPermanent Discontinuation | 2 (3.6)                           | 2                                 | 0                                    | 0                                    | 2 (2.3)                              | 2                                    |
| Deaths                                               | 0                                 | 0                                 | 0                                    | 0                                    | 0                                    | 0                                    |

All patients who received ≥ 1 dose of study drug (SAF).

A TEAE was defined as an adverse event with date of onset occurring on or after the first dose of study medication and up to the end of study.

In Study 178-CL-206A, patients received mirabegron prolonged-release tablets (25 or 50 mg) or mirabegron oral suspension formulation C (prolonged-release granules were reconstituted with water to prepare a suspension with a concentration of 8 mg/mL).

SAF: safety analysis set; TEAE: treatment-emergent adverse event.

- ↑ Possible or probable, as assessed by the investigator, or records where relationship is missing.
- ↑ Includes serious TEAEs upgraded by the sponsor based on review of the sponsor's list of Always Serious terms, if any upgrade was done.

S All reported deaths after the first study drug administration.

## Common TEAEs

In Study 178-CL-206A, the most frequently reported TEAEs in all patients were Escherichia UTI (8 [9.3%] patients), followed by nasopharyngitis, pyrexia and UTI bacterial (5 [5.8%] patients each). UTI is a prespecified TEAE of special interest.

In children, respiratory tract infection viral, UTI and UTI bacterial were most frequently reported (4 [7.3%] patients each).

<div style=\"page-break-after: always\"></div>

In adolescents, Escherichia UTI (5 [16.1%] patients), pyrexia and upper respiratory tract infection (3 [9.7%] patients each) were the most frequently reported TEAEs.

Table 13 - Treatment-emergent Adverse Events Occurring in ≥ 2% of All Patients (SAF)

| MedDRA v16.0 System Organ Class Preferred Term     | Children (3 to <12 Years) n=55   | Adolescents (12 to<18Years) n=31   | All Patients (3 to<18Years) n=86   |
|----------------------------------------------------|----------------------------------|------------------------------------|------------------------------------|
| Overall                                            | 33 (60.0%)                       | 18 (58.1%)                         | 51 (59.3%)                         |
| Gastrointestinal Disorder's                        |                                  |                                    |                                    |
| Constipation                                       | 3 (5.5%)                         | 1 (3.2%)                           | 4 (4.7%)                           |
| Nausea                                             | 2 (3.6%)                         | 0                                  | 2 (2.3%)                           |
| General Disordersand AdministrationSite Conditions |                                  |                                    |                                    |
| Pyrexia                                            | 2 (3.6%)                         | 3 (9.7%)                           | 5 (5.8%)                           |
| Device malfunction                                 | 2 (3.6%)                         | 0                                  | 2 (2.3%)                           |
| Infections andInfestations                         |                                  |                                    |                                    |
| Escherichiaurinary tract infection                 | 3 (5.5%)                         | 5 (16.1%)                          | 8 (9.3%)                           |
| Nasopharyngitis                                    | 3 (5.5%)                         | 2 (6.5%)                           | 5 (5.8%)                           |
| Urinary tract infection bacterial                  | 4 (7.3%)                         | 1 (3.2%)                           | 5 (5.8%)                           |
| Respiratory tract infection viral                  | 4 (7.3%)                         | 0                                  | 4 (4.7%)                           |
| Upper respiratory tract infection                  | 1 (1.8%)                         | 3 (9.7%)                           | 4 (4.7%)                           |
| Urinary tract infection                            | 4 (7.3%)                         | 0                                  | 4 (4.7%)                           |
| Gastroenteritis                                    | 1 (1.8%)                         | 1 (3.2%)                           | 2 (2.3%)                           |
| Rhinitis                                           | 1 (1.8%)                         | 1 (3.2%)                           | 2 (2.3%)                           |
| Urinary tract infection pseudomonal                | 1 (1.8%)                         | 1 (3.2%)                           | 2 (2.3%)                           |
| Viral infection                                    | 1 (1.8%)                         | 1 (3.2%)                           | 2 (2.3%)                           |
| Nervous SystemDisorder's                           |                                  |                                    |                                    |
| Headache                                           | 2 (3.6%)                         | 1 (3.2%)                           | 3 (3.5%)                           |
| Respiratory,Thoracic and MediastinalDisorder's     |                                  |                                    |                                    |
| Cough                                              | 2 (3.6%)                         | 0                                  | 2 (2.3%)                           |

All patients who received ≥ 1 dose of study drug (SAF).

Sorting order: ascending order by System Organ Class Code and descending by thenumber of patients in the all patients group by preferred term.In case of ties, alphabetical order by preferred term was applied

SAF: safety analysis set.

## Drug-related TEAEs

The most frequently reported drug-related TEAEs in all patients were UTI bacterial (3 [3.5%] patients), constipation and nausea (2 [2.3%] patients each).

In children, nausea and UTI bacterial (2 [3.6%] patients each) were considered drug related.

In adolescents, drug-related TEAEs were reported by 1 patient each and included bradycardia, constipation, dermatitis diaper, diastolic hypotension, dry mouth, Escherichia UTI and UTI bacterial.

Overall, these drug-related TEAEs reported in the paediatric study are generally consistent with known adverse drug reactions in adults as well as available post-marketing data in adults, but constipation and nausea were reported in a higher frequency the paediatric population.

<div style=\"page-break-after: always\"></div>

## TEAEs related to sex and race (Study 178-CL-206A)

TEAEs were reported by both sexes in children at comparable rates (54.5% boys and 63.6% girls). This happened also with drug-related TEAEs (13.6% and 15.2%, respectively). However, among adolescents, a greater number of boys than girls reported TEAEs (70.6% and 42.9%, respectively) and drug-related TEAEs (29.4% and 7.1%, respectively).

For the overall patients, the frequencies were comparable respect to TEAEs (61.5% and 57.4%, respectively), but boys reported drug-related TEAEs more frequently than girls (20.5% and 12.8%, respectively).

TEAEs were reported more frequently for Asian patients (15 [75.0%] patients) than by White patients (35 [56.5%] patients) with comparable frequencies across age groups; while drug-related TEAEs were reported less frequently for Asian patients (2 [10%] patients) than White patients (12 [19.4%] patients).

The analysis by ethnicity was uninformative as only 3.5% of patients were Hispanic or Latino and 96.5% were not Hispanic or Latino.

## TEAEs related to drug formulation and dosing regimen (Sutdy 178-CL-206A)

TEAEs were reported at the same frequency by patients taking mirabegron tablets (28 [59.6%] patients) and patients taking mirabegron oral suspension (23 [59.0%] patients). Across all patients, drug-related TEAEs were reported more frequently for patients taking tablets (11 [23.4%] patients) than for those taking oral suspension (3 [7.7%] patients), but the number of adolescents taking the oral suspension was too low (3 patients) to draw conclusions, so it should be noted that the subgroup analysis by drug formulation may have been confounded by age.

Because the proportion of patients on the 25-mg only dosing regimen (17/86) was relatively small compared to the proportion of patients on the 25/50-mg dosing regimen (69/86) and 76.5% of patients on the 25-only dosing regimen had discontinued by week 2, the results of the analyses of TEAEs and drug-related TEAEs by dosing regimen are not meaningful.

## 2.6.8.3. Serious adverse event/deaths/other significant events

As stated before, serious TEAEs were reported in 14 (16.3%) patients in study 178-CL-206A: 9 (16.4%) children and 5 (16.1%) adolescents, and none of them were considered related to the study drug.

In the supportive studies, 178-CL-202 and 178-CL-203, there were no other serious TEAEs reported.

The only serious TEAE reported by more than 1 patient was device malfunction (i.e., dysfunction of ventriculo-peritoneal shunt), reported by 2 children. Shunt malfunction was also reported by 1 adolescent.

<div style=\"page-break-after: always\"></div>

Table 14 - Serious Treatment-emergent Adverse Events (SAF)

<!-- image -->

| Patient Number                | Age/ Sext                     | MledDRA (vl6.0)Preferred Term (investigator'sverbatim term)            | Last Dose Day                 | Ouset/ Stop Day               | Outcome                       | Relationship to Study Drug    |
|-------------------------------|-------------------------------|------------------------------------------------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|
| Children (3 to<12years)       | Children (3 to<12years)       | Children (3 to<12years)                                                | Children (3 to<12years)       | Children (3 to<12years)       | Children (3 to<12years)       | Children (3 to<12years)       |
| 3700110030                    | 6/F                           | Bronchitis (worsening of acute obstructive bronchitis)                 | 80                            | 62/66                         | Recovered/Resolved            | Not related                   |
| 3700110030                    | 6/F                           | Pneumonia bacterial (acute bacterial pneumonia)                        | 80                            | 81/90                         | Recovered/Resolved            | Not related                   |
| 3700210080/                   | 7/F                           | Device malfunction (ventniculoperitoneal shunt dysfunction)            | 379                           | 359/370                       | Recovered/Resolved            | Not related                   |
| 3850310104                    | 10/F                          | Pyelonephritis acute (acute pyelonephritis)                            | 364                           | 72/83                         | Recovered/Resolved            | Not related                   |
| 4500110001                    | 11/M                          | Urethral perforation (false route in urethra worsening)                | 362                           | 111/122                       | Recovered/Resolved            | Not related                   |
| 4700110097                    | 9/M                           | Talipes (Worsening of walking difficulties [due to Pes Calcaneovalgus] | 356                           | 326/329                       | Recovered/Resolved            | Not related                   |
| 4800210050                    | 5/M                           | Device malfinction (dysfunction of ventriculo-peritoneal shunt)        | 365                           | 28/30                         | Recovered/Resolved            | Not related                   |
| 6300110055                    | 10/F                          | Talipes correction (clubfoot conrection left)                          | 374                           | 182/275                       | Recovered/Resolved            | Not related                   |
| 6300110089                    | 6/M                           | Viral infection （systemic viralinfection)                              | 371                           | 301/308                       | Recovered/Resolved            | Not related                   |
| 8200110062                    | 6/F                           | Benign neoplasm of skin (benign scalp tumor)                           | 365                           | 103/106                       | Recovered/Resolved            | Not related                   |
| Adolescents (12 to <18 years) | Adolescents (12 to <18 years) | Adolescents (12 to <18 years)                                          | Adolescents (12 to <18 years) | Adolescents (12 to <18 years) | Adolescents (12 to <18 years) | Adolescents (12 to <18 years) |
| 3810110009                    | 17/M                          | Colitis (segmental colitis)                                            | 364                           | 202/218                       | Recovered/Resolved            | Not related                   |
| 4700110023                    | 15/M                          | Shunt malfunction (shunt failure)                                      | 376                           | 307/NR                        | Not recovered/ Not resolved   | Not related                   |
| 4700110023                    | 15/M                          | Hydrocephalus (hydrocephalus with shunt failure)                       | 376                           | 307/NR                        | Not recovered/ Not resolved   | Not related                   |
| 4700110023                    | 15/M                          | Convulsion (seizure)                                                   | 376                           | 320/NR                        | Recovering/Resolving          | Not related                   |
| 6000210102                    | 16/M                          | Pyrexia (fever)                                                        | 364                           | 86/104                        | Recovered/Resolved            | Not related                   |
| 6000210102                    | 16/M                          | Escherichfa urinary tact infection (E. colf urinary tract infection)   | 364                           | 108/136                       | Recovered/Resolved            | Not related                   |
| 6000210102                    | 16/M                          | Epididymitis (acute bilateral epididymitis)                            | 364                           | 181/252                       | Recovered/Resolved            | Not related                   |
| 9620110007                    | 13/F                          | Appendicitis (appendicitis)                                            | 364                           | 141/144                       | Recovered/Resolved            | Not related                   |
| 9720210075                    | 12/M                          | Rash generalised (full body rash NOS)                                  | 364                           | 31/33                         | Recovered/Resolved            | Not related                   |

All patients who received ≥ 1 dose of study dnug (SAF)

NOS: not otherwise specified; NR: not reported; SAF: safety analysis set.

十 Age (years) at screening

No deaths were reported in any of the 3 studies.

<div style=\"page-break-after: always\"></div>

## TEAEs of Special Interest

The predefined TEAEs of special interest are listed in the following Table 15:

Table 15 - Predefined TEAEs of Special Interest; Studies 178-CL-206A, 178-CL-202 and 178-CL-203

| TEAE of Special Interest                                                                                   | 178-CL-206A   | 178-CL-202   | 178-CL-203   |
|------------------------------------------------------------------------------------------------------------|---------------|--------------|--------------|
| Cardiovascular                                                                                             | X             | NA           | NA           |
| Increased blood pressure                                                                                   | X             | X            | X            |
| Increased heart rate, tachycardia                                                                          | Ix            | X            | X            |
| QT prolongation                                                                                            | X             | X            | X            |
| Cardiac electrophysiology (QTc)/Cardiac anhythmia cardiovascular AEs                                       | NA            | NA           | X            |
| Tachycardia                                                                                                | NA            | NA           | X            |
| Neoplasm                                                                                                   | X             | NA           | NA           |
| Hypersensitivity reactions                                                                                 | X             | X            | X            |
| Hypersensitivity                                                                                           | NA            | NA           | X            |
| Hepatotoxicity                                                                                             | NA            | NA           | X            |
| Urinary tract infection                                                                                    | X             | NA.          | NA           |
| Urinary retention                                                                                          | X             | NA           | X            |
| Seizures                                                                                                   | X             | NA           | NA           |
| Syncope                                                                                                    | X             | NA           | NA           |
| Nervous system (seizure/syncope)                                                                           | NA            | NA           | X            |
| Fetal disorders after exposure during pregnancy                                                            | X             | NA           | NA           |
| Concomitant treatment with CYP2D6 substrates with narrow therapeutic indices or individually dose-titrated | X             | NA           | NA           |

AE: adverse event:; CYP2D6: cytochrome P450 2D6: NA: not applicable; QTc: conrected QT interval;

TEAE: treatment-emergent adverse event

十Also included atrial fibrillation,palpitations

In the study 178-CL-296A, UTI was the most frequently reported TEAE of special interest, seen in 21 (24.4%) patients, with similar frequencies between children and adolescents.

Hypersensitivity reactions were reported by 5 (5.8%) patients, more frequently in adolescents than children.

The incidence of cardiovascular TEAEs of special interest was low (2 [2.3%] patients).

1 (1.8%) child reported a benign neoplasm (benign scalp tumor) and 1 (3.2%) adolescent experienced a seizure.

The TEAE coded as 'foetal disorders after exposure during pregnancy' was defined in the search strategy; however, there was no pregnancy. The TEAE was worsening of talipes, a congenital condition, in a 9-year old boy.

Changes in SBP, DBP and pulse rate were previously reported in the adult population and are expected with mirabegron. None of those changes were reported as TEAEs in the paediatric Study 178-CL-206A.

The incidence of TEAEs of special interest in the study 178-CL-206A are listed in the Table 16 below:

<div style=\"page-break-after: always\"></div>

Table 16 - Overview of Incidence of TEAEs of Special Interest (SAF); Study 178-CL-206A

| MedDRA v16.0 IEAE of Special Interest, n (%)                                                               | Children (3 to <12 Years) n=55   | Adolescents (12 to <18 Years) n=31   | All Patients (3 to <18 Years) n=86   |
|------------------------------------------------------------------------------------------------------------|----------------------------------|--------------------------------------|--------------------------------------|
| Cardiovascular                                                                                             | 1 (1.8)                          | 1 (3.2)                              | 2 (2.3)                              |
| Increased blood pressure                                                                                   | 0                                | 0                                    | 0                                    |
| Increased heart rate, tachycardia, atrial fibrillation, or palpitations                                    | 0                                | 1 (3.2)                              | 1 (1.2)                              |
| QT prolongation                                                                                            | 1 (1.8)                          | 0                                    | 1 (1.2)                              |
| Neoplasm                                                                                                   | 1 (1.8)                          | 0                                    | 1 (1.2)                              |
| Hypersensitivity reactions                                                                                 | 2 (3.6)                          | 3 (9.7)                              | 5 (5.8)                              |
| Urinary tract infection                                                                                    | 13 (23.6)                        | 8 (25.8)                             | 21 (24.4)                            |
| Urinaryretention                                                                                           | 0                                | 0                                    | 0                                    |
| Seizures                                                                                                   | 0                                | 1 (3.2)                              | 1 (1.2)                              |
| Syncope                                                                                                    | 0                                | 0                                    | 0                                    |
| Fetal disorders after exposure during pregnancy                                                            | 1 (1.8)                          | 0                                    | 1 (1.2)                              |
| Concomitant treatment with CYP2D6 substrates with narrow therapeutic indices or individually dose-titrated | 0                                | 0                                    | 0                                    |

All patients who received ≥ 1 dose of study drug (SAF)

In Study 178-CL-206A, patients received mirabegron prolonged-release tablets (25 or 50 mg) or mirabegron oral suspension formulation C (8 mg/mL)

↑ The hypersensitivity reactions included dermatitis, dermatitis allergic, rash generalized, rhinitis allergic and uticaria, each of which was reported by 1 (1.2%) patient.

CYP2D6: cytochrome P450 2D6; SAF: safety analysis set; TEAE: treatment-emergent adverse event.

<div style=\"page-break-after: always\"></div>

The adverse events of special interest reported were the included in the list below:

Table 17 - Treatment-emergent Adverse Events of Special Interest: Cardiovascular and Hypersensitivity Reactions (FAS)

<!-- image -->

All patients who received ≥ 1 dose of study drug (SAF).

NA: not available: SAF: safety analysis set.

Overall, there were few isolated changes of clinical relevance observed for haematology, biochemistry and urinalysis variables throughout Study 178-CL-206A.

There were 2 TEAEs related to clinical laboratory evaluations, AST increased and blood creatine phosphokinase increased, both reported by a 3-year old girl.

The event of AST increased lead to the permanent discontinuation of the study drug.

None of the paediatric patients in Study 178-CL-206A had levels of liver enzymes that met the definition of biochemical criteria for Hy's law.

There was 1 (3.3%) adolescent who reported a potentially clinically significant total bilirubin &gt; 2 x upper limit of normal without concomitant elevations in transaminases. Patients with AEs of hepatic origin accompanied by liver function test abnormalities had to be carefully monitored.

In Study 178-CL-206A, for all patients with available data, creatinine clearance levels were normal throughout the study.

## Blood pressure

Blood pressure measurements for the majority of patients (46/55 children and 29/31 adolescents) were made with the oscillometric method. The auscultatory method was used for 9 children and 2 adolescents.

Of the 86 patients who received study drug, 8 patients discontinued before first postbaseline assessment of vital signs, resulting in 78 patients (50 children and 28 adolescents) with postbaseline vital sign data.

Blood pressure shifts and potentially clinically relevant (PCR) values in blood pressure were analysed using the American Academy of Paediatrics' Clinical Practice Guidelines, and the Fourth Report on the diagnosis,

<div style=\"page-break-after: always\"></div>

evaluation, and treatment of high blood pressure in children and adolescents. No differences were seen for the central tendency between these 2, while slightly fewer numbers of children and adolescents displayed a change in category using the Fourth report. PCR values in pulse rate were analysed using Fleming et al.

Analyses of the blood pressure and pulse rate data from both clinic and home measurements in aggregate (changes over time, shifts from normal, individual changes along with potential confounders, PCR data) demonstrated changes in SBP and DBP and pulse rate that have been previously reported in adult populations and are expected with mirabegron. None of those changes were reported as TEAEs.

Mirabegron can increase blood pressure in paediatric patients. Blood pressure increases may be larger in children (3 to 12 years of age) than in adolescents (12 to less than 18 years of age).

Blood pressure should be measured at baseline and periodically during treatment with mirabegron.

## Cardiac Monitoring

There were no reports of torsades de pointes or ventricular arrhythmia during the paediatric development program.

Throughout Study 178-CL-206A, no clinically significant ECG abnormalities were seen.

QT interval corrected by Friderici's formula (QTcF) prolongation ≥ 30 ms from baseline was observed in 2 patients (1 child, 1 adolescent) at week 24 and in a third patient (a child) at week 52, none of which were reported as TEAEs.

None of the patients experienced QTcF prolongation ≥ 60 ms from baseline. Cardiac monitoring over 24 hours (Holter) was captured for cardiac arrhythmias in the supportive phase 1 paediatric single-dose Studies 178CL-202 and 178-CL-203. Overall, there were no clinically relevant changes in ECG results.

## Growth and development

Mirabegron had no impact on growth and development based on the changes from baseline to final visit in height, weight or body mass index as observed in Study 178-CL-206A.

## Urinary Tract Ultrasound and Postvoid Residual Volume

At week 52 in Study 178-CL-206A, results of the upper urinary tract ultrasound examinations were interpreted as normal in 83.1% of patients and as abnormal but not clinically significant in 16.9% of patients. No change-from-baseline analyses were conducted.

Postvoid residual volume (PVR) was assessed using ultrasonography or bladder scan in patients not using CIC, i.e., all patients in Study 178-CL-202 and 3 patients with OAB in Study 178-CL-203, but no patients in Study 178-CL-206A.

In Study 178-CL-202, no post-dose PVRs exceeding the 20 mL threshold, as defined by the ICCS, were noted.

In Study 178-CL-203, a bladder scan could not detect any PVR volume at 5 h postdose in any of the 3 patients with OAB (PVR volume = 0 mL).

## 2.6.8.4. In vitro biomarker test for patient selection for safety

No data was provided.

<div style=\"page-break-after: always\"></div>

## 2.6.8.5. Safety in special populations

No data was provided.

## 2.6.8.6. Immunological events

No data was provided.

## 2.6.8.7. Safety related to drug-drug interactions and other interactions

For the purposes of this application to register the product in paediatric patients, no specific analyses were conducted to assess the influence of drug interactions, overdose, drug abuse, withdrawal and rebound, or effects on ability to drive or operate machinery on the safety profile of mirabegron oral suspension in children and adolescents. Recommendations to be included in the labelling are consistent with those in the currently approved labelling for adults.

## 2.6.8.8. Discontinuation due to adverse events

Discontinuations happened only in the main study. Among all the discontinuations, only 3 patients reported a TEAE resulting in permanent discontinuation of study drug, all them were female children.

These TEAEs included increased aspartate aminotransferase (AST), urinary incontinence, both assessed as related, and dermatitis allergic. No adolescent patients reported a TEAE leading to discontinuation.

Table 18 - TEAEs Leading to Permanent Discontinuation of Treatment (SAF); Study 178-CL-206A

| MledDRAv16.0                         | Children （3 to <12 Years) n=55   | Children （3 to <12 Years) n=55   | Adolescents (12 to <18 Years) n=31   | All Patients (3 to <18 Years) n=86   |
|--------------------------------------|----------------------------------|----------------------------------|--------------------------------------|--------------------------------------|
| System Organ Class Preferred Term    | n (%)                            | PatientID/Link to Narrative      | n (%)                                | n (%)                                |
| Overall                              | 3 (5.5)                          |                                  | 0                                    | 3 (3.5)                              |
| Investigations                       |                                  |                                  |                                      |                                      |
| Aspartate aminotransferase increased | 1 (1.8)                          | [3200110070]                     | 0                                    | 1 (1.2)                              |
| Renaland UrinaryDisorders            |                                  |                                  |                                      |                                      |
| Urinaryimcontinence                  | 1(1.8)                           | [8200110094]                     | 0                                    | 1 (1.2)                              |
| Skin and SubcutaneousTissueDisorders |                                  |                                  |                                      |                                      |
| Dermatitis allergic                  | 1 (1.8)                          | [3700110030]                     | 0                                    | 1 (1.2)                              |

All patients who received 2 1 dose of study drug (SAF)

ID:identification: SAF:safety analysis set:TEAE:treatment-emergent adverse event.

## 2.6.8.9. Post marketing experience

Mirabegron tablets were first launched for use in Japan on 1 st  July 2011 and were indicated for the treatment of OAB with symptoms of urge, urinary incontinence, urgency and urinary frequency in adults. As of 30 June 2021, approximately 23 million patients have been exposed to mirabegron cumulatively since launch. Myrbetriq (mirabegron tablets) and Myrbetriq (mirabegron prolonged-release granules for oral suspension) were approved by the FDA on 25 Mar 2021 for the NDO indication in paediatric patients aged 3 and older. Mirabegron 25 mg or 50 mg is also approved for co-administration with solifenacin succinate 5 mg for the treatment of OAB in adult patients in the US, Colombia and Taiwan.

<div style=\"page-break-after: always\"></div>

Mirabegron prolonged-release granules for oral suspension is not yet marketed for use in the EU, but there is the long-term experience with mirabegron in adults with OAB (approximately 23 million patients as of 30 June 2021). Furthermore, as of 30 June 2021, the global safety database contains 511 post marketing cases reported in the paediatric population of less than 18 years of age exposed to mirabegron tablets. The review of the data shows that the safety data is consistent with the known safety profile of mirabegron and does not reveal any new safety concerns detected in the paediatric population treated with mirabegron. The important identified and potential risks in adults are also applicable for the paediatric population.

## 2.6.9. Discussion on clinical safety

The safety of mirabegron is assessed in the paediatric population by 3 studies conducted in 129 patients. Only 103 of these patients suffer from NDO, the intended indication for the proposed application. The main Study, 178-CL-206A, is carrying out in 86 paediatric patients, all of which suffer from NDO. This is a longterm safety study, of 52 week duration. Similar proportion of both sexes participated in the study; most of them were White. Only 70 patients completed the study.

In addition, 2 supportive studies were carried out in order to assess the PK and safety of mirabegron (178CL-202 and 178-CL-203). Both studies were a single-dose studies. Only 17 patients in total among both studies suffered from NDO (the rest was suffering from OAB).

Based on the known safety concerns of this medication in the adult population, both safety parameters and safety endpoints are considered appropriate. However, taking into account that no data in adult NDO patients is available, the safety database for this new indication appears limited for this new population. A number of studies have been conducted in children with OAB. Although differences between conditions the MAH was requested to provide the safety results of these studies. Only two SAEs were performed in children suffering from OAB in the ongoing Study 178-CL-204 (until 30th April 2022): the first one occurred before the patient took the study drug, and the second one was assessed as unrelated by the investigator. For adult patients, only safety data in off-label use is available since this product is not authorized for adults.

All the cases received were non-serious (71 cases), and only 11 AEs were reported. There were reported also 64 special situations, including off-label use and non-compliance. All this data was in line with the known safety information.

In the Study 178-CL-206A, most of patients complied with the administration protocol of the study drug. First, all patients started at the PED25 dose, and by week 8 it was expected that all patients were taking the PED50 dose, this was achieved for all but 4 patients only. Since this week, until the end of the study, there were no changes in dose in any patient.

Only 12 patients discontinued the study drug in any moment of the study from week 8 to the end of the study, due to TEAEs or dosing noncompliance.

In total, 70 patients, out of 86, completed the study. The mean duration of treatment was around 300 days.

In the supportive studies, all patients recruited took the single dose of the study drug.

Regarding the exposure of the drug, the reduced number of patients, is the main limitation of the study given that only 70 patients were taking mirabegron during 52 weeks. This reduced exposure does not allow to detect uncommon but significant adverse events.

<div style=\"page-break-after: always\"></div>

Another limitation of the study is the lack of a placebo arm, which would help us to establish the relationship of an adverse event with the study drug.

In addition, from the supportive studies significant information cannot be drawn as both of them were single dose studies.

During the 52 weeks of treatment, TEAEs were reported by 59.3% patients, while just 16.9% of the patients reported TEAEs that were classified as related to the study drug. A similar trend between age groups was seen in both not related and related-drug TEAEs.

Most of TEAEs reported were mild in severity. Severe and moderate TEAEs were more frequently reported in adolescents than in children. None of the severe adverse events were drug-related.

UTIs were the most reported TEAEs, especially caused Escherichia (9.3%) and other bacteria (5.8%), followed by nasopharyngitis (5.8%).

Among children, UTI bacterial, respiratory tract infection viral and UTI were the most reported TEAEs (7.4% each); while in adolescents, the most frequently reported TEAEs were UTI caused by Escherichia (16.1%) followed by upper respiratory tract infection and pyrexia (9.7% each).

UTI bacterial was the most frequently reported drug-related TEAE.

Low frequencies of drug-related TEAEs were reported by both sexes across all age groups, but a slightly higher trend in male adolescents was observed.

No significative conclusions can be obtained in relation to the race, as the majority of the patients enrolled in the study were White.

Taking into account the drug formulation and dosing regimen, data can be confounded as many of the adolescents (all but 3) were taking tablets and the majority of patients were dosed with the PED50 dose (all but 4).

Events in the supportive studies acknowledge the safety profile seen in the main study.

Taking into account the limitations described in the exposure section, generally, it appears that the safety profile is consistent with the already known for adults, and no new safety problems were identified, except for a difference in the frequency of TEAEs reported between paediatric and adult population, i.e. constipation and nausea are more frequently reported in paediatric population according to the study data.

Serious adverse events were observed in a 16.3% of patients overall, in 16.4% of children and 16.1% of adolescents.

There was only 1 serious TEAE reported by more than 1 patient: shunt malfunction. This adverse event was reported also by 1 adolescent, but this one was not classified in the same group than those reported by children. According to the narratives, the events of 'shunt malfunction' reported in children were in the ventriculo-peritoneal shunt.  The Applicant provided an explanation, as requested, about the different classification of these events. Based on the verbatim terms reported by the investigators, the 3 events of 'shunt malfunction' were classified into 2 different groups. In addition, these events had a minor medical relevance on the aim of the study.

The rest of the drug-related TEAEs were reported by just 1 patient, including pyelonephritis acute, bronchitis or pneumonia bacterial.

None of these adverse events were drug related, and no deaths were reported neither.

<div style=\"page-break-after: always\"></div>

In the supportive studies, no severe adverse events or deaths were reported.

There were pre-specified adverse events of interest. These TEAEs were selected because most of these AEs are identified or potential risks in adults taking mirabegron for OAB. The TEAE of interest most frequently reported was UTI (21.4%), and hypersensitivity (5.8%). This is in accordance with the known safety data of mirabegron in adult population.

Regarding cardiovascular TEAEs of interest, an event of 'bradycardia' was reported by an adolescent patient. This kind of event is not listed in the pre-specified list of TEAEs of interest. The applicant was  asked why the event 'bradycardia' was considered an event of especial interest if it is not stated on the list, and if this event is thought to need special monitoring in paediatric population. According to the response given by the MAH, this event was already included as an adverse event of special interest but not explicitly mentioned as a standalone term, this term was included in the broader search of cardiovascular events.

Analyses of the blood pressure and pulse rate data from both clinic and home measurements in aggregate (changes over time, shifts from normal, individual changes along with potential confounders, PCR data) demonstrated changes in SBP and DBP and pulse rate that have been previously reported in adult populations and are expected with mirabegron. None of those changes were reported as TEAEs. Mirabegron can increase blood pressure in paediatric patients. Blood pressure increases may be larger in children (3 to 12 years of age) than in adolescents (12 to less than 18 years of age). Accordingly a precautionary statement was added to SmPC 4.4 that blood pressure should be measured at baseline and periodically during treatment with mirabegron in paediatric patients.

Abnormal results of laboratory test were observed in few patients. 1 patient with AST increased discontinued the study. There was 1 patient who reported a potentially clinically significant total bilirubin abnormality, but neither outcome nor narrative about this case is provided.

Regarding all vital signs and explorations conducted in the Study 178-CL-206A, there were few isolated cases of reactions or abnormalities. In addition, all of these changes from baseline observed in this study population were expected because they were previously reported in the adult population and are expected with mirabegron.

Considering the urinary tract ultrasound results, the applicant provided an explanation as requested for the anomalies observed in 16.9% of the patients. According to the details provided by the Applicant, none of these events was related to the study drug, and all the anomalies observed were not clinically significant. Taking into account the assessment made by the investigators, no new safety concerns are raised from these findings

No specific analyses were conducted to assess the influence of drug interactions, overdose, drug abuse, withdrawal and rebound, or effects on ability to drive or operate machinery on the safety profile of mirabegron oral suspension in children and adolescents.

In the Study 178-CL-206A, just 3 patients permanently discontinued the study drug, but there are also many patients that temporarily discontinued the study treatment.  The MAH provided details about treatment interruption and, excepting treatment non-compliance, AEs leading to interruption seen in children were vomiting (1), device malfunction (1), gastroenteritis (1), pneumonia bacterial (1), bronchitis (2), blood creatine phosphokinase increased (1), and surgical and medical procedures (2); AEs leading to interruption of the treatment seen in adolescents was rash generalised (1). Most of these AEs are in line with the already known safety profile of mirabegron, and the AEs observed during the Study 178-CL-206A, so no new safety concerns are raised at this point.

<div style=\"page-break-after: always\"></div>

There is a broad experience with mirabegron in the use for OAB in adult population. The identified or potential risks in adults in this indication are supposed to be applicable also in the targeted population in this application. No studies have been performed in adult population taking mirabegron suffering from NDO, as stated before, given that this product is not authorized for this indication, therefore, no safety information is available to draw any conclusions.

Mirabegron was recently approved for its use on NDO in paediatric population by FDA. The Applicant submitted the post marketing data (a summary) involving this authorization, as it was solicited so the post marketing case reports in paediatric population could be assessed. The data provided of the 511 post marketing case reports in NDO paediatric population in USA is in accordance with the already known safety profile of mirabegron for the authorized population and the safety data of the Study 178-CL-206A.

Regarding the post marketing data provided, most of the AEs reported were due to an off-label use or misuse of the product, and except them, the majority of the AEs reported are stated in the product information of mirabegron. This data endorses the safety profile of the product.

From the safety database all the adverse reactions reported in clinical trials and post-marketing have been included in the Summary of Product Characteristics.

## 2.6.10. Conclusions on the clinical safety

All risks identified in the paediatric population in the main study (178-CL-206A) and data provided from Study 178-CL-204 were previously identified in the adult population, in which there is a broad experience of use with mirabegron in the treatment of OAB. The safety profile on NDO is expected to be similar to that known for OAB. In addition, the adverse events observed from the main study, were also expected with mirabegron, given its nature. There were also performed 2 supportive studies submitted for the assessment of the safety profile (178-CL-202 and 178-CL-203), which safety results were consistent with those seen in the main study. However, these two supportive studies were one single dose studies, so not much information can be drawn from them. No new safety concerns were raised from either of the studies.

Data provided of the 511 post marketing case reports in NDO paediatric population in USA was in accordance with the already known safety profile of mirabegron for the authorized population in OAB. The main limitation regarding safety assessment is the reduced size of the safety database since the population of the main study counted only 70 children and adolescents and the two supportive studies are single dose studies. However, available safety data from Study 178-CL-204 in children 5 to &lt; 18 years of age with overactive bladderdid not show new safety problems either. Although it cannot be excluded that differences between the conditions OAB and NDO could impact the safety profile the submitted data can be considered sufficiently supportive of an acceptable safety profile. The final study report of study 178-CL-204 will be provided post authorisation as well as the data of an open label dose titration study in children from 6 months to less than 3 years of age with neurogenic detrusor overactivity (178-CL-207). Both studies are listed as category 3 studies in the RMP and will complement the safety profile post-authorisation..

<div style=\"page-break-after: always\"></div>

## 2.7. Risk Management Plan

## 2.7.1. Safety concerns

| Summaryofsafetyconcerns    | Summaryofsafetyconcerns                                                                                                                                                            |
|----------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks | None                                                                                                                                                                               |
| Important potential risks  | QT prolongation Fetal disorders after exposure during pregnancy Cardiac failure, particularly in patients with pre-existing cardiovascular diseases or cardiovascular risk factors |
| Missing information        | Safety in patients from 3 to less than 5 years old NDO pediatric patients without clean intermittent catheterization (CIC)                                                         |

CIC: clean intermittent catheterization; NDO: Neurogenic detrusor overactivity; QT: QT interval.

## 2.7.2. Pharmacovigilance plan

Table Part III.3.1: On-going and planned additional pharmacovigilance activities

| Study Status                                                                                                                                                                                                                                                                           | Summary of objectives                                                                                                                                                                                                      | Safety concerns addressed                                                                                                                                                                                                  | Milestones                                                                                                                                                                                                                 | Due dates                                                                                                                                                                                                                  |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                                                                             | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 |
| Not applicable                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                            |                                                                                                                                                                                                                            |                                                                                                                                                                                                                            |                                                                                                                                                                                                                            |
| Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances                                                             | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances |
| Not applicable                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                            |                                                                                                                                                                                                                            |                                                                                                                                                                                                                            |                                                                                                                                                                                                                            |
| Category 3 - Required additional pharmacovigilance activities                                                                                                                                                                                                                          | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              |
| A phase 3, Double-blind, randomized, multicenter, parallel group, placebo controlled sequential dose titration study to evaluate efficacy, safety, and pharmacokinetics of mirabegron in pediatric subjects from 5 to < 18 years of age with overactive bladder (178- CL-204). Ongoing |                                                                                                                                                                                                                            | Safety in patients from 3 to less than 5 years old                                                                                                                                                                         | Final CSR                                                                                                                                                                                                                  | Estimated Jan 2024                                                                                                                                                                                                         |
| Open label, multicenter, baseline-controlled sequential dose titration study followed by a fixed                                                                                                                                                                                       |                                                                                                                                                                                                                            | Safety in patients from 3 to less than 5 years old                                                                                                                                                                         | Protocol submission                                                                                                                                                                                                        | Finalized 16- Nov-2021                                                                                                                                                                                                     |
| Open label, multicenter, baseline-controlled sequential dose titration study followed by a fixed                                                                                                                                                                                       |                                                                                                                                                                                                                            | Safety in patients from 3 to less than 5 years old                                                                                                                                                                         | Final CSR                                                                                                                                                                                                                  | Estimated Jan 2026                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

| Study Status                                                                                                                                                                                                                                               | Summary of objectives   | Safety concerns addressed   | Milestones   | Due dates   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|-----------------------------|--------------|-------------|
| dose observation period to evaluate pharmacokinetics, efficacy, and safety of mirabegron prolonged- release microgranula-based suspension in children from 6 months to less than 3 years of age with neurogenic detrusor overactivity (178-CL-207) Planned |                         |                             |              |             |

## 2.7.3. Risk minimisation measures

| Safety concern                                  | Risk minimization measures                                                                                                                                                                                                                                                                                                                                                                                                   | Pharmacovigilance activities                                                                                                      |
|-------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------|
| QT prolongation                                 | Routine risk communication: SmPC Section 4.4 PL Section 2 Routine risk minimization activities recommending specific clinical measures to address the risk: Specific recommendation to exercise caution when administering mirabegron in patients with a known history of QT prolongation or patients who are taking medicinal products known to prolong the QT interval, are provided in SmPC Section 4.4 and PL Section 2. | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Use of Follow up Questionnaire      |
| Fetal disorders after exposure during pregnancy | Routine risk communication: SmPC Section 4.6 PL Section 2 Routine risk minimization activities recommending specific clinical measures to address the risk: Specific recommendation not to use mirabegron during pregnancy in women of childbearing potential not using contraception, as well as discussing with the doctor or pharmacist first before breastfeeding, are provided in SmPC Section 4.6 and PL Section 2.    | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Use of Follow up Data Questionnaire |

<div style=\"page-break-after: always\"></div>

| Safety concern                                                                                                      | Risk minimization measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Pharmacovigilance activities                                                                                                                                                                                                                                                                                                                                                        |
|---------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Cardiac failure, particularly in patients with pre- existing cardiovascular diseases or cardiovascular risk factors | There are no risk minimization measures specific to cardiac failure. Cardiac failure is not included in the EU SmPC however it was added to the EU-RMP as a potential important risk per EMA PRAC request with the PRAC's rationale that 'it is difficult to conclude a relationship between mirabegron and cardiac failure, it cannot be ruled out that patients with pre-existing risk factors developed cardiac failure after the use of mirabegron.' The EMA PRAC considered this risk better managed as an important potential risk based on this rationale. | Routine pharmacovigilance signal detection activities via monitoring of cardiac failure events within the cardiac events TME.                                                                                                                                                                                                                                                       |
| Safety in patients from 3 to less than 5 years old                                                                  | Routine risk communication: • SmPC Sections 4.2 • PL Section 2 Routine risk minimization activities recommending specific clinical measures to address the risk: Specific recommendation that the safety and efficacy of mirabegron children below 18 years of age for the treatment with OAB have not yet been established (detailed in SmPC Section 4.2) and not to give this medicine to children and adolescents under the age of 18 years for the treatment of OAB (detailed in PL Section 2).                                                               | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: • Implementation of an approved Pediatric Investigational Plan Post marketing use in pediatric population is considered a special situation and are routinely monitored via PV signal detection activities Additional pharmacovigilance activities: Study 178-CL-204 Study 178-CL-207 |
| NDO pediatric patients without clean intermittent catheterization (CIC)                                             | Routine risk communication: • SmPC Section 5.1 • PL Section 2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Implementation of an approved Pediatric Investigational Plan Post marketing use in pediatric population is considered a special situation and are routinely monitored via PV signal detection activities Additional pharmacovigilance activities: None                                |

CIC: clean intermittent catheterization; EMA: European Medicines Agency; EU-RMP: European Union risk management plan; NDO: Neurogenic detrusor overactivity; PL Package Leaflet; PRAC: Pharmacovigilance Risk Assessment Committee; PV: Pharmacovigilance; QT: interval between the start of the Q wave to the end of the T wave on electrocardiogram; SmPC: Summary of Product Characteristics; TME: targeted medical event.

<div style=\"page-break-after: always\"></div>

## 2.7.4. Conclusion

The CHMP considered that the risk management plan version 9.2. is acceptable.

## 2.8. Pharmacovigilance

## 2.8.1. Pharmacovigilance system

The CHMP considered that the pharmacovigilance system summary submitted by the MAH fulfils the requirements of Article 8(3) of Directive 2001/83/EC.

## 2.8.2. Periodic Safety Update Reports submission requirements

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.9. Product information

## 2.9.1. User consultation

The results of the user consultation with target patient groups on the package leaflet submitted by the MAH show that the package leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

The claimed indication for Betmiga is for the Treatment of neurogenic detrusor overactivity (NDO) in paediatric patients aged 3 to less than 18 years.

Neurogenic bladder describes a variety of bladder dysfunction disorders that result from a lesion at any level in the central or peripheral nervous system. Among children, congenital neural tube defects, such as myelomeningocele, spinal dysraphism, or tethered cord lesions, are the most common causes. For older patients acquired condition as secondary to spinal cord injury or to malignancies in the spine may occur 20 .

20  Lucas E. Top Spinal Cord Inj Rehabil 2019;25(3):195-204

<div style=\"page-break-after: always\"></div>

Patients with neurogenic bladder may present urinary incontinence, urinary tract infections, vesicoureteral reflux and eventually, renal scarring and renal failure. 21,22  The management is primarily directed at improving symptoms and avoiding kidney damage.

## 3.1.2. Available therapies and unmet medical need

The main objective of the treatment should be to maintain a low bladder pressure as assessed by cytometry 23 . Clean intermittent catheterization (CIC) combined with antimuscarinic agents is the standard recommended treatment. Despite its efficacy, antimuscarinics have associated systemic effects (blurry vision, cognitive impairment, dry mouth, gastroesophageal reflux, constipation, and urinary retention) that may be limiting.  Alpha adrenergic receptor antagonists and botulinum toxin are additional options for intolerant or nonresponsive patients.

Long-term treatment may be suboptimal, and many patients discontinue their medications because of lack of efficacy, and/or significant bothersome side effects, especially patients in whom higher doses of medications are needed 24 .

## 3.1.3. Main clinical studies

The evidence supporting the therapeutic indication on NDO in children and adolescents is primarily based on a phase 3 study (178-CL-206A) in which 86 paediatric patients with NDO using CIC received daily doses of mirabegron, as oral suspension or prolonged-release tablets, for up to 52 weeks. This study was agreed with the PDCO and the design is in line with the recommendations provided in the guideline on the clinical investigation of medicinal products for the treatment of urinary incontinence (CPMP/EWP/18/01/Rev. 1) on NDO.

Supportive exposure and safety data were obtained from 4 phase 1 single-dose studies in 17 paediatric patients with NDO and 26 paediatric patients with OAB (178-CL-202 and 178-CL-203) and 49 healthy adult subjects (178-CL-201 and 178-CL-208).

## 3.2. Favourable effects

After 24 weeks of treatment a statistically significant increase in Maximum Cystometric Capacity (mean [SD]) was shown in children aged 3 to 12 years of 72.09 (87.09) ml and in adolescents aged 12 to 18 years of 87.20 (87.30) ml, compared to the baseline values (both p &lt; 0.001). This improvement was also observed for the global population, with an increase of 87.20 (87.30) ml compared to baseline values (p &lt; 0.001). Per Protocol and sensitivity analyses conducted were consistent with the primary analysis. The treatment effect is in line with published studies conducted with antimuscarinics.

The increase in Maximum Cystometric Capacity was observed at Week 4 in both groups: 41.36 (71.64) ml in children and 80.78 (96.15) ml in adolescents (both p &lt; 0.001).

21  Sager C. IBJU 2022; 48 (1): 31-51.

22  Tyler K. Research and Reports in Urology 2021:13 647-657

23  Committee for Medicinal Products for Human Use (CHMP). Guideline on the clinical investigation of medicinal products for the treatment of urinary incontinence. (27 June 2013). http://www.ema.europa.eu/docs/en\\_GB/document\\_library/ Scientific\\_guideline/2013/07/WC500146177.pdf

24 Kaviani A, Khavari R. Urol Clin North Am 2017;44(3): 463-474.

<div style=\"page-break-after: always\"></div>

At the end of the 24-week period of treatment patients improved bladder compliance in 14.22 (33.99) mL/cm H2O and reduced detrusor activity. A significantly lower number of detrusor contractions (-1.45 [4.05]) and reduced detrusor pressure at the end of filling was measured with respect to baseline levels. The bladder capacity until first contraction was also increased.

With respect to the voided volumes recorded in the bladder diaries, the treatment with mirabegron increased the volumes catheterized during the day (maximum daytime volume), during the night (average morning volume) and the average volume per catheterization.

According to the clinicians' global impression of the treatment the condition was reported as much improved or very much improved in &gt; 70% of patients.

## 3.3. Uncertainties and limitations about favourable effects

The lack of a control arm (placebo or active comparator) and a limited number of patients (55 children, 31 adolescents) included in the Study 178-CL-206A is a limitation for reaching sound conclusions on the efficacy of the mirabegron on the treatment of paediatric NDO subjects. Considering that Clean Intermittent Catheterisation was one of the requisites for entering the trial, a placebo control arm could have been an option in line with the EMA Guideline recommendation. Alternatively, an active comparator could have been used given the pharmacotherapy (mainly based on antimuscarinics) is considered as first line therapy and several antimuscarinics (oxybutynin, solifenacin) have been approved for this indication. The finally performed one single arm trial is also considered as an acceptable design, similar to other clinical trials conducted in the field. It should also be taken into account that the primary endpoint (MCC) is a cystometric measure less prone to bias.

The selection of the dose was based on the effect of mirabegron in OAB indication in adults since the NDO indication is not approved in adults. Since tablets and granules for prolonged release oral suspension are not equivalent mg to mg specific recommendations for dosing at switching has been included in 4.2 of the SmPC.

When the effect of the treatment was assessed by the patients (PIN-Q) no changes with respect to baseline were observed in children and the changes in adolescents were not significant. Similarly, according to the global impression of the treatment perceived by the patients only a modest improvement was reported.

As for the maintenance of the effect, the long-term efficacy assessment was based only on results of catheterized volumes from e-diaries since no urodynamic studies were performed beyond 6 months of treatment. A reduction of the effect was observed with respect to that achieved at Week 26, being numerically lower for most of the measures (especially in adolescents and all the patients groups). Whereas the limitations of the study for achieving sound conclusions in this respect are acknowledged, concerns on the maintenance of the effect were raised. At Day 180 the MAH has presented the results of catheterized volumes at Week 52 using baseline MCC volume values for correction for bladder volume. This approach shows no relevant differences between volumes measured at Week 24 and those measured at Week 52, which partially alleviates this uncertainty.

## 3.4. Unfavourable effects

During the 52 weeks of treatment UTIs were the most reported TEAEs, especially caused by Escherichia (9.3%) and other bacteria (5.8%), followed by nasopharyngitis (5.8%).

<div style=\"page-break-after: always\"></div>

Among children, UTI bacterial, respiratory tract infection viral and UTI were the most reported TEAEs (7.4% each); while in adolescents, the most frequently reported TEAEs were UTI caused by Escherichia (16.1%) followed by upper respiratory tract infection and pyrexia (9.7% each). UTI bacterial was the most frequently reported drug-related TEAE.

Serious adverse events were observed in a 16.3% of patients overall, in 16.4% of children and 16.1% of adolescents. There was only 1 serious TEAE reported by more than 1 patient: shunt malfunction.

It appears that the safety profile is consistent with the already known for adults, and no new safety problems were identified, except for a difference in the frequency of TEAEs reported between paediatric and adult population, i.e. constipation and nausea are more frequently reported in paediatric population.

## 3.5. Uncertainties and limitations about unfavourable effects

A total of 86 NDO paediatric patients (55 children, 31 adolescents) were treated with mirabegron. The supportive studies were single-dose studies.  The safety database for this new indication appears limited for this new population. A number of studies are being conducted in children with OAB. Of Study 178-CL-204, available safety results were provided, and they did not show new safety problems. Although it cannot be excluded that differences between these conditions could impact the safety profile this information was considered supportive. The final study report of this study will be provided post authorisation as well as the data of an open label dose titration study in children from 6 months to less than 3 years of age with neurogenic detrusor overactivity (178-CL-207) to complement the safety profile. Both studies are listed as category 3 studies in the RMP. Furthermore, the PSUR frequency will be shortened to a once yearly reporting.

Mirabegron was recently approved for its use on NDO in paediatric population by FDA. The Applicant have submitted the post-marketing data involving this authorization. There were 511 post-marketing case reports in paediatric population, but no new safety concerns were raised from this data as the majority of the AEs reported were in line with the already known safety profile of mirabegron.

For the long-term safety assessment only 70 children and adolescents were taking mirabegron during 52 weeks. This reduced number does not allow to detect uncommon but significant adverse events in the chronic exposure.

Clinical data is limited and especially in the long-term. In addition, in the PIP, there is no other study planned except for patients from 6 months to 3 years old, although the PIP is in line with the discussion maintained with the Paediatric Committee.

The examination of renal function does not show abnormal values of creatinine clearance. With respect to renal morphology results of the upper urinary tract ultrasound examinations showed abnormal but not clinically significant findings in 16.9% of patients, and all of these anomalies were classified as unrelated with the study drug by the investigators.

Cardiovascular safety is one of the area of interest for safety. An event of 'bradycardia' was reported by an adolescent patient. This kind of event was not listed in the pre-specified list of TEAEs of interest. The applicant has clarified that this event is included in the broad search term 'cardiovascular events', and should update the information to include this event in the list. Bradycardia, like the rest of cardiovascular events, will need special monitoring in paediatric population.

<div style=\"page-break-after: always\"></div>

## 3.6. Effects Table

Table 19 - Effects Table for mirabegron for the treatment of NDO in children and adolescents.

| Effect                                                                        | Short Description                                                                               | Unit                 | Mirabegron           | Control              | Uncertainties/ Strength of evidence   | References           |
|-------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|----------------------|----------------------|----------------------|---------------------------------------|----------------------|
| Favourable Effects                                                            | Favourable Effects                                                                              | Favourable Effects   | Favourable Effects   | Favourable Effects   | Favourable Effects                    | Favourable Effects   |
| Primary endpoint MCC                                                          | Change from BL (ml) at W24 (FAS)                                                                | Mean (SD)            | 87.20 (87.30)        |                      | 95%CI (66.07, 108.33) P< 0.001        | Study 178-CL- 206A   |
| Secondary endpoint MCC                                                        | Change from BL (ml) at W4 (FAS)                                                                 | Mean (SD)            | 55.53 (82.76)        |                      | 95%CI (34.85, 76.20) P< 0.001         | Study 178-CL- 206A   |
| Secondary endpoint Bladder                                                    | Change from BL (ml/cm H 2 O) at W24 (FAS)                                                       | Mean (SD)            | 14.22 (33.99)        |                      | 95%CI (4.94, 23.49) P= 0.003          | Study 178-CL- 206A   |
| Secondary endpoint No. of Overactive Detrusor Contractions Until End of       | Change from BL (n) at W24 (FAS)                                                                 | Mean (SD)            | - 1.45 (4.05)        |                      | 95%CI (-2.51, -0.38) P= 0.009         | Study 178-CL- 206A   |
| Secondary endpoint Detrusor Pressure at End of Bladder Filling at             | Change from BL in detrusor pressure(cm H 2 O) at W24 (FAS)                                      | Mean (SD)            | -16.24 (19.92)       |                      | 95%CI (-21.48,-11.01) P< 0.001        | Study 178-CL- 206A   |
| Secondary endpoint Maximum Catheterized Volume per Catheterization            | Change from BL in maximum catheterized volume (ml) at W24 (FAS)                                 | Mean (SD)            | 62.28 (110.91 )      |                      | 95%CI (34.6, 90.0) P< 0.001           | Study 178-CL- 206A   |
| Secondary endpoint Average Catheterized Volume per Catheterization at Week 24 | Change from BLin average catheterized volume (mL) per catheterization after 24 wks of treatment | Mean (SD)            | 47.99 (67.62)        |                      | 95%CI (31.1, 64.9) P< 0.001           | Study 178-CL- 206A   |
| Unfavourable Effects                                                          | Unfavourable Effects                                                                            | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects                  | Unfavourable Effects |
| TEAEs                                                                         | Incidence of TEAEs regardless of causality                                                      | n (%)                | 51 (59.3%)           |                      |                                       | Study 178-CL- 206A   |
| Related TEAEs                                                                 | Proportion                                                                                      | n (%)                | 14 (16.3%)           |                      |                                       | Study 178-CL- 206A   |
| Serious TEAEs                                                                 | Incidence of serious adverse events                                                             | n (%)                | 14 (16.3%)           |                      |                                       | Study 178-CL- 206A   |

<div style=\"page-break-after: always\"></div>

| Effect                            | Short Description   | Unit   | Mirabegron   | Control   | Uncertainties/ Strength of evidence   | References         |
|-----------------------------------|---------------------|--------|--------------|-----------|---------------------------------------|--------------------|
| Escherichia UTI                   | Common TEAE         | n (%)  | 8 (9.3%)     |           |                                       | Study 178-CL- 206A |
| Nasopharyngitis                   | Common TEAE         | n (%)  | 5 (5.8%)     |           |                                       | Study 178-CL- 206A |
| Pyrexia                           | Common TEAE         | n (%)  | 5 (5.8%)     |           |                                       | Study 178-CL- 206A |
| UTI bacterial                     | Common TEAE         | n (%)  | 5 (5.8%)     |           |                                       | Study 178-CL- 206A |
| Constipation                      | Common TEAE         | n (%)  | 4 (4.7%)     |           |                                       | Study 178-CL- 206A |
| Respiratory tract infection viral | Common TEAE         | n (%)  | 4 (4.7%)     |           |                                       | Study 178-CL- 206A |
| Upper respiratory tract infection | Common TEAE         | n (%)  | 4 (4.7%)     |           |                                       | Study 178-CL- 206A |
| UTI                               | Common TEAE         | n (%)  | 4 (4.7%)     |           |                                       | Study 178-CL- 206A |

Abbreviations: BL = Baseline; MCC= Maximum Cystometric Capacity; W24= Week 24; UTI= Urinary tract infection; TEAE= Treatment emergent adverse event

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

One of the main objectives of the NDO treatment should be to maintain a low bladder pressure. For this purpose mirabegron administered to children and adolescents on CIC for 24 weeks reduced detrusor activity as assessed by cytometry and increased the catheterized volumes reported in e-bladder diaries with respect to baseline values. The treatment effect can be considered in line with that reported in published studies with antimuscarinics such as oxybutinin or solifenacin 25,26 . The long-term efficacy data are less solid as they are not supported by urodynamic outcomes but 4.2 of the SmPC advises to evaluate patients periodically for treatment continuation and for potential dose adjustment which is acceptable.

In addition to the achievement of a better reservoir function of the bladder the preservation of the upper urinary tract is also a relevant objective of the treatment. In this regard, there was no signal of impairment of renal function although the study may not be sensitive enough.

The safety profile of mirabegron in this population is consistent with that already known for OAB indication in adults. UTIs were the most frequently reported AE. In this population a reduction of UTI rates is one of the goals in the management of the condition. UTI was one the most reported AE during the study, however the lack of a control group prevents from concluding on the relevance of the results.

25  Franco I, Horowitz M, Grady R, Adams RC, de Jong TPVM, Lindert K, et al. J Urol 2005;173:221e5.

26  Franco I, Hoebeke P, Baka-Ostrowska M, Bolong D, Davies LN, Dahler E, Snijder R, Stroosma O, Verheggen F, Newgreen D, Bosman B, Vande Walle J. J Pediatr Urol. 2020 Apr;16(2):180.e1-180.e8.

<div style=\"page-break-after: always\"></div>

As for the impact of the treatment with mirabegron on the quality of life the benefit perceived by the patients seems more modest than that reported by the clinicians.

Even though anticholinergic drugs are the first-line pharmacotherapy for patients with NDO the limited effectiveness and moderate adverse side effect profiles, lead some patients to discontinuing the treatment. Mirabegron with a different mechanism of action may provide an additional option before being treated with more invasive therapies.

A new formulation (prolonged-release granules for oral solution) has been developed for the younger subjects or those patients unable to swallow the tablets.

## 3.7.2. Balance of benefits and risks

Mirabegron has shown an effect on the control of detrusor activity assessed by urodynamic studies and increasing the bladder volumes when patients performed catheterization in children and adolescents with NDO on CIC treated for 6 months. Even considering the limitations of the study design, mirabegron has shown an improvement in the reservoir function of the bladder and the effect can be considered in line with that reported in published studies with antimuscarinics such as oxybutinin or solifenacin 27,28 .

The long-term efficacy data are less solid as they are not supported by urodynamic outcomes but acceptable in view of the periodic monitoring of patients for treatment continuation as advised in 4.2 of the SmPC.

The observed safety profile of mirabegron in this population does not raise any severe or unexpected concerns in any of the studies assessed and is in general consistent with that known for mirabegron in OAB adults. The safety information in this indication is based on a very limited safety database but can be considered sufficient considering a shortening of the PSUR cycle to a one yearly reporting. Further safety information will also become available upon provision of the data of study 178-CL-207 (safety data on children with NDO from 6 months to less than 5 years of age) in post-authorization as described in the RMP.

## 3.8. Conclusions

The overall benefit/risk balance of Betmiga is positive, subject to the conditions stated in section 'Recommendations'.

## 4. Recommendations

## Outcome

Based on the CHMP review of data on quality, safety and efficacy, the CHMP considers by consensus that the benefit-risk balance of, Betmiga 8 mg/ml, granules for prolonged-release oral suspension as well as for the existing formulations 25 mg and 50 mg prolonged-release tablets is favourable in the following indication:

Betmiga is indicated for treatment of neurogenic detrusor overactivity (NDO) in paediatric patients aged 3 to less than 18 years.

The CHMP therefore recommends the extension(s) of the marketing authorisation for Betmiga subject to the following conditions:

27  Franco I, Horowitz M, Grady R, Adams RC, de Jong TPVM, Lindert K, et al. J Urol 2005;173:221e5.

28  Franco I, Hoebeke P, Baka-Ostrowska M, Bolong D, Davies LN, Dahler E, Snijder R, Stroosma O, Verheggen F, Newgreen D, Bosman B, Vande Walle J. J Pediatr Urol. 2020 Apr;16(2):180.e1-180.e8.

<div style=\"page-break-after: always\"></div>

## Conditions or restrictions regarding supply and use

Medicinal product subject to medical prescription.

## Conditions and requirements of the marketing authorisation

## Periodic Safety Update Reports

The newly agreed indication comprises a paediatric population of a different disease entity with underlying neurologic cause. The safety database is still limited and a different safety profile in this patent population cannot be fully excluded. Therefore, the PRAC is of the opinion that the data in the PSUR submissions should be split by indication and the already existing entry in the EURD list for mirabegron needs to be amended as follows: the PSUR cycle for the medicinal product should follow a yearly cycle. The next data lock point will be 30/06/2025.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## · Risk Management Plan (RMP)

The Marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

In addition, CHMP recommends the variation(s) to the terms of the marketing authorisation, concerning the following change(s):

| Variations requested   | Variations requested                                                                                                           | Type           | Annexes affected    |
|------------------------|--------------------------------------------------------------------------------------------------------------------------------|----------------|---------------------|
| C.I.6.a                | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II        | I, IIIA and IIIB    |
| X.02.III               | Annex I_2.(c) Change or addition of a new strength/potency                                                                     | Line Extension | I, IIIA, IIIB and A |
| X.02.IV                | Annex I_2.(d) Change or addition of a new pharmaceutical form                                                                  | Line Extension | I, IIIA, IIIB and A |

Extension application to introduce a new pharmaceutical form associated with new strength (8 mg/ml prolonged-release granules for oral suspension), grouped with a type II variation (C.I.6.a) to include treatment of neurogenic detrusor overactivity (NDO) in paediatric patients aged 3 to less than 18 years. The RMP (version 9.2) is updated in accordance.

Furthermore, the PI is brought in line with the latest QRD template version 10.4.